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Abstract 
Previous work at York demonstrated that fragment molecules can increase 
the activity of the glycoside hydrolase, BtGH84. The initial aim of this 
project was to use fragment-based discovery methods to identify activators 
of several enzymes used in cellulose degradation where low activity is one 
of the limiting steps in the industrial process. This was successful for one 
enzyme, the fungal glycoside hydrolase, TrBgl2. The characterisation of the 
mechanism of activation for this enzyme is the main focus of this thesis.   
A fragment screen of a library of 560 commercially available fragments 
using a kinetic assay identified a small molecule activator of TrBgl2. An 
analogue by catalogue approach and detailed kinetic analysis identified 
compounds that behaved as nonessential activators with up to a 2-fold 
increase in maximum activation. The compounds did not activate the 
related bacterial glycoside hydrolase CcBglA demonstrating specificity. 
Interestingly, an analogue of the initial fragment inhibits both TrBgl2 and 
CcBglA, apparently through a mixed-model mechanism.  
Although it was not possible to determine crystal structures of activator 
binding to 55 kDa TrBgl2, solution NMR experiments demonstrated a 
specific binding site for the activator. A partial assignment of the NMR 
spectrum gave the identity of the amino acids at this site, allowing a model 
for TrBgl2 activation to be built.  The activator binds at the entrance of the 
substrate binding site, stabilizing the enzyme-substrate complex.  
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Chapter 1: Introduction 
1.1. Enzyme activation 
The binding of a small organic molecule can affect an enzyme in two 
possible ways: it can either decrease (inhibit) or increase (activate) the 
activity of the enzyme. There are numerous examples where binding has 
evolved to inhibit activity in biological systems –such as direct inhibition by 
binding to the active site (for example Vemurafenib for BRAF kinase) [3] or 
indirect inhibition by disrupting a protein-protein interaction (for example 
Venetoclax for B-cell lymphoma 2 [4-6]). There are many enzymes whose 
inhibition can generate a therapeutic effect. Although there are some 
examples of inhibition through compounds that bind to an allosteric site 
(for example the allosteric inhibitor of BCR-ABL1 [7-8]) most drug 
discovery projects aim to generate inhibitors that bind directly to active 
sites and inhibit enzyme activity, typically with small organic molecules with 
a molecular weight (MW) of less than 500 Da.  
The phenomenon of activation through non-covalent binding of small 
molecules is well established for receptors –that is proteins which increase 
biological activity through binding of a ligand, known as agonist action.  
Examples include the nuclear hormone receptors (such as the estrogen 
receptor [9]) and G-protein coupled receptors (such as the α-adrenergic 
receptor [10]) where binding of the ligand induces an active conformation.   
Covalent modification of an enzyme is a widely observed mechanism for 
modulating the biological activity of an enzyme, affecting cellular function.  
 26 
 
The most widely described enzyme modification is the phosphorylation of 
amino acids such as serine, threonine or tyrosine at specific sites in an 
enzyme by selective protein kinases. This modification can alter the activity 
of an enzyme in various ways, for example by changing localization such 
as in the DAP kinase-related apoptosis-inducing kinase 2 (DRAK2) which 
changes between the nucleus and cytoplasm [11], by releasing inhibition 
by a domain such as in the phospholipase C (PLC)-γ isozyme [12] or by 
changing an enzyme’s conformation to an active one such as in the MAP 
(mitogen-activated protein) kinase ERK2 (extracellular signal-regulated 
protein kinase) [13]. Enzyme modifications also include covalent 
modifications by carbohydrates (such as widespread addition of GlcNAc 
sugars to many intracellular proteins), which affect the overall activity of a 
cell.  
Although, there are relatively few examples of naturally occurring small 
molecules that activate an enzyme through binding non-covalently, there 
have been some well characterized non-natural small molecules that lead 
to remarkable increase in enzyme activity. Enzyme activators usually act 
by binding to an allosteric pocket. An allosteric site is a site other than the 
orthosteric site of a protein where effectors can bind, often causing the 
enzyme to undergo a conformational change involving protein dynamics 
that may alter its catalytic or binding properties. It is thought that only a 
small increase in activation (as low as 10%) may be sufficient to elicit an 
effective therapeutic response whereas enzyme inhibitors usually require 
at least 90% inhibition to completely block a phenotype [14]. In addition, 
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allosteric sites are less likely to be conserved, increasing the opportunity 
for selectivity. Although enzyme inhibition is the most widely used approach 
in drug discovery, enzyme activation may provide new approaches for 
disease related studies. For example, there are some widely known 
marketed drugs that act as activators (Table 1.1). 
Table 1.1. Widely known marketed drugs as activators 
Drug Target Structure 
Colforsin Adenylate cyclase 
 
Ingenol Protein kinase C 
 
Carbaglu 
Carbamoyl 
phosphate 
synthetase  
Adempas Guanylate cyclase 
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1.2. Mechanisms of enzyme activation 
A review by Zorn et al. [15] defined four general mechanisms (A1, A2, B1 
and B2) of activation describing how the activity of an enzyme can be 
increased by a small molecule to a site other than the primary or orthosteric 
binding site. These are summarized in Figure 1.1. The classification 
proposed by Zorn et al. provides a general framework for classifying modes 
of activation. The main focus of the studies reported in this thesis is the A1 
mechanism, where in a small molecule binds directly to the catalytic domain 
of the enzyme, thereby affecting some aspect of the enzyme kinetics.  
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Figure 1.1. Mechanisms of small molecule enzyme (orange square) activation 
[15]. The type A1 mechanism involves a direct binding interaction of the small-
molecule activator (yellow) with an allosteric site on the enzyme's catalytic domain 
stabilizing an active conformation. The type A2 mechanism results from an 
irreversible post-translational modification. One example is proteolysis induced by 
binding of a small molecule to the catalytic domain of a protease, as in the case 
of MARTVc toxin activator. In a type B1 mechanism, the activator (yellow) binds to 
a regulatory subunit resulting in a conformational change in the catalytic domain. 
One example is AMP-activated protein kinase (AMPK). Type B2 mechanisms are 
where additional oligomerisation of the catalytic domain generates the active 
enzyme either by binding of small molecules to an allosteric site on the catalytic 
domain or by interaction of small molecules with a regulatory subunit. One 
example is RNAse L activators. The substrate is shown as an orange triangle. 
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1.3. Examples of enzyme activation by small 
molecules 
A search of the literature using the keywords “small molecules’’, 
“activators’’ and “enzyme activation’’, identified reports of small molecule 
activators of enzymes. These fall into two main classes depending on 
whether or not there is clear evidence that the ligands bind to the activated 
target. Table 1.2 summarises the papers published since 2012 where there 
is no clear evidence for binding of the ligands to the activated target.  
Table 1.2. Recent examples of enzyme activation through unidentified 
mechanism. 
Target How activators found Refs 
 
Coactivator-associated 
arginine methyltransferase 
1 (CARM1) 
 
HTS [16] 
 
Insulin-degrading enzyme 
(IDE) 
 
HTS [17] 
 
Porcine pancreatic alpha-
amylase (PPA) 
 
HTS of compounds with 
similar structure to 
natural metabolites 
[18] 
 
Glutamate dehydrogenase 
(GDH) 
 
HTS [19] 
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Target How activators found Refs 
 
15-lipoxygenase (15-LOX) 
 
Virtual screening against 
predicted allosteric sites [20] 
 
Coproporphyrinogen 
oxidase (CgoX) 
 
HTS [21-22] 
 
Death associated protein 
kinase 1 (DAPK1) 
 
HTS [23] 
Glucose-6-phosphate 
dehydrogenase (G6PD) HTS [24] 
The second class of examples which is the focus of this thesis are those 
where there is evidence that the activation is through an A1 type 
mechanism –that is wherein the small molecule binds to an allosteric site 
on the catalytic domain of the enzyme to achieve activation. Some 
examples demonstrating this mechanism are discussed in detail below.  
1.3.1. Glucokinase (GK) 
GK is the mammalian enzyme that catalyzes the ATP-dependent 
phosphorylation of glucose to glucose-6-phosphate (G-6-P) [25]. In the 
liver, GK is retained in the nucleus by the glucokinase regulatory protein 
(GKRP) at low glucose levels whilst on increase of glucose concentration it 
is released into the cytoplasm where it promotes the conversion of glucose 
to glycogen [26-27]. In β-cells GK acts as a “glucose sensor” [28-30] and  
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inactivating mutations are associated with maturity-onset of type 2 
diabetes while activating mutations are linked to improved glucose 
tolerance [31]. This suggests that activation of GK is a promising target for 
the treatment of type 2 diabetes. 
A 120,000-compound library was screened for compounds that reverse 
inhibition by GKRP.  This identified a glucokinase activator (GKA) that binds 
to an allosteric site of GK close to the active site without affecting GKRP. 
This led to the synthesis of a chemically optimised GKA (1) (Figure 1.2), 
which decreases the AC50 (the concentration of compound required to 
increase enzyme activity by 50%) of GK for glucose by approximately 4-
fold and increases its Vmax by 1.5-fold in a dose-dependent manner 
[29][32]. 
 
Figure 1.2.  Chemical structure of GK activator 1. 
In vivo studies in diabetic rodent models have shown that GKAs reduce 
blood glucose levels, increase plasma insulin and improve glucose tolerance 
[29]. Following this, a number of structurally unique GKAs (Table 1.3) [33-
34] and patents have since been reported [35-48]. Some of these GKAs 
are in clinical trials in human patients with type 2 diabetes [49-50]. 
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Table 1.3. Main classes and chemical structures of GKAs. 
Class Compound Company 
Carbon- 
centered 
 
Hoffman-La 
Roche 
Benzene- and 
pyridine- 
centred 
 
Astra-Zeneca 
 
Amino acid- 
based 
 
 
Takeda 
 
Pyrrolone-based 
 
 
Johnson & 
Johnson 
 
The crystal structures of active (in complex with glucose and a novel GKA 
(2)) and inactive (unbound) forms of GK provide an insight into the 
mechanism of GKAs [30]. GK is a monomeric enzyme consisting of a large 
and a small domain. Its single active site is located on the connection region 
between the domains [30]. Figure 1.3 shows the large conformational 
change in GK triggered by glucose binding, which result in a large rotation 
of its small domain [51]. This conformational change slowly interconverts 
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the enzyme from an '’open’' low affinity glucose form to a '’closed'’ high- 
affinity glucose active form [30], which exposes an allosteric pocket that is 
located around 20 Å away from the active site in the low affinity form 
(Figure 1.3.A) [51]. This interconversion is affected by glucose 
concentration and liver specific GKA [52]. Thus, GKAs appear to bind to this 
allosteric site, thereby stabilising the '’closed'’ active form of GK. 
Interestingly, the structural analysis of GK revealed that the GK activating 
mutations are clustered at the same allosteric site where GKAs interact [29-
30]. 
More recently, it has been reported that some GKAs are able to function in 
a glucose-independent manner by promoting an active enzyme 
conformation similar to the effects produced by glucose binding [53].  
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Figure 1.3. A. Structural overlay of bound and unbound GK. The protein backbone 
is shown as ribbon diagram. GK bound to a novel GKA 2 and glucose (PDB ID 
1V4S) is shown in cyan and the unbound GK (PDB ID 1V4T) is shown in green. 
Glucose and GKA 2 are shown as spheres in red and orange respectively. B. GKA 
allosteric site in closed form glucokinase. GKA forms hydrogen bonds with Arg63 
(R63) and Tyr215 (Y215) and makes hydrophobic interactions with Val452 (V452) 
and Val455 (V455) in the small domain and with Val62 (V62), Met210 (M210), 
Ile211 (I211), Tyr214 (Y214), and Met235 (M235) in the large domain [30] (cyan 
stick model). Activator 2 is shown as lines in orange. Oxygen atoms are shown in 
red and nitrogen in blue. Hydrogen bonds are shown as black dashed lines. C. 
Chemical structure of 2.  
 
1.3.2. Phosphoinositide-dependent protein kinase 1 
(PDPK1)  
Protein kinases catalyze the phosphorylation of specific sites on other 
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proteins to affect their activity, providing the most common mechanism for 
intracellular regulation. An example is the AGC protein kinase family where 
mutation that leads to deregulation has been linked to human diseases, 
such as diabetes and cancer [54-55]. AGC protein kinase family enzymes 
are activated by phosphorylation of a serine or threonine to stabilize the 
active conformation of the so-called activation loop within the kinase 
domain as well as phosphorylation of a residue in the hydrophobic motif 
(HM) Phe-Xaa-Xaa-Phe of the conserved region at the C-terminus of the 
catalytic domain. In some cases, the phosphorylated hydrophobic motif can 
function as a docking site that can recruit a HM-binding site in the catalytic 
domain of the protein kinase catalytic domain [56-57]. 
One member of the AGC protein kinase family is phosphoinositide- 
dependent protein kinase 1 (PDPK1). This enzyme phosphorylates the 
activation loop of other protein kinases from the AGC family, thereby 
activating them [56-58]. PDPK1 does not have a HM instead, it has a 
regulatory homologous pocket in its N-terminal lobe which is called the PIF 
(PDPK1-interacting fragment)-binding pocket, “PIF pocket”. The PIF pocket 
recruits only phosphorylated HM of substrate protein kinases and 
allosterically activates itself through a process involving conformational 
change of its ATP binding site [58-60]. 
Engel et al. reported the first rational design of small compounds that mimic 
the phosphorylation-dependent docking interaction of the PIF-pocket with 
HM-containing substrates [61]. In silico screening of a 60,000-compound 
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library identified small-molecule compounds that possess features similar 
to those essential for the HM PIF-pocket interaction (such as Phe347 and 
Phe350) [61]. The hits that were selected from the computational screening 
were further evaluated in vitro. 
Compound 3 (Figure 1.4) showed a 5-fold activation of PDPK1, with an AC50 
of 34 µM [61]. This compound contains a negatively charged carboxylate 
that mimics the phosphate group of the phosphorylated HM, and two 
aromatic ring hydrophobic moieties that probably mimic the two 
phenylalanine residues on the HM of substrates [61]. The ability of 3 to 
activate PDPK1 relies on the specific interaction with the regulatory HM/PIF-
pocket to induce the required conformational change [61].   
 
Figure 1.4. Chemical structure of PDPK1 activators. 
Structure-activity relationships (SARs) guided further optimization of the 
initial compound 3 leading to improved compounds with AC50 in the range 
2.8 to 41.3 µM and maximum activation (Amax) increased between 1.4 to 
4.4-fold [62]. The AC50 values were consistent with the binding affinities 
that were derived from ITC experiments. Compound 4 was identified as the 
best compound with an AC50 value of 8 µM, showing a 4-fold increase in 
Amax as compared to the PDPK1 activity levels. The crystal structure of 
PDPK1 in complex with activator 4 and ATP gives an insight into the 
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mechanism of its activation [63] (Figure 1.5). The binding of the small-
molecule activator results in modest structural changes local to the PIF-
pocket producing local changes that lead to allosteric modifications in the 
ATP binding site and the activation loop (Figure 1.6) [63]. Furthermore, all 
the surface residues of the PIF-pocket appear to have decreased B-factors 
in the presence of activator 4, indicating a dynamic rearrangement of the 
surface residues, thereby stabilising the bound activator [63]. 
 
Figure 1.5. Structural overlay of bound and unbound PDPK1. The protein 
backbone is shown as ribbon diagram. PDPK1 bound to 4 and ATP (PDB ID 3HRF) 
is shown in grey and 4-unbound PDPK1 (PDB ID 3HRC) is shown in magenta. 
Compound 4 and ATP are shown as spheres in orange and red respectively.  
 39 
 
 
Figure 1.6. Structural overlay of PDPK1 bound to 4 and ATP (PDB ID 3HRF) and 
PDK1 not bound to 4 (PDB ID 3HRC) is shown in grey and magenta respectively. 
A. Moderate conformational changes local to the PIF-pocket upon binding of 4; 
Lys76 (K76) became ordered upon binding of 4, Arg131 (R131) moved to interact 
with the carboxylate of 4 and Phe157 (F157) changed position to leave free space 
for 4 to bind. B. Allosteric conformational changes to the activation loop and 
glycine-rich loop upon binding of 4. The activation loop became more ordered after 
4 binding and Phe93 (F93) in the glycine-rich loop shifted. Compound 4 is shown 
as stick diagram in orange. Oxygen atoms are shown in red and nitrogen in blue. 
Hydrogen bonds are shown as black dashed lines.  
 40 
 
More recently, Wei et al. designed a novel binder compound 5 (Figure 1.7), 
through virtual docking of compounds into the PIF pocket of PDPK1.  
 
Figure 1.7. Chemical structure of activator 5, 6 and 7. 
Molecular modeling showed that compound 5 binds to the PIF pocket 
through the hydrophobic interaction of its two aromatic groups with the PIF 
pocket and through a specific interaction between the tail substitute and 
the residues that form the phosphate-binding site of PDPK1. Compound 5 
resulted in a 5-fold increase in binding affinity with an AC50 of 23 µM, 
compared to the previously reported compound 3 which was measured with 
an AC50 of 133 µΜ [64]. Compound 5 and two other benzodiazepine-2-ones 
(Compound 6 and 7) were further tested in an in vitro enzymatic assay 
using a peptide substrate. Compounds 5, 6 and 7 increased the activity of 
PDPK1 by 14-fold, 10-fold and 2-fold respectively at 25 µΜ. Compound 6 
and 7 were measured with an AC50 of 53 and 45 µΜ respectively, which 
shows the absence of strong correlation between the activity levels of 
PDPK1 and the AC50 values. This suggests that small molecules interacting 
with the HM/PIF pocket may result in slightly different conformational 
changes which lead to differential activation of PDK1 [64]. 
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1.3.3. Sirtuins (SIRT) 
Sirtuins are nicotinamide adenine dinucleotide (NAD+)-dependent 
deacetylases.  Their primary biological function is to remove acetyl groups 
from modified lysine residues in histone proteins, thus releasing DNA for 
transcription.  This regulation of transcription has been shown to influence 
aging in yeast; the SIR2 gene is overexpressed in response to calorie 
restriction (CR) suppressing rDNA circle formation which results in slow 
ageing [65]. Mammals have seven sirtuin homologues (SIRT1-7). SIRT1, 
SIRT6 and SIRT7 are mainly located in the nucleus while SIRT2 is mainly 
cytosolic although nucleus functions have also been described. SIRT1 and 
SIRT6 are associated to ageing and stress responses. The most studied 
sirtuin, SIRT1, also links to CR while SIRT6 has been found to have low 
expression in many cancers. SIRT3, SIRT4 and SIRT5 are regulating 
mitochondrial proteins and processes. Sirtuins bind substrate polypeptide 
in a cleft between a Rossmann-fold and Zn2+-binding domain allowing the 
substrate to react with the co-substrate NAD+. This reaction releases 
nicotinamide and forms an alkylimidate intermediate which is then 
hydrolyzed [66].  
SIRT1 
Resveratrol (3,5, 4’-trihydroxystilbene), a polyphenolic plant metabolite, 
(Figure 1.8) was the most potent natural compound proposed as a SIRT1 
activator that can mimic CR effects. Resveratrol was identified through a 
high-throughput screen (HTS) from a small molecule library that included 
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analogues of natural effectors such as ε-acetyl lysine, NAD+, NAD+ 
precursors, nucleotides and purinergic ligands [67]. A fluorimetric assay in 
which an acetyl lysine is linked to a fluorophore-labelled peptide substrate 
revealed that resveratrol decreases the Michaelis constant (Km) of SIRT1 
for an acetylated substrate 35-fold and NAD+ over 5-fold without significant 
effect on Vmax [67].  
Subsequent to the discovery of resveratrol, an HTS of a 290,000-compound 
library identified an imidazothiazole scaffold, chemically distinct from 
resveratrol, using a high-throuput in vitro fluorescence assay. This initial 
compound was optimized to give a second generation of SIRT1 activators 
such as compound 8, 9, and 10 (Figure 1.8) which provide better AC50 
values than resveratrol; resveratrol: AC50 = 46.2 µM and Amax = 201%, 
Compound 8: AC50 = 2.9 µM and Amax = 447%, Compound 9: AC50 = 0.36 
µM and Amax = 296%, Compound 10: AC50 = 0.16 µM and Amax = 781% 
[68]. None of the compounds were found to affect the Vmax or Km for NAD+ 
but all of them decreased the Km for the acetylated peptide substrate. 
Isothermal titration calorimetry (ITC) showed that these compounds 
activate SIRT1 by binding to a SIRT1-peptide substrate complex. The 
binding of an acetylated peptide substrate seems to promote a more 
productive conformational change that results in the exposure of an 
allosteric site [68].  
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Figure 1.8. Chemical structure of SIRT1 activators. 
However, a number of reports have claimed that the activation of SIRT1 
seen for resveratrol and imidazothiazoles is an in vitro artefact due to the 
intrinsic fluorescence of the compounds interfering with the assay reagents  
[69-70]. Following this, new studies reported that if the fluorescent 
moieties on the substrates are replaced by hydrophobic residues, this 
results in SIRT1 activation [71-73], which suggests that the fluorophore-
modified peptide substrate “Fluor-de-Lys” 1 (FdL1) possibly mimics natural 
hydrophobic amino acids that occur on native sirtuin substrates.  
More recent work offers a better understanding of the molecular basis of 
SIRT1 activation. Dai et al. has designed an engineered human SIRT1 (Mini-
hSIRT1) which includes the minimum structural elements for the activity of 
SIRT1: (1) the main catalytic domain, (2) the N-terminal STAC (Sirtuin-
activating compounds) binding domain (termed SBD) that is located before 
the main catalytic domain in full-length hSIRT1 and (3) the remote human 
C-terminal regulatory segment (CTR), which enhances the stability and 
activity of the truncated hSIRT1 [20]. The crystal structure of Mini-hSIRT1 
showed that the conserved catalytic domain of all sirtuins [74] comprise a 
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large Rossmann-fold lobe, a small zinc-binding lobe, the three-helical N-
terminal SBD and the β-strands C-terminal CTR peptide [20]. The activator 
was further shown to interact with specific hydrophobic residues (Leu206, 
Thr209, Pro211, Pro212, Leu215, Thr219, Ile223, Ile227) that are located 
on the helix-turn-helix (H2-T-H3) motif within the SBD and form a shallow 
hydrophobic surface with a deeper off-center hydrophobic pocket (Figure 
1.9) [20]. This explains the requirement reported in previous studies for 
specific hydrophobic motifs in allosteric activators for human SIRT1 [71-
73]. After modeling, it was speculated that the N-terminal SBD domain 
swings through the flexible linker towards the active site resulting in a direct 
contact between activator and substrate [20]. 
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Figure 1.9. Structure of Mini-hSIRT1 in complex with 11 and substrate peptide. 
A. Structure of Mini-hSIRT1 in complex with 11 and substrate peptide is shown as 
ribbon diagram (PDB ID 4ZZJ). Compound 11 is shown in orange and substrate 
peptide in green as spheres. The zinc ion is shown as yellow sphere. B. hSIRT1-
binding site of 11 with the interacting hydrophobic residues shown as stick 
diagram in blue. Compound 11 is shown as stick diagram in orange. Oxygen atoms 
are shown in red and nitrogen in blue. Hydrogen bonds are shown as black dashed 
lines. C. Chemical structure of 11. 
This structure determination of a hSIRT1-activator complex provides the 
proof of direct allosteric activation of hSiRT1 by small molecule activators, 
however the detailed mechanism of SIRT1 activation is still elusive. 
SIRT3 and SIRT5 
SIRT5 activation by resveratrol was also detected against the artificial FdL1 
substrate, resulting in approximately 2.5-fold activation at 0.2 mM 
P211
N-terminal 
SBD
A.
Q222T219
L215
P212
T209
E230
N226
B.
C.
Compound 11
Flexible 
linker
Substrate 
peptide
NAD+
analog
L206
I227
N
N
NH
O
O
N
N
CF3
 46 
 
resveratrol concentration. A resveratrol natural metabolite, piceatannol 
(Figure 1.10), which carries an additional hydroxyl group was also found to 
stimulate SIRT3 displaying an AC50 of 0.07±0.02 mM.  
 
Figure 1.10. Chemical structure of piceatannol. 
The crystal structure of human SIRT5 with FdL1 and resveratrol revealed a 
direct contact of resveratrol to the substrate (Figure 1.11). According to 
this, the C-terminal FdL1 fluorophore is positioned in a hydrophobic tunnel 
made by Tyr255 (Y255) and Pro256 (P256). Resveratrol is located in direct 
contact with this FdL1 fluorophore while the A-ring of resveratrol binds 
between Thr278 (T278) and Thr279 (T279) of a loop on one side of FdL1, 
and between Gly72 (G72) and Ala73 (A73) on the other side of it (Figure 
1.11B). The B-ring of resveratrol binds between Arg71(R71) and Gly72 
(G72) while it interacts in a perpendicular direction with the FdL1 
fluorophore (Figure 1.11). Binding of the activator seems to close the active 
site entrance, thereby trapping the bound substrate and resulting in a more 
suitable substrate orientation for the subsequent binding and reaction [75].  
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Figure 1.11. Crystal structure of SIRT5 in complex with the FdL1-peptide and 
resveratrol. A. Overall structure of the SIRT5/FdL1/resveratrol complex (PDB ID 
4HDA) is shown as ribbon diagram. FdL1-peptide and resveratrol are shown as 
spheres in blue and orange respectively. The zinc ion is shown as a yellow sphere. 
B. FdL1-peptide and the resveratrol-binding site with the interacting residues 
shown as stick diagram. Resveratrol and FdL1-peptide are shown as blue and 
orange stick diagrams respectively. Oxygen atoms are shown in red and nitrogen 
in blue. Hydrogen bonds are shown as black dashed lines. 
The crystal structure of SIRT3 in complex with FdL1-peptide and 
piceatannol showed direct contact between FdL1-peptide and piceatannol 
similar to that displayed in the SIRT5/FdL1/resveratrol complex [75] and 
thus is not discussed in detail here.  
SIRT6 
A weak molecule activator (12) for SIRT6 was determined through a 
docking screen and subsequent FdL assays after efforts to identify isoform-
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specific sirtuin inhibitors [76]. A more potent compound (15) was identified 
from a group of activator 12 derivatives, yielding a dose-dependent 
enhancement in SIRT6 activity with an AC50 of 38 µM and a maximum 2-
fold activation [77]. Due to the limited solubility of 15, definitive 
calculations of Km and Vmax values could not be performed. The crystal 
structures of SIRT6 in complex with derivatives of 12 (compound 13, 14 
and 15) were determined revealing the same binding site. The SIRT6 
complex with ADP-ribose and the most potent activator 15 is described 
below as a representative example of the interactions between these 
compounds and SIRT6 [77].  
 
Figure 1.12. Chemical structures of SIRT6 activators  
Compound 15 is located in a hydrophobic pocket at the exit of the SIRT6 
active site that is formed by residues Phe64/82/86 (F64/82/86), Ile61 
(I61), Pro62(P62), Val115(V115) and Met136/157(M136/157). The bottom 
of the pyrrolo[1,2-α] quinoxaline moiety of 15 is exposed to solvent (Figure 
1.13). The pyridine nitrogen atom could potentially make a polar interaction 
and hydrogen bond to the Pro62(P62) backbone oxygen (Figure 1.13B) 
[77]. 
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Figure 1.13. Crystal structure of human SIRT6 in complex with ADP-ribose and 
15. A. Overall structure of the SIRT6/ADP-ribose/15 complex (PDB ID 5MF6) is 
shown as ribbon diagram. Compound 15 and ADP-peptide are shown as spheres 
in orange and blue respectively. The Zinc ion is shown as yellow sphere. B. 
Compound 15-binding site with the interacting residues is shown as stick diagram. 
Compound 15 and ADP-ribose are shown in orange and blue stick diagram 
respectively. Oxygen atoms are shown in red and nitrogen in blue. 
The discovery of compound 15 was followed by the identification of 16 and 
17 after virtual screening of more than 5,000,000 compounds on the 
predicted allosteric site of SIRT6 around Phe82 (F82) and Phe86 (F86) [78]. 
Kinetic characterization of the compounds using an acetylated peptide 
(RHKK-ac-AMC) as substrate showed an activation with AC50 values of 
approximately 174 and 218 µM respectively. Chemical optimization of the 
initial hits resulted in selective SIRT6 activator 18 and 19 with improved 
AC50 values of approximately 10 and 6 µM respectively and significantly 
increased activity by more than 22-fold at 100 µM. Compound 18 and 19 
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were found to decrease the Km by 3.2-fold and 7.8-fold and strongly 
increase the kcat by 7.8-fold and 41-fold respectively for the acetylated 
substrate and NAD+ [78].  
 
Figure 1.14. More chemical structures of SIRT6 activators. 
Both compounds 18 and 19 were found to efficiently increase the 
deacetylation activity of SIRT6 on another physiologically acetylated H3K9 
peptide (KQTARK-ac-STGGWW, H3K9ac) and on the H3K9ac peptide, which 
lacks two tryptophan residues at the C-terminus (KQTARK-ac-STGG) to 
exclude the possibility of nonspecific effects [78]. Cellular SIRT6 activation 
has also been observed through decreasing H3K9ac levels and inhibiting 
the proliferation of human hepatocellular carcinoma (HCC) by the addition 
of 10 [78].  
The crystal structure of SIRT6, H3K9-Myr peptide-ADPR (a product analog 
of deacetylation) with 19 revealed that 19 is located in the same 
hydrophobic pocket as 15 in a location other than the substrate-binding 
site (Figure 1.13) [78]. Compounds 18 and 19 were found to stabilize a 
more active form of SIRT6 through a mechanism similar to that of SIRT6 
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allosteric compound 15 (Figure 1.13).  
As described above, several sirtuin isoforms (SIRT1, SIRT3, SIRT5, SIRT6) 
can be activated by direct activator-substrate contacts and mostly through 
hydrophobic interactions between SIRT6 amino acids and the activators. To 
date, only activators of SIRT1 have been assessed through clinical trials but 
results from these trials suggest that compounds with better 
pharmacokinetic and tolerability profiles are needed. 
1.4. Characterising enzyme activation 
Michaelis-Menten kinetic analysis can be used to assess enzyme activators 
although it doesn't apply as well as in the case of enzyme inhibitors [15]. 
Usually, reversible activators follow Michaelis-Menten kinetics. The ordered 
binding of the substrate to the enzyme following by activator binding is 
analogous to uncompetitive inhibition and represents the simplest 
activation mechanism (eq 1).  
   
where E is the enzyme, S is the substrate, P1 and P2 are the products, A is 
the activator, ES is an enzyme-substrate complex, Ks is the dissociation 
constant for the ES complex, KA is the dissociation constant for the AES 
complex to A+ES, k2 is the rate constant and β is a constant.  
The nonessential activator model (eq 2) which is similar to the proposed 
reversible mixed inhibition mechanism [79] is represented schematically as 
(1) 
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The kinetic constants kcat (kcat = catalytic rate constant), Km (Km = Michaelis 
constant) and Vmax are used to characterise the potency of an enzyme 
activator. Vmax and Km values are determined by fitting a plot of initial 
velocity versus substrate concentration. Consequently, the kcat value is 
measured using the following equation: 
kcat = Vmax/ [E] i 
Where [E]i is the initial enzyme concentration and Vmax is the maximum 
velocity. 
There are two important measures of activation; the maximum activation 
obtained following addition of the activator (Amax) and the concentration of 
the activator required to half-increase the maximum activation of the 
enzyme (AC50). Amax values in combination with structural information of a 
series of activators bound to an enzyme often helps to get more insight 
about the relationship between the chemical structures of compounds and 
the increased activation observed. The AC50 value correlates well with a 
compound’s binding affinity for the enzyme, but there is an important 
caveat for activators that facilitate irreversible modification (this kind of 
activator is not described here) [15]. 
(2) 
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1.5. Discovery of small molecules that activate 
enzymes 
High-Throughput Screening (HTS) is the most widely used approach for 
small molecule discovery in large pharmaceutical organisations. This 
approach uses robotic automation and liquid handling devices to test 
typically up to tens of thousands of compounds per day in an assay.  As 
well as considerable amounts of equipment, HTS has two main 
requirements –a compound library and a robust assay that can be 
performed in miniaturised plate format (usually between 96 to 1536 
samples per plate). Organisations that perform these assays typically invest 
large sums of resources in preparation and curation of the compound library 
which can vary from 100s of thousands to millions of compounds in the 
largest organisations. Screening large numbers of modulators produces a 
number of hits that is lower in small molecule activator screens in 
comparison to inhibitor screens. HTS libraries are typically selected to focus 
on randomly picked compounds as seen with GK or natural metabolites and 
precursors related to the target such as seen with SIRT1. The primary role 
of HTS is to detect lead compounds which are characterized and are then 
optimized [15]. 
Metal contaminants in stock compounds need to be regularly checked as 
they are known to cause the most false positives in activator discovery 
screening approaches.  
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Rational design approaches that mimic endogenous interactions looking for 
allosteric sites on enzymes have also proven successful as seen with PDPK1 
[61]. 
1.6. Previous work 
The York laboratory has previously demonstrated the use of fragments to 
identify the first small-molecule activator 20, 4-ethoxyquinazoline, 
discovered for any glycoside hydrolase, which was in this case the bacterial 
O-GlcNAc hydrolase (OGA) from Bacteroides thetaiotaomicron, BtGH84 
[73]. BtGH84 removes the post-translational attachment of N-
acetylglucosamine (GlcNAc) to the hydroxy groups of serine and threonine 
residues. The small molecule activator (20) (Figure 1.15) was identified 
from a fragment screen of 1,000 compounds in the presence of the known 
O-GlcNAcase inhibitor PUGNAc. In vitro kinetic characterization of the 
compound using 4-methylumbelliferyl-N-acetyl glucosamine (4MU-GlcNAc) 
and p-nitrophenyl-N-acetyl-glucosamine (pNP-GlcNAc) as substrate 
showed an activation with an AC50 value of 3.5 mM. The activator was found 
to decrease the Km value from 1.7 to 0.87 mM and increases the kcat/Km 
values from 28000 to 54000 M-1 s-1 following the nonessential type of 
activation. 
 
Figure 1.15. Chemical structure of GlcNAc hydrolase activator 20. 
N
N
O
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Further optimization of the initial compound using the analogue-by 
catalogue approach resulted in compounds with better AC50 values and 
significantly improved kcat/Km values with factors of around 8-fold (Table 
1.4.); these compounds also had a small effect on the Vmax [73].  
Table 1.4. Activator data from a 4MU-GlcNAc cleavage assay.  
Compound AC50 [µΜ] Amax [%] Km [µΜ] kcat/Km [M-1 s-1] 
- - - 1700 29000 
20 575 284 809 92000 
21 259 371 416 210000 
22 274 329 643 125000 
23 702 234 649 77500 
 
The crystal structure of BtGH84 provides more details about the mechanism 
of activation (Figure 1.16) [73]. BtGH84 is observed in either an ''open'' or 
''closed'' form depending on the interactions made by any ligands. More 
specifically, the loops that present the catalytic and substrate binding 
residues shift between two distinct conformational states (Figure 1.16.B). 
The activator binds directly to the catalytic domain in close proximity to the 
active site of the enzyme. Activator 20 is located on top of Tyr137 (Y137) 
and forms a hydrogen bond with Arg347 (R347). The binding of BtGH84 
activators occurs with the ''loop closed'' form of the enzyme, where the 
Tyr137 (Y137) residue can form a hydrogen bond with catalytic Asp243 
(D243), thus stabilising it, and is potentially enhanced by the π-stacking 
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interaction with the activator. In the “loop open” structure the loop 
containing the catalytic residues Asp242 (D242) and Asp243 (D243) is 
shifted away from the active site and the hydrogen bond between Tyr137 
(Y137) and Asp243 (D243) breaks (Figure 1.16.B) [73]. 
 
Figure 1.16. A. Structural overlay of bound and unbound structure BtGH84. The 
protein backbone is shown as ribbon diagram. BtGH84 bound to 20 and PUGNAc 
(PDB ID 4UR9) is shown in magenta and unbound BtGH84 (PDB ID 2W4X) is 
shown in grey. Compound 20 and PUGNAc are shown as spheres with carbon 
atoms of 20 in orange and of PUGNAC in blue. B. The binding sites of 20 and 
PUGNAc on BtGH84. The protein backbone of the catalytic loop is shown 
schematically with key active site residues in stick representation. The ligands are 
shown as stick diagrams with carbon atoms of 20 in orange and of PUGNAC in 
blue. Hydrogen bonds are shown as black dashed lines.  
Following this study, the small molecule activator was covalently tethered 
to the enzyme; Tyr550 was mutated to Cys and an activated fragment 
Compound 20
PUGNAc
A. B.
Compound 20
R347 Y137
PUGNAc
D243_C
D242
D243_OK166
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designed and synthesized inducing a 35-fold increase in catalytic activity 
(kcat/Km). The successful attachment was confirmed by mass spectroscopy 
and determination of the crystal structure of the covalently modified 
BtGH84 [80]. 
1.7. Fragment based ligand discovery (FBLD) 
 
FBLD has emerged over the last two decades and is now well established 
as an approach for the discovery of novel lead compounds. There are many 
examples of compounds derived from fragments that are in clinical trials, 
Vemurafenid and Venetoclax being two examples (Figure 1.17) that are 
now being used to treat patients with lymphocytic leukaemia and 
metastatic melanoma respectively.  
 
Figure 1.17. Chemical structures of Vemurafenib and Venetoclax. 
The key feature of FBLD is to find a low molecular weight molecule (typically 
between 120-250 Da) by screening a small library (usually 1000-2000 
fragments) that is big enough to probe interactions in the target protein 
but also small enough to minimize unfavourable interactions. Focusing on 
lower molecular weight compounds allows a significant region of chemical 
space to be explored using fewer compounds and avoiding the need to 
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perform very large high-throughput screens. Fragments bind with very 
weak affinity (dissociation constant for complex, KD) requiring high 
compound concentrations during screening and the use of a biophysical 
method that is sensitive enough to reliably detect interactions in the low 
millimolar (mM) range. The most robust screening method is ligand-
observed NMR which has a dynamic range between 10 mM and 100 nM and 
which does not require protein labelling and can be used for proteins of any 
molecular weight. A small fragment hit can be further optimised to larger, 
higher affinity lead compounds. There are three main strategies for the 
development of fragments: growing, merging and linking. In the growing 
approach, which is the most widely used, a fragment hit either provides a 
central scaffold with which to search a database of accessible compounds 
or is used as a basis to grow more effective ligands, by structure-guided 
ligand design. In the linking approach is to link together two fragments that 
bind in adjacent sites while in the merging approach, binding mode 
information of fragments combined with data from literature, HTS hits or 
virtual screening are used to synthesize new scaffolds.  
FBLD has been widely used to identify enzyme inhibitors and protein-
protein interactions. However, very little has been reported on the use of 
FBLD to identify activators of enzyme activity; notable exceptions being the 
activator of BtGH84 described above [73]. For this artificial system wherein 
in mechanistic insight was obtained, the mechanism of activation requires 
that the activator concentration is in excess of the enzyme concentration. 
Darby et al. demonstrated that this limitation can be overcome through 
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developing a rational covalent strategy to design structure guided covalent 
modifications at the site identified from fragment screening leading to a 
modified enzyme with significantly increased activity [80].   
Therefore, FBLD could be an alternative to traditional genetic approaches 
to identify compounds that affect the conformational changes occurring 
with the large number of enzymes that perform catalysis through 
mechanisms involving conformational changes. There are many studies 
wherein in conditions such as pH, solvents and immobilisation were altered 
to affect the activity of industrially important enzymes, but no such studies 
have been reported regarding enzyme activators. Indeed, non-covalent 
activators may not be commercially feasible due to the cost of the 
activators and the probable need to separate activator from the products. 
However, covalent attachment could address this issue by providing the 
foundation for a combined FBLD and tethering approach as a general 
strategy for enzyme optimisation (Figure 1.18). Previous work on subtilisin 
Bacillus lentus demonstrated activation by introducing a cysteine in the 
substrate binding site [81-82]. A different tethering approach includes 
screening of disulphide-containing compounds that react with natural or 
introduced cysteine residues as seen with a kinase [83-84]. Although, these 
strategies show that covalent attachment of a molecule to an enzyme can 
result in increased activity, prior knowledge of structure to rational design 
such modifications is required. 
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This approach may have general applicability for improving the activity of 
enzymes but also for developing probes to study the impact of modulating 
enzymes in cell biology. 
 
Figure 1.18. The FBLD process for discovery of activators. 
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1.8. Aims of the project 
This project is to use FBLD methods to explore the activation by small 
molecules of carbohydrate processing enzymes used in key industrial 
applications. The idea arose from previous research described above on the 
enzyme BtGH84 which can be considered a model system. This provided 
the experience to identify the requirements of an enzyme suitable for 
identification of activators using  fragment based lead discovery (FBLD): 
catalytically active proteins that can be sourced easily and in large 
quantities, for example by being produced through bacterial over-
expression, the availability of  a high resolution crystal structure of the 
enzyme, the availability of an activity assay suitable for screening the 
enzyme’s activity against ligands in high concentrations, and the availability 
of specific inhibitors for assay validation and competition in screening.   
The degradation of cellulose is an important and challenging area for 
industrial biotechnology. The first-generation biofuels and sugar production 
from corn starch industries are one of the largest markets worldwide for 
industrial enzymes. Three enzymes used in these processes were chosen 
for investigation: Two cellulose degrading enzymes (β-glucosidase from 
Trichoderma reesei (TrBgl2) and β-glucosidase from Clostridium 
cellulovorans (CcBglA) and a “Termamyl-like” Geobacillus 
stearothermophilus α-amylase. 
The aims of this project are to identify small molecules that activate these 
enzymes, and to characterise the kinetics, mechanism of action, and any 
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changes to substrate and product profiles. A longer-term aim (not realised 
in this thesis) was to design covalent strategies in order to attach the small 
molecules to the enzymes for constitutive enzyme activation. 
In this thesis, work towards the identification and validation of a series of 
novel activators of the fungal TrBgl2 is described in Chapter 2. Chapter 3 
describes characterisation of binding of the compounds to TrBgl2 using a 
number of biophysical techniques. Chapter 4 describes attempts to 
characterise the structure and interaction of the activator with the enzyme.  
It was not possible to obtain a crystal structure of activator bound to the 
enzyme so advanced NMR experiments were used to generate insight into 
the mechanism of activation. Chapter 5 summarises work on other 
enzymes that were investigated for enzyme activation and Chapter 6 is a 
discussion and conclusion of the results of the thesis. A number of 
established biomolecular and biophysical techniques were used in these 
studies. The relevant section in Chapter 7 (Materials and Methods) provides 
a summary of the principles, limitations and information generated for each 
of the techniques.   
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Chapter 2: Identifying and validating activators of the 
fungal glycosyl hydrolase, TrBgl2 
2.1. Introduction 
The depletion of fossil fuel in combination with the increasing demand for 
energy worldwide has instigated research on alternative and sustainable 
energy sources. Lignocellulosic (LC) biomass such as wood, agricultural 
residues and dedicated energy crops is abundant and available at low cost 
and has received considerable attention as the most promising alternative, 
renewable source for second-generation biofuel production such as 
cellulosic ethanol [85]. This thesis contains studies to identify activators of 
a number of enzymes that can break down cellulose.  
LC biomass, the structural backbone of all plant cell walls, is composed 
mainly of cellulose (40-50%), in combination with hemicellulose (25-30%) 
and lignin (15-20%) [86]. Cellulose is a linear polymer formed by D-glucose 
units linked by β-1,4-glycosidic bonds that are further stabilised by 
hydrogen bonds (Figure 2.1). Cellulose linear chains arrange themselves to 
form rod-like structures of 3-4 nm diameter called microfibrils, which 
contains highly ordered crystalline structures [85]. Hemicellulose is an 
amorphous branched or linear heteropolymer of 200-400 units of different 
hexoses (C6 sugars), pentoses (C5 sugars) and uronic acids. Lignin is a 
crosslinked polymer of the three phenyl propane units p-coumaryl, coniferyl 
and sinapyl alcohol with an amorphous structure [85].  
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Figure 2.1. Schematic representation of cellulose structure and its breakdown to 
D-glucose. 
A mixture of enzymes that together are known as cellulases catalyse 
cellulose degradation and comprise three categories of enzymes; 
endoglucanases (EG) (EC 3.2.1.4), exoglucanases or cellobiohydrolases 
(CBH) (EC 3.2.1.91) and β-glucosidases (BG) (EC 3.2.1.21) [85][87]. 
Endoglucanases cleave the internal β-1,4-glycosidic bonds of cellulose 
microfibrils releasing small fragments. Subsequently, exoglucanases or 
cellobiohydrolases (CBH) act on the reducing and non-reducing ends 
resulting in short chain cello-oligosaccharides such as cellobiose, which are 
hydrolysed into glucose by the action of β-glucosidases (Figure 2.2) 
[85][88]. 
Biotechnology companies, such as Novozymes, have already developed 
cellulolytic enzyme cocktails for LC biomass degradation. Breakdown of LC 
requires pre-treatment of plant material to disrupt the cell wall structure to 
improve access of enzymes to breakdown the cellulose. This is not 
straightforward due to the heterogeneity and the tight three-dimensional 
structure that is created by the main components of LC; lignin, cellulose 
and hemicellulose. The cost of such breakdown has so far limited the 
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amount of LC biomass entering the global energy market. In addition, 
fluctuations in oil prices (political events as well as fracking in the US) has 
recently limited investment. However, the increasing environmental 
concern over burning of fossil fuels may eventually lead to renewed focus 
on LC biomass conversion. Once the LC biomass is pre-treated, the 
accumulation of cellobiose is regarded as the main limiting step in 
degradation due to the low efficiency of β-glucosidase, resulting in 
endoglucanase and exoglucanase inhibition [85][89-93]. Exogenous 
supplementation of β-glucosidase has been used in some case as an 
alternative to overcome this issue [94-95]. Therefore, β-glucosidases with 
improved catalytic activity could address one of the main limiting factors in 
the production of second-generation biofuels. 
 
Figure 2.2. Cellulose degradation. Three classes of enzymes are working 
synergistically for the hydrolysis of cellulose: EG act on the internal β-1,4-
glycosidic bonds releasing small fragments, subsequently CBH act on the reducing 
and non-reducing ends resulting in short chain cello-oligosaccharides and then BG  
hydrolase soluble short cello-oligosaccharides to glucose units [85].  
glucose
cellobiose
Reducing end
cellulose
Exoglucanase
Endoglucanase
β-glucosidase
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2.1.1. Glycosyl hydrolases mechanism  
Glycosyl hydrolases occur in all kingdoms of life and play crucial roles in 
many biological pathways, such as degradation of carbohydrates for 
nutrient uptake [96-97], cellular signalling and defence against pathogen 
attack [98-100]. Glycosyl hydrolases hydrolyse the glycosidic bond 
between carbohydrates or between a carbohydrate and a non-carbohydrate 
moiety. The hydrolysis of the glycosidic bond takes place via general acid 
catalysis by two critical residues: a general acid (proton donor) and a 
nucleophile/base. Hydrolysis occurs with either an overall retention, or an 
overall inversion of the anomeric configuration depending on the spatial 
position of these critical residues [101]. In both mechanisms, the position 
of the general acid (proton donor) is identical however the nucleophile/base 
differs between mechanisms. In retaining enzymes, the base is located near 
to the sugar anomeric carbon whereas in inverting enzymes, there is a 
water molecule between the nucleophile/base and the sugar. This results 
in an average distance between the two catalytic residues of approximately 
5.5 and 10 Å in retaining and inverting enzymes respectively (Figure 2.3) 
[102]. The foundations of these widely adopted mechanistic models of 
glycosyl hydrolases were first proposed by Koshland [1].  
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Figure 2.3. Retaining mechanism of glycosyl hydrolases as first proposed by 
Koshland [1]. 
2.1.2. The fungal glycosyl hydrolase Trichoderma 
reseei, TrBgl2  
Trichoderma reseei produces large amounts of thermostable cellulolytic 
enzymes, which make them attractive targets for industrial applications 
[103]. As such, they have been widely studied in previous years [104-105]. 
Genetically modified β-glucosidases from Trichoderma reesei have been 
commercialised and are included in cellulolytic enzyme cocktails that have 
been developed by companies such as Novozymes 
(http://www.novozymes.com/) and Genencor(http://www.genencor.com/) 
[105]. TrBgl2 belongs to the β-retaining glycoside hydrolase family 1, 
according to the classification of Carbohydrate-Active enzymes (CAZY) 
(http://www.cazy.org/) [106-108]. The structure and biochemical 
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properties of apo TrBgl2 have been elucidated by Jeng [2]. TrBgl2 adopts 
a (α/β)8-ΤΙΜ barrel-like fold as a typical member of the GH1 enzyme (Figure 
2.4). The Protein Interfaces, Surfaces and Assemblies (PISA) server 
predicts that the protein does not share any specific interactions that 
promote oligomerisation. Nevertheless, four protein molecules of TrBgl2 
crystallised in an asymmetric unit. There is no evidence that the tetramer 
is functionally relevant [2].  
 
Figure 2.4. Cartoon representation of the TrBgl2 structure (PDB ID 3AHY). The 
catalytic acid/proton donor, Glu165 (E165) and the catalytic nucleophile/base, 
Glu367 (E367) are shown as red stick diagram. The helices are shown in cyan, 
whereas strands in orange, loops in wheat.  
E367
E165
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Figure 2.5. The secondary structure elements of TrBgl2. Numbering of the 
principal secondary structure elements underlines the (α/β)8-TIM barrel structure; 
additional secondary elements are indicated by letters. The 310-helices are 
indicated by the character η [2]. Figure generated with ESPript 3.0 
(http://espript.ibcp.fr/ESPript/ESPript/) [109].  
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The active site of the enzyme is in a 15-20 Å deep slot-like cleft and is 
surrounded by negatively charged residues. The catalytic acid/proton donor 
is Glu165, located on the TXNEP motif at the end of β-strand 4 (where X is 
a hydrophobic amino acid) (Figure 2.5), while the catalytic nucleophile/base 
is Glu367 for TrBgl2. Two cis-peptide bonds were found, Ala180-Pro181 
and Trp417-Ser418, which their presence is very common for the glycosyl 
hydrolase family 1 [110]. 
A TRIS molecule was found to bind in different orientations in the active 
site of TrBgl2 which forms five direct hydrogen bonds with three residues 
of TrBgl2 (Glu165 (E165), Glu367 (E367) and Glu424 (E424)) resulting in 
slight inhibition of the enzyme (Figure 2.6) [2]. TRIS-based buffers are 
reported as extremely potent glycosidase inhibitors. The positively charged 
amino-center of TRIS partially mimics the positive transition state charge 
of the reaction while the various flexible alkyl hydroxyl moieties mimic the 
oxygen atoms of the sugar substrates. This results in such tight binding 
that it has proven difficult to remove [111-112]. In this project, TRIS was 
only present in the purification scheme (Section 7.5.1) and crystallisation 
conditions (Section 7.9.1) due to the difficulties faced to crystalize TrBgl2 
when TRIS was replaced by HEPES. The rest of the experiments were 
performed in the absence of TRIS to avoid TRIS binding at the active site 
which could potentially displace low affinity ligand binding during the library 
screening.  
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Figure 2.6. TrBgl2 active site (PDB ID 3AHY) is shown as stick diagram. TRIS 
molecule is shown as pink stick diagram. The helices are shown in cyan, whereas 
strands in orange, loops in wheat. Oxygen atoms are shown in red and nitrogen 
in blue. The hydrogen bonds are shown as black dashed lines.   
2.2. Cloning and protein expression 
Trbgl2 gene was cloned into the pET-YSBLIC3C plasmid under the control 
of T7 promoter as described in section 7.2. Figure 2.7 shows the construct 
pET-YSBLIC3C_Trbgl2 which incorporated a His6 cleavable extension on the 
N-terminus.  
DNA sequencing confirmed the success of the cloning process. The 
construct pET-YSBLIC3C_Trbgl2 was transformed into the E. coli BL21 DE3 
bacterial strain and TrBgl2 was successfully overexpressed (as described in 
Section 7.4.1) in soluble form, present in the supernatant after 
centrifugation. The molecular weight of the recombinant protein with the 
His6 cleavable extension on the N-terminus is 55 kDa. 
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Figure 2.7. Plasmid map of pET-YSBLIC3C with Trbgl2 cloned into the YSBL-
LIC3C site. The ORF containing a gene encoding TrBgl2 is under control of the T7 
promoter and begins transcription with an N-terminal 3C-cleavage His6 affinity 
tag. The plasmid map generated using SnapGene® Viewer.   
2.3. Protein production and characterisation 
The protein purification protocol (Section 7.5.1) that was used for TrBgl2 
yields approximately 60 mg/L in optimal conditions. It was isolated in two 
chromatographic steps comprising a Ni2+ affinity capture of the His6-tagged 
protein and subsequent size-exclusion (S200) chromatographic separation 
with purity more than 90% as determined by SDS-PAGE. TrBgl2 protein is 
eluted in TRIS buffer as one population at a volume that was consistent 
with the protein being monomeric (Figure 2.8).  
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Figure 2.8. S200 column TrBgl2 eluate. A. S200 elution peaks detected by UV 
absorbance at 280 nm, obtained after 2 mL injection of TrBgl2 at 17 mg/mL 
concentration. B. SDS PAGE of the Sephacryl S200 column TrBgl2 eluate. Samples 
were electrophoresed on a 12% polyacrylamide gel under denaturing and reducing 
conditions. 
 
Figure 2.9. SDS PAGE of the purified TrBgl2. 1. Broad molecular weight marker, 
2. Cell culture crude extract, 3. Ni-NTA agarose column eluate, 4. Sephacryl S200 
column eluate. Samples were electrophoresed on a 12% polyacrylamide gel under 
denaturing and reducing conditions.  
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2.4. Oligomerisation studies 
Size Exclusion Chromatography with Multi-Angle Light Scattering (SEC-
MALS) analysis was carried out to investigate the oligomeric state of the 
recombinant TrBgl2. SEC-MALS measures absolute molar mass and size of 
molecules in solution using the intensity and the light scattered by the 
sample at a range of angles (Section 7.7) [113]. The analysis revealed the 
presence of one main population of TrBgl2 which corresponds to an average 
mass of approximately 53 kDa (Figure 2.8). This mass was consistent with 
the monomeric form of purified TrBgl2 in solution. 
 
Figure 2.10. SEC-MALS chromatogram of the elution of TrBgl2 from a S200 
10/300 analytical column. The chromatogram displays the UV at 280 nm (dotted 
lines), light scattering at 90o angle, LS, (solid line), refractive index, RI, (dashed 
line) together with the molar mass of each peak calculated by MALS. 
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2.5. Crystal structures 
2.5.1. Apo TrBgl2  
TrBgl2 protein was screened against commercially purchased screens 
(Table 7.1) in a 96-well plate format, using sitting drop vapour diffusion 
methodology. Crystals of apo-TrBgl2 were obtained in the Index Screen 
(Hampton). The initial conditions for protein crystallisation were optimised 
and the best results were obtained with 35% (w/v) PEG 3350 and 0.25 M 
NaCl in 0.1 M TRIS pH 8.5 at 293 K (Section 7.8). The final crystal size was 
obtained in 3 days.  
 
Figure 2.11. Crystals of TrBgl2 protein.   
The apo structure of TrBgl2 was determined and refined at a resolution of 
1.8 Å and contained four protein and TRIS molecules in the asymmetric 
unit (details of data collection, structure determination and refinement are 
in section 7.9.2). Data-processing and refinement statistics are 
summarized in Table 2.1. The crystal structures of the current apo TrBgl2 
and the previously determined apo TrBgl2 (PDB ID 3AHY) were superposed. 
This superposition gives an overall RMSD of 0.39 Å and on the active site 
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residues a RMSD of 0.17 Å which shows that the apo TrBgl2 structure 
obtained is almost identical to the already determined apo TrBgl2 structure 
(PDB ID 3AHY).  
Table 2.1. Data collection and refinement statistics for apoTrBgl2. 
X-ray-source Diamond I04 
Wavelength [A] 0.976250 
Space group P 1 21 1 
a, b, c (Å) 93,04, 103.78, 94.76 
α, β, γ (
ο
) 90.00, 105.56, 90.00 
Resolution range (Å) 74.76-1.83 
Completeness (%) 100 (100) * 
Multiplicity 4.1 (3.8) 
Total reflections 653030 (66163) 
Unique reflections 160317 (15913) 
<Iσ(Ι)> 8.1 (2.3) 
Rmerge 0.089 (0.518) 
Rpim 0.078 (0.455) 
CC1/2 0.990 (0.680) 
Rcryst 0.192 
Rfree 0.238 
Bond [Å] 0.0103 
Angle [
ο
] 1.440 
*Values in parentheses are for highest-resolution shell. 
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2.5.2. TrBgl2 complexed with isofagomine 
 
Crystals of TrBgl2 liganded with the known inhibitor for any glycoside 
hydrolase, isofagomine (Figure 2.12) were obtained after co-crystallisation 
in the same conditions as apo TrBgl2. This novel crystal structure of the 
TrBgl2/isofagomine complex was determined at 1.9 Å resolution and 
contained four protein molecules in the asymmetric unit. 
The structure was solved using the previously determined structure of apo 
TrBgl2 (Section 7.9.2). The electron density of the Fourier difference map, 
calculated by including all refined atoms except isofagomine, showed all 
atoms of the isofagomine which has displaced the TRIS molecule seen in 
the apo-structure. A total of 5 residues of TrBgl2 (Gln16, His119, Glu367, 
Glu424 and Trp425) form seven direct hydrogen bonds with isofagomine 
(Figure 2.12). Data-processing and refinement statistics are summarized 
in Table 2.2. 
 
Figure 2.12. Chemical structure of isofagomine.  
 
 
 
H
N
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Table 2.2. Data collection and refinement statistics for TrBgl2 complexed with 
isofagomine. 
X-ray-source Diamond I04 
Wavelength [A] 0.979499 
Space group P 1 21 1 
a, b, c (Å) 93.003, 103.532, 94.370 
α, β, γ (
ο
) 90.00, 105.285, 90.00 
Resolution range (Å) 74.46-1.93 
Completeness (%) 100(99.9) 
Multiplicity 4.2(4.2) 
Total reflections 568096 (57558) 
Unique reflections 135630 (13462) 
<Iσ(Ι)> 5.7(1.1) 
Rmerge 0.123(1.327) 
Rpim 0.105(0.128) 
CC1/2 0.959(0.385) 
Rcryst 0.20 
Rfree 0.25 
Bond [Å] 0.01 
Angle [
ο
] 1.643 
*Values in parentheses are for highest-resolution shell. 
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Figure 2.13. Isofagomine binding site on TrBgl2. The active site is shown with 
key active site residues as stick diagram. The isofagomine-bound structure is 
shown as stick diagram, with carbon atoms in orange with the SA-FO-FC omit map 
contoured at 2.3σ r.m.s. The isofagomine is bound within TrBgl2 active site and 
forms H-bond to Glu367 (E367), His119 (H119), Gln16 (Q16), Trp 425 (W425) 
and Glu424 (E424). Oxygen atoms are shown in red and nitrogen in blue. 
Hydrogen bonds are shown as black dashed lines. The figure was created in 
CCP4MG [114]. 
2.6. Assay development  
The kinetic properties of TrBgl2 were investigated by continuous assay 
using synthetic p-Nitrophenyl-β-D-glucopyranoside (pNPG) and 4-
methylumbelliferyl-β-D-glucopyranoside (MUG) as substrate at the optimal 
conditions (40oC, pH 6.0) -the previously determined pH and temperature 
optimum for enzymatic activity (Section 7.6) [2]. The Michaelis-Menten 
parameters were calculated (pNPG: kcat = 34±4.5 s-1, Km = 1.73±0.69 mM, 
MUG: kcat = 24±0.4 s-1, Km = 0.46±0.02 mM) (Figure 2.13.) through direct 
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E424 W425
Q16
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N164
E165
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W417
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fit to the Michaelis-Menten equation and are displayed in Table 2.3. TrBgl2 
shows higher affinity and catalytic efficiency toward the latter substrate, 
MUG, which is consistent with the results obtained previously by Jeng [2].  
Table 2.3. Catalytic activity of TrBgl2 
p-Nitrophenyl-β-D-
glucopyranoside 
(pNPG) 
 
4-methylumbelliferyl-β-D-
glucopyranoside 
(MUG) 
 
kcat 
(s-1) 
Km 
(mM) 
kcat/Km 
(s-1 mM-1) 
kcat 
(s-1) 
Km 
(mM) 
kcat/Km 
(s-1 mM-1) 
34±4.5 1.73±0.69 19.68±6.54 24±0.4 0.46±0.02 53±19.8 
 
 
Figure 2.14. Michaelis-Menten plots for TrBgl2. A. pNPG cleavage assay 
Michaelis-Menten plot for TrBgl2 (100 nM) and B. MUG cleavage assay Michaelis-
Menten plot for TrBgl2 (100 nM). 
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The inhibition efficiency of TrBgl2 by the known glycosyl hydrolase inhibitor 
isofagomine was assessed by continuous assay of hydrolysis of MUG at the 
optimal conditions (40oC, pH 6.0) (Figure 2.15) [115-116].   
Isofagomine showed an inhibition of TrBgl2 with an IC50 value of 0.53±0.12 
µM (Figure 2.15; IC50 =compound concentration causing 50% inhibition). 
Isofagomine can thus be used to categorize any hit compound as either 
competitive or non-competitive with isofagomine.  
 
Figure 2.15. Inhibition of TrBgl2 by isofagomine. 
2.7. Fragment screening 
The York fragment library at the time of these experiments consisted of 
570 compounds (MW less than 250 Da). This was screened in the TrBgl2 
enzymatic assay using MUG as substrate at the optimal conditions of the 
enzyme (40oC, pH 6.0). The MUG activity-based assay was previously 
validated with the well-known inhibitor for any glycoside hydrolase, 
isofagomine to show that the assay is robust enough for compound 
screening (Section 2.6).  
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In the initial screen of 570 compounds, 65 fragments inhibited TrBgl2 
activity (Appendix E) and 5 fragments enhanced the ability of TrBgl2 protein 
to cleave MUG. Only 1 (21) (Figure 2.16) of the 5 fragments was 
reconfirmed as activator after repeating the MUG activity-based assay at 
different compound concentrations and running negative controls in order 
to reject any false positives due to possible fluorescent compounds. 
Interestingly, when one of the initial hits (31) (Appendix D) was 
synthesized in-house by James Firth or when different chemical reagents 
such as 1 mM EDTA and 1 mM reducing agents (DTT, TCEP) were added in 
the presence of purchased compound were found to be inactive suggesting 
possible metal contamination.  
 
Figure 2.16. Chemical structure of the initial hit (21)  
Kinetic characterization of the hit compound (21), using 500 µM MUG as a 
substrate and 100 nM TrBgl2 at the optimal conditions (40oC, pH 6.0), 
yielded measurable AC50 values and showed an approximately 160% 
maximum activation (Figure 2.17). 
Rational exploration of commercially available analogues of 21 through an 
“analogue-by-catalogue’’ approach (with the help of Dr James Firth) was 
used to identify compounds that could have greater impact on the 
maximum rate of TrBgl2, better solubility and chemotypes that are 
essential for the activation. 
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Figure 2.17. A. MUG cleavage assay AC50 curve for 21. Substrate concentration 
= 500 µM. B. MUG cleavage assay Michaelis-Menten plot for TrBgl2 in the absence 
and presence of 21. [S] = substrate concentration.  
Replacement of the thiourea group by a thio-amide or replacement of 
sulphur by oxygen yielded an inactive analogue. Other available 
compounds that retained thiourea but had a methyl group meta or para to 
thiourea instead of ortho to thiourea were also inactive. On the other hand, 
as summarised in Table 2.4, chemical groups other than methyl group 
(chrolo, fluoro, methoxy) ortho to thiourea yielded active compounds. 
Attempts to alter the morpholino moiety were more successful and led to 
more active compounds.  
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Table 2.4. Activator data from a MUG cleavage assay.  
Compound Chemical structure AC50 [µM] Amax [%] 
22 
 
 
>5000[1] 
 
~120[1] 
23 
 
 
~1800[1] 
 
~150[1] 
24 
 
 
>5000[1] 
 
~160[1] 
25 
 
 
>5000[2] 
 
~140[2] 
26 
 
 
>5000[2] 
 
~160[2] 
27 
 
 
~1500[2] 
 
~170[2] 
28 
 
~1600[1] ~130[1] 
29 
 
>5000[1] ~140[1] 
[1] Maximum activation obtained with a titration of compound from 30 µM to 3.8 
mM (substrate conc. = 500µM) 
[2] Maximum activation obtained with a titration of compound from 63 µM to 8 
mM (substrate conc. = 500µM) 
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Figure 2.18. MUG cleavage assay AC50 curve for the hit compounds. AC50 values 
obtained with a titration of compounds from 30 µM to 3.8 mM (substrate 
concentration = 500 µM). The optimal temperature (40oC) and the optimal pH of 
TrBgl2 (pH 6.0) were used in the assay. 
 
Figure 2.19. MUG cleavage assay AC50 curve for the hit compounds. AC50 values 
obtained with a titration of compounds from 63 µM to 8 mM (substrate 
concentration = 500 µM). The optimal temperature (40oC) and the optimal pH of 
TrBgl2 (pH 6.0) were used in the assay. 
Methyl groups ortho to thiourea causes the aryl ring to twist out of the 
plane with the thiourea to limit steric clashes between the thiourea and the 
ortho groups. Groups other than methyl groups in the ortho position also 
result in this twist while substituents in the meta or para positions do not 
cause this to happen. This twist of aryl ring out of the plane with thiourea 
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might be essential for the activation and could explain why compounds that 
retained thiourea but had a group meta or para to thiourea instead of ortho 
to thiourea appeared to be inactive. 
Compound 27 retains the important thiourea and the methyl group ortho 
to thiourea generating a better activator of TrBgl2 with improved maximum 
activation and much better solubility (up to 16 mM) (Table 2.4). The 
properties of this most potent activator (27) will be characterised below.   
A series of kinetics experiments were performed with covariation of 
substrate and compound 27 concentration to study the mode of activator 
27 interaction with TrBgl2. Substrate titrations were performed at four 
concentrations of 27 that confer 0, 25, 50 and 75% activation when 
measured at [S] = Km (Figure 2.21). The resulting data were fitted to 
nonessential reversible activator kinetic model, similar to reversible mixed 
inhibition model in which the compound displays binding affinity for both 
the free enzyme and the enzyme-substrate complex.  
 
Figure 2.20. Nonessential reversible activator kinetic model. E = enzyme; S = 
substrate; A = activator; P = product [73].  
In nonessential type activation model, the dissociation constant of the 
substrate and activator are modified in the presence of activator and 
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substrate respectively by the constant α. In addition, the kcat of the enzyme 
in the presence of activator is modified by the constant β (Figure 2.20). The 
modifier α and β were calculated as 0.64 and 1.5 respectively, which 
indicate a decreased dissociation constant for the MUG substrate and 
increased catalytic rate in the presence of 27.   
 
Figure 2.21. Covariation curve fits to the non-essential activator model for 
activator 27. [A] = compound concentration. 
Interestingly, one of the fragment analogues (Table 2.5) appears to inhibit 
TrBgl2. 
Table 2.5. Inhibition data from a MUG cleavage assay. 
Compound Chemical structure IC50 [µM] Maximum inhibition [%] 
30 
 
~300[2] ~95[2] 
[2] Maximum activation obtained with a titration of compound from 63 µM to 8 
mM (substrate conc. = 500µM) 
 
A series of kinetics experiments were performed with covariation of 
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performed at four concentrations of 30 that confer 0, 25, 50 and 75% 
inhibition when measured at [S] = Km (Figure 2.23).  
 
 
Figure 2.22. MUG cleavage assay IC50 curve for inhibitor 30. IC50 values obtained 
with a titration of compounds from 63 µM to 8 mM (substrate concentration = 500 
µM). The optimal temperature (40oC) and the optimal pH of TrBgl2 (pH 6.0) were 
used in the assay. 
 
Figure 2.23. Covariation curve fits to the reverse mixed inhibition model for 
inhibitor 30. [I] = inhibitor concentration 
The resulting data were consistent with reversible mixed inhibition model. 
In this situation, two dissociation constants are defined, one for the binary 
enzyme-inhibitor complex (KI) and one for the ternary ESI complex (αkI). 
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The modifier α was calculated as 3.65 after covariation analysis for 
compound 30 which indicates an increased dissociation constant for the 
MUG substrate in the presence of 30.  
2.8. Effect of chemical reagents  
There have been a number of reports (unpublished) [117] that changes in 
enzyme activity in high concentration screening can be non-specific due to 
contaminants in the ligand sample (such as traces of metals left over from 
synthesis), oxidation of the enzyme or due to aggregation of the ligand.  
 
Figure 2.24. Effect of chemical reagents on the TrBgl2 activity with the hit 
compound (21). A. Effect on the TrBgl2 activity in the presence of 1 mM EDTA, B. 
Effect on the TrBgl2 activity in the presence of 1 mM TCEP and DTT, C. Effect on 
the TrBgl2 activity in the presence of 0.1% Tween-20. The optimal temperature 
(40oC) and the optimal pH of TrBgl2 (pH 6.0) were used in the assay.  
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A series of experiments were therefore performed to investigate the effect 
of different chemical reagents. TrBgl2 with the hit compound 21 was 
assayed in the presence of 1 mM EDTA, 1 mM reducing agents (DTT, TCEP) 
or 0.1% Tween-20 as shown in Figure 2.24. No significant change in the 
activator activity can be observed indicating that the change in activity 
observed is due to specific binding of the activator. 
2.9. Specificity  
Chapter 5 will describe the work on a closely related homology enzyme, 
bacterial β-glycosidase Clostridium cellulovorans, CcBglA (Figure 5.1). The 
activators showed no activity on this enzyme which demonstrates that the 
effect is specific. Interestingly, the inhibitor 30 inhibits both enzymes.  
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2.10. Conclusion 
Expression, purification and kinetic analysis of TrBgl2 was carried out 
successfully following the published work by Jeng et al [2]. TrBgl2 does not 
show any oligomeric pattern after SEC- MALS analysis. The crystal structure 
of apo TrBgl2 and the novel structure of TrBgl2 in complex with the known 
inhibitor, isofagomine, was determined at 1.8 and 1.9 Å resolution, 
respectively and both contained four proteins in the asymmetric unit. In 
the structure of apo TrBgl2 a TRIS molecule was found to bind at the active 
site. This TRIS molecule was displaced by the inhibitor in the crystal 
structure of TrBgl2 in complex with the known inhibitor, isofagomine. 
TrBgl2 showed higher affinity and catalytic efficiency for the MUG substrate 
compared to pNPG confirming previous work [2]. 
In the initial screen of the York 570 fragment library, one compound 
appeared to enhance the ability of TrBgl2 to cleave the substrate (MUG). A 
series of experiments investigated the effect of different chemical reagents 
such as reducing agent and detergent. No significant change in the activator 
activity can be observed indicating that the change in activity observed is 
due to specific binding of the activator. The effect is selective as no such 
activation was observed for the homologous enzyme CcBglA (see Chapter 
5 for details). Characterisation of commercially available analogues of the 
initial hit allowed the identification of activators that have greater impact 
on the maximum rate of TrBgl2 yielding up to 170% increased activity and 
solubility; the AC50 ranged from 1500 to more than 5000 mM.  
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Interestingly, one of the fragment analogues of the initial hit displayed 
inhibition of TrBgl2 and also of CcBglA.  
The kinetics of TrBgl2 activation are consistent with a nonessential 
activation model similar to reverse inhibition. According to this model, the 
activator binds to both free enzyme and enzyme- substrate complex and 
the affinity of the substrate to the enzyme is increased in the presence of 
the activator leading to an enhanced catalytic rate via the enzyme- 
substrate- activator complex.  
Biophysical characterisation is necessary to further investigate and confirm 
the binding of the hit compound to the TrBgl2. This is described in the 
following chapter (Chapter 3). 
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Chapter 3: Characterisation of compound binding to 
TrBgl2 
The previous chapter describes the identification of compounds that bind to 
the enzyme TrBgl2 and increase its enzymatic activity. This chapter 
describes the studies to characterise the binding of the most potent 
activator to the enzyme, using NMR spectroscopy and thermal shift assay 
(TSA). The chapter begins with a description of the generation and initial 
characterisation of the catalytically inactive E367Q mutant of TrBgl2 that 
can be used to study the possible role of the substrate (MUG) to activator 
binding. NMR spectroscopy and TSA are then performed to confirm the 
binding of the hit compound and investigate the role of the substrate in 
ligand binding.  
3.1. Inactive mutant, E367Q TrBgl2 
A Gibson Assembly Cloning Kit (NEB) was used to mutate the catalytic 
nucleophile/base glutamic acid, Glu (E367) to glutamine, Gln (Q) in the 
previously produced plasmid pET-YSBLIC3C_Trbgl2 (Figure 2.4).  
DNA sequencing confirmed the success of the mutagenesis and was 
followed by transformation of the construct into the E. coli BL21 DE3 
bacterial expression strain. The E367Q TrBgl2 inactive mutant was 
successfully overexpressed in soluble form (Section 7.4.1) and purified 
(Section 7.5.1) in the same manner as the wild type TrBgl2 yielding 
 94 
 
approximately 60 mg/L with a purity greater than 90% as determined by 
SDS-PAGE.  
The activity of the E367Q TrBgl2 mutant was tested in a kinetic assay using 
MUG as the substrate at the optimal conditions (40oC, pH 6.0) (Section 
7.8). The mutant appeared to be completely inactive (Figure 3.1).  
 
Figure 3.1. Plot of Relative Fluorescent Units (RFU) over time for TrBgl2 in blue 
and E367Q TrBgl2 in orange.  
3.2. 1H NMR spectroscopy  
 
The binding of ligands to proteins can be studied in solution using NMR 
spectroscopy. The details of the physics of NMR are not described here but 
a summary of the principles of the technique is as follows [118].  
The principle behind NMR is that certain nuclei (such as 1H, 2H, 13C, 15N) 
have a magnetic spin which can be converted from one spin state to another 
by absorbance of radiofrequency radiation. The frequency at which 
radiation is absorbed is dependent on the magnitude of the applied 
magnetic field, the type of atom and the covalent and non-covalent 
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environment of the atom. Therefore, information about the nucleus 
chemical environment can be derived from its resonant frequency. The 
chemical shift is defined by the frequency of the resonance relative to a 
reference compound in a magnetic field. Chemical shift is expressed in parts 
per million (ppm) and is independent of the spectrometer frequency. 
Chemical	shift	(δ) = 	 frequency	of	signal − frequency	of	referencespectrometer	frequency × 10= 
 
J-coupling (or scalar coupling) is a through shared electrons interaction 
between two nuclei in which the spin of one nucleus perturbs the spins of 
the second spin. This effect can cause the so-called “splitting” of the NMR 
signal for each type of nucleus in multiple peaks. In addition, energy can 
also be transferred through space from one population of spin-active nuclei 
(such as 1H, 13C and 15N) to another that is close in space (known as the 
Nuclear Overhauser Effect, NOE).   
As described in Section 7.11., these different properties can be explored 
through experiments using pulse sequences. The 1-dimensional (1D) NMR 
spectrum shows a signal at a given resonance frequency for each nucleus. 
A combination of pulse sequences can generate a 2-dimensional (2D) 
spectrum, where each axis reflects the chemical shift of the two nuclei 
whose relationship is being explored. 
Figure 3.2 shows 1D 1H NMR of TrBgl2 and the typical distribution of peaks 
expected in a folded protein sample. The amide proton region of the 
spectrum is well dispersed and contains distinctive amide peaks. The 
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presence of peaks at around 0.0 ppm (upfield) indicates folded methyl 
groups packing against aromatic amino acids in the hydrophobic core 
(Figure 3.2) [119-120].  
 
Figure 3.2. 1D 1H NMR spectrum of TrBgl2. Spectrum acquired with 100 µM 
protein in D2O.  
The typical 1H 1D spectrum of ligands contains many fewer peaks, as can 
be seen in Figure 3.3. A number of NMR experiments can be carried out 
where changes in this 1D spectrum can report on the ligand binding to a 
protein.  
 
Figure 3.3. 1D 1H NMR spectrum of the initial hit (21). 
All NMR spectra of this section were acquired in a phosphate buffer at pH 
6.0. These conditions avoid the strong interference peaks generated in 
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protonated buffers and is sufficiently acidic to slow the exchange of some 
amide protons so that they are visible in the spectra.  
3.2.1. Characterising the initial hit (21) 
Compound aggregation has been implicated in giving false positive 
(“promiscuous” compounds) in fragment screening [121]. Therefore, a 
simple NMR assay, using dilution experiments, was used to detect possible 
formation of aggregates of 21. This strategy is effective as aggregates are 
sensitive to changes in concentration and structural changes in the 
aggregate and its environment can be detected by 1H NMR spectroscopy. 
Aggregating compounds can be identified by “unusual” features in the 1H 
NMR spectrum, which appear with increasing concentration. For compounds 
that have “unusual” features, the resonances are broad as expected for 
slow-tumbling aggregate in solution, and there are changes in number, 
shape, and chemical shifts. On the other hand, for soluble compounds that 
have “normal” features, the resonances are sharp and only the resonance 
intensities are expected to change as a function of concentration [121].  
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Figure 3.4. NMR aggregation assay. A series of 1H NMR spectra are superimposed 
from various concentrations of 21 (dilutions from 400 to 12 µM). Spectra were 
collected under identical conditions. 
NMR resonances of 21 are sharp at all concentrations and they do not shift 
left or right. In addition, there is no change in the number and shape of the 
resonances indicating a non-aggregating compound. However, for very 
large precipitates and solids that tumble too slowly, resonances are not 
expected, thus resulting in “ΝMR-invisible” large aggregates. To verify the 
presence of “NMR-invisible” aggregates, peak intensities were plotted as a 
function of 21 concentration. Resonance intensities correlated well with the 
nominal and measured concentrations which confirms that 21 is a soluble 
compound [121]. 
3.2.2. 1H STD NMR  
In the saturation transfer difference (STD) NMR experiment, 
radiofrequency pulses are applied to selected protein resonances (usually 
[400 µM]  
[200 µM]
[100 µM]
[50 µM]
[25 µM]
[12 µM]
[ppm]
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the hydrophobic core); this magnetization is transferred to any bound 
ligand during the timescale of the experiment leading to partial saturation 
and a decrease in the intensity of those ligand resonances in the on-
resonance spectrum. A second off-resonance spectrum is subsequently 
recorded with the selective excitation moved to a point where no protein or 
ligand signals are detectable (usually around 30 ppm). Subtraction of the 
on-resonance from the off-resonance spectrum results in the STD NMR 
spectrum which shows only ligand resonances that are in close contact with 
the protein binding site (Section 7.11.1). 
Compound 27 and 30 are soluble under the conditions of the NMR 
experiment.  Their 1H NMR spectra show narrow lines and no signal overlap 
and therefore the STD approach can be utilized as a tool to characterize the 
binding of these fragments to the protein.   
The STD NMR spectra of compound 27 and 30 were acquired at a ligand: 
TrBgl2 ratio of 50 and 25 respectively (Figure 3.5-3.6).   
 
 100 
 
 
Figure 3.5. STD NMR spectrum of 27 (1 mM) with TrBgl2 (20 µM) shown in 
orange and 1H reference spectrum shown in green (500 µM). Spectra were 
collected under identical conditions. 
 
Figure 3.6. STD NMR spectrum of 30 (500 µM) with TrBgl2 (20 µM) shown in 
orange and 1H reference spectrum shown in green (500 µM). Spectra were 
collected under identical conditions. 
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Evidence of fragment binding was observed in the STD NMR with a clear 
signal intensity for both compound 27 and 30 (Figure 3.5-3.6). Addition of 
the known glycosyl hydrolase inhibitor, isofagomine gave no change in 
intensity for either compounds. This allows categorisation of the hit 
compounds as being non-competitive with isofagomine (Figure 3.7-3.8). 
 
Figure 3.7. STD NMR spectrum of 27 (500 µM) with TrBgl2 (20 µM) shown in 
orange and following addition of isofagomine (40 µM) shown in purple where 
several peaks appear to be the same in intensity following addition of isofagomine. 
Spectra were collected under identical conditions. 
 
 
[ppm] 
+ 40 μΜ isofagomine
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Figure 3.8. STD NMR spectrum of 27 (500 µM) with TrBgl2 (20 µM) shown in 
orange and following addition of isofagomine (40 µM) shown in purple at 7.1-7.3 
ppm where several peaks appear to be the same in intensity following addition of 
isofagomine. Spectra were collected under identical conditions. 
3.2.3. 1H STD NMR in addition of the substrate  
 
The possible role of substrate in the binding of 21-like compounds to TrBgl2 
was also investigated with STD NMR using the inactive E367Q TrBgl2 
mutant that was previously generated. The ability of the E367Q TrBgl2 
mutant to still bind the MUG substrate was confirmed by an STD NMR 
experiment (Figure 3.9). 
The STD-NMR spectra of the mixture of 27 with E367Q TrBgl2, MUG with 
E367Q TrBgl2 and both 27 and the MUG substrate with E367Q TrBgl2 were 
acquired under identical conditions and are shown in Figure 3.10. 
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+ 40 μΜ isofagomine
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Figure 3.9. STD NMR spectrum of MUG (500 µM) with E367Q TrBgl2 (20 µM) 
shown in orange and 1H reference spectrum shown in green (500 µM). Spectra 
were collected under identical conditions. 
 
Figure 3.10. STD NMR spectrum of 27 (500 µM) with E367Q TrBgl2 (20 µM) 
shown in green, MUG (500 µM) with E367Q TrBgl2 (20 µM) in orange and both 27 
(500 µM) and MUG (500 µM) with E367Q TrBgl2 (20 µM) in purple. Spectra were 
collected under identical conditions. 
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In the E367Q TrBgl2/27/MUG spectrum, all the STD signals of compound 
27 and MUG are enhanced compared to E367Q TrBgl2/27 and E367Q 
TrBgl2/MUG spectrums (Figure 3.10-3.13). This observation indicates that 
binding to 27 and the MUG substrate were stronger when both were 
present in full accordance with the kinetic experiments which suggest a 
decreased dissociation constant for the 27 and MUG in the presence of MUG 
and 27 respectively (Figure 2.21). These data suggest a significant 
substrate effect in activator binding to TrBgl2 through a nonessential 
reversible activator kinetic model as described in Section 2.7. 
 
Figure 3.11. STD NMR spectrum of 27 (500 µM) with E367Q TrBgl2 (20 µM) 
shown in green, MUG (500 µM) with E367Q TrBgl2 (20 µM) in orange and both 27 
(500 µM) and MUG (500 µM) with E367Q TrBgl2 (20 µM) in purple at 7.10-7.25 
ppm where the peaks for both 27 and the substrate, MUG were enhanced when 
both were present. Spectra were collected under identical conditions. 
[ppm]
+ 500 μΜ MUG
+ 500 μΜ 27
+ 500 μΜ MUG + 500 μΜ 27
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Figure 3.12. STD NMR spectrum of 27 (500 µM) with E367Q TrBgl2 (20 µM) 
shown in green, MUG (500 µM) with E367Q TrBgl2 (20 µM) in orange and both 27 
(500 µM) and MUG (500 µM) with E367Q TrBgl2 (20 µM) in purple at 2.46-2.50 
ppm where the peak for MUG was enhanced following addition of 27. Spectra were 
collected under identical conditions. 
 
Figure 3.13. STD NMR spectrum of 27 (500 µM) with E367Q TrBgl2 (20 µM) 
shown in green, MUG (500 µM) with E367Q TrBgl2 (20 µM) in orange and both 27 
(500 µM) and MUG (500 µM) with E367Q TrBgl2 (20 µM) in purple at 2.16-2.18 
ppm where the peak for 27 was enhanced following addition of MUG. Spectra were 
collected under identical conditions. 
[ppm]
+ 500 μΜ MUG
+ 500 μΜ 27
+ 500 μΜ MUG + 500 μΜ 27 
[ppm]
+ 500 μΜ MUG
+ 500 μΜ 27
+ 500 μΜ MUG + 500 μΜ 27
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3.2.4. Using WaterLOGSY NMR to characterise ligand 
binding  
WaterLOGSY is another ligand-observed NMR experiment in which radiation 
is transferred from bulk water molecules to a ligand. Free ligands 
experience fast tumbling which results in a positive NOE (negative 
WaterLOGSY signal). By contrast, protein-bound ligands experience 
negative NOE effects (positive WaterLOGSY signal) because they are 
tumbling more slowly. Thefore, the observed WaterLOGSY signs are 
opposite for signals of free and protein-bound ligands which allows 
discrimination of binders and non-binders [122-123].   
The WaterLOGSY spectra of the mixture of 30 with E367Q TrBgl2, MUG 
with E367Q TrBgl2 and both 30 and MUG with E367Q TrBgl2 were acquired 
at identical conditions and are shown in Figure 3.14.  
The WaterLOGSY spectrum of 30 with E367Q TrBgl2 shows positive signals 
for the resonances H1, H2, H3, H4 and H5 which represent the typical 
observation of a bound-ligand. The transfer of NOE from the protein to the 
bound ligand depends on distance and flexibility. Directly bound atoms 
experience the most efficient NOE built up, while the NOE transfer is slower 
and of lower magnitude for more distant and flexible regions. This explains 
why the resonances of the H7, H8, H9, H10 behave more like free ligand 
peaks exhibiting negative signal. This behaviour could indicate that this 
region of the ligand is accessible to bulk water because it may not be 
completely buried in the binding site but protrudes from the protein.  
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Figure 3.14. WaterLOGSY spectrum of MUG (500 µM) with E367Q TrBgl2 (20 µM) 
shown in orange, 30 (500 µM) with E367Q TrBgl2 (20 µM) shown in green and 
both MUG (500 µM) and 30 (500 µM) with E367Q TrBgl2 (20 µM) shown in purple. 
Spectra were collected under identical conditions. 
In the E367Q TrBgl2/30/MUG spectrum, the signals for the resonances H1, 
H2, H4, H7, H8, H9 and H10 of compound 30 were degraded compared to 
that for E367Q TrBgl2/30, whereas the signals for the resonances H3 and 
H5 seem to be not affected (Figure 3.14-3.15). It’s likely that the addition 
of MUG exposes the most of compound’s groups to bulk water while H3 and 
H5 are still buried in the protein. This observation indicates weaker 
compound 30 binding in the presence of MUG in full accordance with the 
kinetic experiments performed which show an increased dissociation 
constant for the 30 in the presence of MUG (Figure 2.23).  
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Figure 3.15. WaterLOGSY spectrum of MUG (500 µM) with E367Q TrBgl2 (20 µM) 
shown in orange, 30 (500 µM) with E367Q TrBgl2 (20 µM) shown in green and 
both MUG (500 µM) and 30 (500 µM) with E367Q TrBgl2 (20 µM) shown in purple 
at 8.8-9 ppm where the peak for 30 was degraded following addition of MUG 
substrate. Spectra were collected under identical conditions. 
3.3. Thermal shift assay (TSA) 
TSA can be used to detect ligand binding which changes the thermostability 
of the protein. This approach uses an environmentally sensitive dye, SYPRO 
orange, which binds non-specifically to hydrophobic surfaces and water 
quenches its fluorescence. By gradually increasing the temperature, the 
protein unfolds, and the exposed hydrophobic surfaces bind to the dye, 
increasing the fluorescence by excluding the quenching water to provide an 
estimation of the Tm of the protein. 
The influence of fragment binding on E367Q TrBgl2 stability was assessed 
by using a TSA, which defined the melting temperature (Tm) of E367Q 
TrBgl2 with and without the substrate, MUG (Figure 3.16). 
[ppm]
+ 500 μΜ MUG
+ 500 μΜ 30
+ 500 μΜ MUG + 500 μΜ 30
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Both fragments, compound 27 and 30, have a destabilising effect on apo 
E367Q TrBgl2 by approximately 1 and 4oC respectively. This may be a 
contributing factor to the difficulty in obtaining co-crystal structures of 
these fragments with apo TrBgl2.  
In contrast, MUG has a stabilising effect on E367Q TrBgl2/27 complex 
whereas the addition of MUG does not affect the significantly large 
destabilising effect on E367Q TrBgl2 caused by 30 (Figure 3.16).  
 
Figure 3.16.  TSA data.  A. DSF curves for TrBgl2 in the presence of 27 (8 mM) 
in purple, 27 (8 mM) and MUG (4 mM) in green, 30 (8 mM) in red, 30 (8 mM) 
and MUG (4 mM) in orange compared to TrBgl2 in presence of DMSO in blue and 
TrBgl2 in presence of MUG (4 mM) in pink. B. Maximum shift in melting 
temperature from the reference (ΔTm). 
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3.4. Conclusion  
A ligand-observed NMR experiment (STD NMR) was used to confirm the 
binding of the hit compounds to TrBgl2. These experiments were repeated 
following addition of the known inhibitor (isofagomine) allowing the 
categorisation of the hit compounds as non-competitive with isofagomine.  
In order to investigate the possible role of substrate to compound binding, 
an inactive mutant E367Q TrBgl2 was generated for further ligand- 
observed NMR and TSA experiments. Substrate and activator binding are 
enhanced in the presence of activator and substrate respectively. On the 
other hand, the fragment inhibitor displayed reduced affinity to TrBgl2 in 
the presence of the substrate. In addition, TSA experiments show that the 
substrate causes a stabilising effect on the enzyme-activator complex 
increasing slightly the melting temperature of the enzyme while the binding 
of substrate on enzyme-inhibitor complex significantly destabilises it 
reducing the melting temperature of the enzyme by approximately 4 
degrees. These results are in full agreement with the kinetic experiments 
performed in Section 2.7 and suggest that these series of analogues are 
allosteric modulators of TrBgl2. They can either allow the enzyme/substrate 
complex to adopt a productive conformation increasing the activity of the 
enzyme or a non-productive conformation inhibiting the enzyme.  
Structural insight into the site at which the activator binds is necessary in 
order to investigate the mechanism of the activation. As no X-ray structure 
of the TrBgl2/activator complex is available, more sophisticated NMR 
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experiments are needed which require isotopic labelling of TrBgl2 and are 
described in the following chapter.  
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Chapter 4: Structural characterisation of compound 
binding to TrBgl2 
The previous chapter described characterisation of the binding of the most 
potent activator compound to TrBgl2 using NMR spectroscopy and TSA.  
This included generation of the catalytically inactive E367Q mutant of 
TrBgl2 which is used to study the role of the substrate (MUG) in activator 
binding. This chapter describes experiments that attempt to obtain 
structural insight into the binding site of the activator using protein 
crystallography, NMR spectroscopy and modelling. The objective was to 
obtain a model of the mechanism of activation of TrBgl2. 
4.1. Attempted ligand complex formation  
 
A number of attempts were made to determine the crystal structure of 
TrBgl2 complexed with an activator. Compound 27 was chosen for the 
crystallisation attempts as it appears to be the most soluble at high 
compound concentrations compared to the other analogues.  
The first attempt was to soak 10, 20 and 30 mM final concentration of 
activator 27, into apo TrBgl2 crystals followed by 2-4 h and overnight 
incubations. This proved unsuccessful. Seeding strategies were explored by 
adding microcrystals of apo TrBgl2 to the mixtures of TrBgl2/27 in solution 
in the crystallisation conditions that previously proved successful for 
crystallisation of apo TrBgl2 (Section 7.9.1). Tiny amounts of powdered 
activator were also added directly into apo TrBgl2 crystals letting the 
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activator dissolve slowly. Diffraction data obtained under these conditions 
produced identical models with no observable density corresponding to 
Compound 27. Despite sustained attempts at co-crystallisation, involving 
the rescreening (Table 7.1) of TrBgl2/27, E367Q TrBgl2/MUG/27 and 
TrBgl2/isofagomine/27 mixtures containing saturated substrate (MUG)(8 
mM) and isofagomine (1 mM), it was not possible to identify conditions 
which gave successful growth of crystals with activator bound. The final 
concentration of 27 used in these experiments ranged from 20 to 30 mM. 
It appears that DMSO inhibits crystal growth, as co-crystallisation of a 
TrBgl2/DMSO mixture did not generate crystals in conditions that otherwise 
did give crystals. Therefore, additional attempts were made after dissolving 
27 at 200 mM in ethanol and methanol. These also proved unsuccessful.  
In addition to DMSO, it was also seen that TRIS binds tightly in the active 
site of apo TrBgl2 as it mimics the positive transition state charge of the 
reaction.  As TRIS is present in the crystallisation medium, this presumably 
further reduces the chance of success for soaking crystals with weakly 
binding (1.5 mM) compound 27. Rescreening of apo TrBgl2 for 
crystallisation in buffers that did not contain TRIS was not successful (Table 
7.1).  
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4.2. 15N labelled protein production and purification 
TrBgl2 was expressed from the pET-YSBL3C_Trbgl2 construct (Section 2.2) 
in M9 minimal media supplemented with 15N NH4Cl (Section 7.4.2). The 
protein was purified according to the previously used protocol for TrBgl2 
(Section 2.3) yielding approximately 50 mg/L culture medium.  
4.3. 2D 1H 15N Transverse relaxation-optimised 
spectroscopy (TROSY) NMR  
NMR spectroscopy was used to validate the binding of compound 27 to 
TrBgl2.  The size of the protein (55 KDa) means that the usual 1H 15N HSQC 
experiments were not possible as the fast transverse relaxation times (T2) 
of large molecules leads to line broadening such that the spectra cannot be 
interpreted. An alternate experiment is to use 2D 1H 15N Transverse 
relaxation-optimised spectroscopy (TROSY) NMR which allows studies of 
larger proteins (>30 kDa) [124]. TROSY NMR results in a correlation of a 
protein’s amide proton and nitrogen resonances generating one peak for 
each backbone amide. Ligand binding will induce chemical shifts of the 
protein’s 1H and 15N nuclei (Section 7.11.3).   
4.3.1. 2D 1H 15N TROSY NMR of apo TrBgl2 
 
Figure 4.1 shows the 2D 1H 15N TROSY spectrum of apo TrBgl2 at 120 µM 
in 50 mM TRIS buffer containing 100 mM NaCl and 10% D2O at pH 8.0. The 
2D 1H 15N TROSY spectrum of apo TrBgl2 was also recorded in 50 mM 
phosphate buffer containing 25 mM NaCl and 10% D2O at pH 6.0 in order 
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to be consistent with the buffer used in the kinetics experiments (Section 
2.7), however the spectra quality was poor, with several peaks being 
missing at pH 6.0 that were visible at pH 8.0. Although more amide peaks 
were expected to be in intermediate exchange with bulk solvent at pH 8.0, 
it seems that the protein is less stable in the absence of TRIS and at lower 
salt concentration at pH 6.0 resulting in broadening of the signal beyond 
detection [125]. Therefore, the generally accepted rule that lower pH gives 
better NH spectra seems to not be the case for TrBgl2. The quality of apo 
TrBgl2 spectra obtained at pH 8.0, which includes mainly separate and 
distinguishable peaks is unusually good for such a large protein. Each 
residue that has an amide proton attached to a nitrogen in the peptide bond 
is visible except for proline. The sidechains of asparagine and glutamine 
residues are observed to yield two peaks at the same nitrogen but different 
hydrogen values.  
The 1H 15N TROSY spectrum of apo TrBgl2 contains 403 peaks (including 
sidechains) out of the 529 peaks predicted from the sequence of the TrBgl2 
sample (Figure 4.1).  
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Figure 4.1. 1H 15N TROSY spectrum (700 MHz, 298 K) of apo TrBgl2 at 120 µM. 
The 1H 15N TROSY spectra were unchanged following protein storage at 298 
K for several (~5) days. This demonstrates that the sample is sufficiently 
stable for long multi-dimensional NMR experiments which can be used for 
studies of TrBgl2 in complex with the compound and substrate to 
investigate the mechanism of activation and the possible role of the 
substrate in compound binding.  
4.3.2. 2D 1H 15N TROSY NMR of TrBgl2 with activator 
27 
The activity of 27 on TrBgl2 was first tested in a kinetic assay using MUG 
as the substrate in 50 mM TRIS buffer at pH 8.0. Compound 27 showed 
similar activity on TrBgl2 in both phosphate and TRIS buffer at pH 6.0 and 
8.0, respectively (Figure 4.2).   
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Figure 4.2. MUG cleavage assay AC50 curve for compound 27 at pH 8.0. AC50 
values obtained with a titration of compound from 63 µM to 8 mM (substrate 
concentration = 500 µM). The optimal temperature (40oC) was used in the assay. 
Figure 4.3 shows the TROSY spectrum of apo TrBgl2 at 120 µM (red), 
TrBgl2 at 120 µM with 27 at 8 mM (light purple) and TrBgl2 at 120 µM with 
27 at 16 mM (dark purple) in 50 mM TRIS buffer containing 100 mM NaCl 
and 10% D2O at pH 8.0. The peaks of all spectra are very well dispersed, 
characteristic of a fully folded protein. Following addition of 27 at 8 mM and 
16 mM some changes in amide chemical shifts across the protein were 
observed, clearly indicating a specific binding event and not any 
denaturation or other nonspecific effect (Figure 4.3-4.4).  
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Figure 4.3. 1H 15N TROSY spectrum (700 MHz, 298 K) of apo TrBgl2 (blue) 
overlaid with spectra of TrBgl2 with 27 at 8 mM (green) and 16 mM (magenta) 
concentration. Spectra collected under identical conditions.  
 
Figure 4.4. Expanded panel of 1H 15N TROSY spectrum (700 MHz, 298 K) of apo 
TrBgl2 (blue) overlaid with spectra of TrBgl2 with 27 at 8 mM (green) and 16 mM 
(magenta) concentration. Red arrows indicate the direction of chemical shifts on 
increasing ligand concentration. Spectra collected under identical conditions.  
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4.3.3. 2D 1H 15N TROSY NMR of TrBgl2 with inhibitor 
30 
Figure 4.5 shows the TROSY spectra of apo TrBgl2 at 120 µM (blue) and 
TrBgl2 at 120 µM with 30 at 8 mM (red) in 50 mM TRIS buffer containing 
100 mM NaCl and 10% D2O at pH 8.0. The peaks of all spectra are very 
well dispersed, characteristic of a fully folded protein. Following addition of 
30 at 8 mM, smaller changes in amide chemical shifts were observed than 
those observed on addition of 27 indicating that a binding event had taken 
place. It was not possible to measure the TROSY spectra of TrBgl2 with 30 
at concentration higher than 8 mM due to the limited solubility of the 
compound.  
 
Figure 4.5. 1H 15N TROSY spectrum (700 MHz, 298 K) of TrBgl2 (blue) overlaid 
with spectra of TrBgl2 with 30 at 8 mM (red) concentration. Spectra collected 
under identical conditions. 
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4.3.4. 2D 1H 15N TROSY NMR of E367Q TrBgl2  
The possible role of substrate in fragment binding was further investigated 
by TROSY NMR. Figure 4.6 shows the TROSY spectra of apo E367Q TrBgl2 
at 120 µM in 50 mM TRIS buffer containing 100 mM NaCl and 10% D2O at 
pH 8.0.  
  
Figure 4.6. 1H 15N TROSY spectrum (700 MHz, 298 K) of apo E367Q TrBgl2 
(black) overlaid with spectra of apo TrBgl2 (blue) at 120 µM.  
Although the peaks of the spectra are very well dispersed, characteristic of 
a fully folded protein, the resonances are broader than observed in the wild 
type TrBgl2 spectra (Figure 4.6). This may be due to internal dynamic 
and/or conformational changes of TrBgl2 caused by the inactive mutation 
introduced to the wild type protein. A single amino acid substitution can 
influence protein structure stability and binding affinity with ligands. 
Although, the ability of the E367Q TrBgl2 mutant to still bind the substrate 
(MUG) has been previously confirmed by ligand observed NMR (Section 
3.2.3) and TSA (Section 3.3), such protein changes induced by the E367Q 
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mutation could result in different effect of 27 and MUG substrate binding 
between the wild type and E367Q-mutated protein.     
Comparison of the spectrum when 27 was added at 8 mM concentration to 
the apo E367Q TrBgl2 spectrum (Figure 4.7), several resonances are 
missing. This may be due to potential changes in dynamics as discussed 
above. Although few changes in chemical shifts were observed, there were 
three peaks which have similar chemical shifts in both wild type TrBgl2 and 
inactive mutant E367Q TrBgl2 indicating that 27 binds to the same site to 
both wild type and inactive protein.  
 
Figure 4.7. 1H 15N TROSY spectrum (700 MHz, 298 K) of apo E367Q TrBgl2 (black) 
overlaid with spectra of E367Q TrBgl2 with 27 at 8 mM concentration (green). 
Spectra collected under identical conditions. 
The addition of MUG at 5 mM resulted in several changes in amide chemical 
shifts and signal disappear across the E367Q TrBgl2 consistent with tight 
substrate binding (Figure 4.8).  
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Figure 4.8. 1H 15N TROSY spectrum (700 MHz, 298 K) of apo E367Q TrBgl2 (black) 
overlaid with spectra of E367Q TrBgl2 with MUG at 5 mM concentration (orange). 
Spectra collected under identical conditions. 
 
Figure 4.9. 1H 15N TROSY spectrum (700 MHz, 298 K) of apo E367Q TrBgl2 (black) 
overlaid with spectra of E367Q TrBgl2 with MUG at 5 mM concentration (orange) 
and spectra of E367Q TrBgl2 bound with both MUG and 27 at 5 and 8 mM 
concentration respectively (green). Spectra collected under identical conditions. 
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Following the addition of 27 at 8 mM, the same substrate specific chemical 
shifts were seen indicating that the interaction site remains the same in the 
ternary complex. Moreover, the magnitude of the substrate specific 
chemical shifts that are not affected by 27 binding to the apo protein is 
larger in the ternary complex, compared to the binary E367Q TrBgl2/MUG 
complex, suggesting an increase in the amount of enzyme that is in 
complex with the substrate (Figure 4.7). Therefore, considering that the 
conditions and concentration of MUG were kept identical, these results also 
indicate higher substrate affinity to the enzyme in the presence of the 
activator 27 (Figure 4.9-4.10).  
 
Figure 4.10. Expanded panel of 1H 15N TROSY spectrum (700 MHz, 298 K) of apo 
E367Q TrBgl2 (black) overlaid with spectra of E367Q TrBgl2 with MUG at 5 mM 
concentration (orange) and spectra of E367Q TrBgl2 bound with both MUG and 
27 at 5 and 8 mM concentration respectively (green). Red arrows indicate the 
direction of chemical shifts. Spectra collected under identical conditions. 
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Figure 4.11. 1H 15N TROSY spectrum (700 MHz, 298 K) of apo E367Q TrBgl2 
(black) overlaid with spectra of E367Q TrBgl2 with MUG at 5 mM concentration 
(orange) and spectra of E367Q TrBgl2 bound with both MUG and 30 at 5 and 4 
mM concentration respectively (cyan). Spectra collected under identical 
conditions. 
 
Figure 4.12. Expanded panel of 1H 15N TROSY spectrum (700 MHz, 298 K) of apo 
E367Q TrBgl2 (black) overlaid with spectra of E367Q TrBgl2 with MUG at 5 mM 
concentration (orange) and the spectra of E367Q TrBgl2 bound with both MUG at 
5 mM and 30 at 4 mM (red). Spectra collected under identical conditions. 
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On the other hand, following the addition of 30 at 4 mM, the substrate 
specific chemical shifts were smaller suggesting lower substrate affinity to 
the enzyme in the presence of the fragment inhibitor 30 (Figure 4.11-4.12).  
Both observations are in full agreement with the kinetic experiments 
performed which indicate a decreased and increased dissociation constant 
for MUG in the presence of 27 and 30 respectively (Section 2.7). 
4.3.5. Constant time (CT) 1H 13C HSQC of IIe (I), Val 
(V), and Leu (L) methyl sidechains 
TROSY spectroscopy is the most common approach used for large proteins 
to determine chemical shift perturbations (CSPs) caused by ligand binding. 
Backbone TROSY CSPs are limited by the fact that most ligand-protein 
interactions are mediated by sidechains that are distant from the detected 
backbone amides. Methyl groups are frequently located in hydrophobic 
cores and at protein-protein interfaces and NOEs between methyl protons 
provide valuable structural restraints [126-127]. Methyl resonances are 
also usually intense since there are three protons per methyl group and 
quite narrow due to rapid rotation around their three-fold axis so that even 
for high molecular weight systems methyl spectra are of good quality [126-
127]. Selective protonation of methyl groups allows protons to be retained 
in key positions of a structure to allow study of specific features of structure 
or dynamics. Methyl groups could also serve as probes of molecular 
interactions and additional chemical shift studies [127]. To investigate 
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ligand-IVL methyl side-chains interactions, therefore, an IVL methyl 
protonated sample of deuterated TrBgl2 (Section 7.4.4) was used. 
A CT 1H 13C HSQC experiment is the carbon equivalent of the 1H 15N HSQC 
measuring the correlation of the H-C resonances in the protein (clear 
description in Section 7.11.4). Ligand binding induces chemical shifts of the 
protein’s H-C nuclei. Figure 4.13 shows the CT 1H 13C HSQC spectra of a 
methyl protonated {I(δ1 only), L(13CH3,12CD3), V(13CH3,12CD3)} U-[15N, 
13C, 2H] sample of apo TrBgl2 at 250 µM (green) in 50 mM TRIS buffer 
containing 100 mM NaCl and 10% D2O at pH 8.0. 
 
Figure 4.13. CT 1H 13C HSQC spectrum of an IVL methyl protonated sample (700 
MHz, 298 K) of apo TrBgl2 at 250 µM. 
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Figure 4.14. CT 1H 13C HSQC spectrum of an IVL methyl protonated sample (700 
MHz, 298 K) of apo TrBgl2 (purple) overlaid with spectra of TrBgl2 with 27 at 8 
mM (red). Spectra collected under identical conditions. 
Following addition of 27 at 8 mM concentration, significant chemical shift 
perturbations for several protein methyl groups were observed confirming 
binding of 27 to the enzyme (Figure 4.14).  
4.4. Resonance assignment 
The NMR spectra presented so far in this chapter show that only a few 
chemical shifts are affected by binding of the activator, consistent with the 
activator binding to a specific site on the enzyme. If the resonance 
assignment of TrBgl2 is available, mapping of chemical shifts onto the 
available apo structure of TrBgl2 can provide information about the 
activator’s binding site. 
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Historically, the complete assignment of resonances is usually only possible 
for proteins of less than 30 kDa [127-129]. TrBgl2 has a molecular weight 
of 55 kDa, which is usually considered too large for analysis by many NMR 
methods. However, the relatively good quality of the spectra observed 
above (Figure 4.1) using the TROSY-based pulse sequences and the 
apparent stability of the protein considering its size suggested that it could 
be possible, through challenging, to obtain partial assignments for TrBgl2.  
Replacement of the non-exchangeable protons by deuterons while retaining 
1H occupancy at backbone amide positions has helped assignment through 
spin diffusion suppression and reduction in relaxation rates of 13C and 15N 
spins. Due to the efficient distribution of magnetization through the spin 
system of dipolar coupled protons, the linewidths of the NMR signals 
increase with molecular weight thereby lowering signal-to-noise. The use 
of a deuterated protein reduces the number of proton signals and therefore, 
eliminate many relaxation pathways and improve the signal-to-noise of 
NMR spectra [130]. Deuteration also decreases the dipolar interaction 
between 13C or 15N and the bound proton spin which mainly causes 
relaxation. The relaxation times of 13C and 15N spins are then increased 
which results in smaller linewidths and higher signal-to-noise [131].  
Protein samples were therefore generated with uniform 15N, 13C, 2H isotopic 
backbone labelling and methyl protonated {I(δ1 only), L(13CH3, 12CD3), 
V(13CH3, 12CD3} U-[15N, 13C, 2H] sidechain labelling (Section 7.4.4). This 
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protein was then used in experiments that correlate resonances via both 
bond and space interactions between the nuclei [126] (an overview of 
several experiments used for assignment of proteins by NMR can be found 
in [132]). This section outlines the approach taken to assign the resonances 
observed for apo TrBgl2.  
4.4.1. Backbone assignments 
Backbone sequential assignments of TrBg2 were made using a set of seven 
3D experiments; HNCO, HN(CA)CO, HNCA, HN(CO)CA, HN(CO)CACB, 
HNCACB and HN(CA)CB. In these experiments, different nuclei are 
correlated on the basis of via bond scalar couplings  (a fuller description is 
provided in Appendix A) [132]. The nuclei enclosed in parentheses above 
were not frequency labelled during the pulse sequence. Each of these 
experiments expands the 2D 1H 15N TROSY into a third 13C dimension, thus 
allowing correlation of 13C resonances to the amide backbone resonances 
identified in the TROSY spectra.  
Strips of the seven 3D spectra at a specific 1H 15N resonance TROSY peak 
were displayed and compared together in pairs (Figure 4.15). The HNCACB 
and HN(CO)CACB spectra show the resonances of Cα and Cβ correlated to 
a specific amide resonance. The HNCACB spectrum contains the Cα and Cβ 
shifts of the current (i) and previous (i-1) residues as contrasted with the 
HN(CO)CACB spectrum, which only has peaks for Cα and Cβ of the i-1 
residue (Figure 4.15). To compliment this, HNCA, HN(CO)CA and HN(CA)CB 
experiments were recorded allowing further assignment. The HNCA and 
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HN(CO)CA spectra contains only the Cα shifts compare to HNCACB and 
HN(CO)CACB spectra while the HN(CA)CB spectra contains the Cβ shifts of 
the current (i) and previous (i-1) residue. These experiments were useful 
in the cases where Cα and Cβ resonances were not visible in the HNCACB 
and HN(CO)CACB spectra. By an analogous method, the C’ resonances can 
be assigned to amide frequencies using the HNCO with the HN(CA)CO 
experiments which show the C’ shifts of the previous (i-1) and current (i) 
residues respectively. The HNCO and HNCA–type spectra are in general 
more sensitive than the HNCACB spectra, however they provide less 
information about the amino acid type than the Cβ chemical shift [132].  
 
Figure 4.15. 13C 1H strips from 3D HN(CO)CACB (first strip of each amino acid) 
and HNCACB (second strip of each amino acid) spectrum (700MHz, 298 K) of 2H, 
15N, 13C TrBgl2.  
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The strips were taken at 15N chemical shifts of residues 127-130 and 
centered on the corresponding 1H chemical shifts (indicated at the bottom 
of each strip). The sequence-specific assignment is indicated at the top of 
each strip by the one-letter amino acid code and the sequence number. The 
sequential and intra-residual connectivities are indicated by dashed lines. 
13Cα and 13Cβ peaks are coloured in blue and black, respectively.  
Chemical shifts of each backbone experiment were submitted to the 
automated resonance assignment algorithm FLYA to determine as far as 
possible sequential assignment of TrBgl2 peaks on the basis of peak lists 
from through-bond experiments [133]. The initial FLYA run assigned 
approximately 50% of the backbone to a high degree of confidence. The 
assigned peaks were inspected manually by visually correlating i peaks to 
(i-1) peaks of the following spin system and adjusted in areas of 
uncertainty. The assigned peaks and regions of sequence that caused 
difficulty in assignment by FLYA were inspected manually.  
The sidechain resonances of tryptophans are assigned by combined 
analysis of the backbone experiments and the 15N-resolved NOESY and 13C-
resolved NOESY spectra. The 13C-resolved NOESY experiment did not yield 
highly resolved spectra with good sensitivity, preventing assignments for 
tryptophan (W) sidechains in TrBgl2.    
Recombinant TrBgl2 consists of 488 amino acids (including N-terminal His6 
cleavable tag). In total, 265 backbone amide resonances from 459 non-
proline residues were sequentially assigned (Figure 4.17). Some regions of 
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the sequence were unable to be assigned due to missing peaks, spectral 
overlap, many spin systems with similar chemical shifts, or a combination 
of all these factors (Figure 4.16).  
 
Figure 4.16. Sequence of TrBgl2 used for NMR studies. Tag residues are 
underlined, and the assigned sequence is coloured green.  
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Figure 4.17. 2D 1H 15N TROSY spectrum (700 MHz, 298 K) of 15N-labeled TrBgl2. 
Backbone resonance peaks are indicated by the one-letter amino acid code and 
the sequence number is shown in black.  
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TrBgl2 secondary structure motifs were predicted by the TALOS-N software 
(Figure 4.18) [134]. The software indicated that the overall secondary 
structures are in agreement with the X-ray structure of TrBgl2 (PDB ID 
3AHY) [2].  
 
Figure 4.18. Secondary structure prediction of TrBgl2 analyzed with TALOS-N 
using the assigned chemical shifts compared to the secondary structure of the X-
ray structure of TrBgl2. Top: colored bars (red and blue bars indicate a-helix and 
b-strands respectively) show the secondary structure type predicted by TALOS-N. 
The bar height represents the prediction confidence. The black line shows the 
predicted S^2 order parameter, a measure of flexibility. Bottom: the secondary 
structure of TrBgl2 as determined by X-ray crystallography (PDB ID 3AHY) [2].  
4.4.2. IIe (I), Val (V), and Leu (L) Methyl sidechain 
assignment  
As most Cα, Cβ and C’ assignments are known during backbone 
assignment, methyl resonances can be assigned using COSY-type 
magnetisation transfers from the methyl carbon and proton to already 
assigned atoms [129]. This approach makes use of a biosynthetic precursor 
that leads to labelling of Leu (L) and Val (V) at only a single methyl position 
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resulting in linear arrangement of coupled carbons for these residues 
[126][129]. 
Data was then added from experiments that relay magnetisation from 
methyl carbon and proton spins of Ile (I), Leu (L) and Val (V) residues to 
aliphatic carbons (HMCM(CG)CBCA) and from methyl groups to carbonyls 
and back (Val-HMCM(CBCA)CO and Ile, Leu-HMCM(CGCBCA)CO) (clear 
description in Appendix A) [126][135]. Further, additional methyl-methyl 
NOESY, 15N-resolved NOESY and 13C-resolved NOESY experiments (clear 
description in Appendix A) were performed, in which the different nuclei are 
correlated via space interactions. The known crystal structure of apo TrBgl2 
with respect to the already assigned backbone peak lists was also analysed 
to allow more complete assignment of the expected resonances. Rerunning 
the automated resonance assignment algorithm (FLYA) on the combined 
data resulted in an improved output. The assigned peaks were inspected 
manually. 
Methyl side-chains were assigned by identifying the corresponding Cα, Cβ 
and C’ resonances in the relevant amide strip of the HNCA, HNCACB and 
HN(CA)CO spectra, respectively. Further confirmation of the assignment 
was performed by comparison with the through space 3D CH3-CH3 NOESY, 
15N-resolved NOESY and 13C-resolved NOESY spectra.  
In total, approximately 55% of methyl sidechain resonance peaks were 
assigned (Figure 4.19). 
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Figure 4.19. 1H 13C HSQC spectrum (700 MHz, 298 K) of an IVL methyl 
protonated sample of apo TrBgl2. Methyl sidechain resonances are indicated by 
the one-letter amino acid code and the sequence number is shown in black.  
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4.5. Binding site mapping   
CSPs do not completely correlate with proximity to the ligand-binding site 
as CSPs can also result from ligand-induced conformational changes. 
Nevertheless, when ligand binding does not cause significant 
conformational changes, most of the largest CSPs are caused by the ligand 
contacting atoms within or around the ligand binding site. However, 
resonances that are shifted by nearby aromatic groups undergo large CSPs 
even when distant from the ligand binding site [136-137].  
A high percentage of backbone assignments of a protein is required to 
locate the binding site of a ligand based on CSPs. This allows correlation of 
the CSPs to amino acids within the protein sequence. When the 3D 
structure is available, as is the case for TrBgl2, CSPs can be mapped to the 
surface of the protein structure and clusters of shifts in continuous 
structural regions of the protein can be used to predict ligand binding sites. 
The assigned backbone CSPs in the TROSY spectrum and the IVL methyl 
chemical shifts in the 1H 13C HSQC after compound 27 titration were 
mapped onto the known crystal structure of TrBgl2 using the resonance 
peaks determined for the protein.  
A scaled Pythagoras equation was used to calculate backbone CSP values 
(Δδ) for each resonance following addition of 27. The typical range of shifts 
is significantly different for 1H, 13C and 15N nuclei which means the 
importance of changes in one dimension would be overstated without the 
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adjustment. Therefore, a scaling factor (c) of 0.1 and 0.2 was used to 
balance the contributions of 1H-15N and 1H-13C respectively to the 
magnitude of the perturbation [137]. CSPs were quantified using an 
adjusted chemical shift value (Δδ) of the following equation:  
Δδ = >(𝛥𝛿H)A + (𝑐𝛥𝛿N/C)A 
Standard practice was used to decide which shifts are large enough to be 
considered indicators of 27 interaction to TrBgl2. The standard deviation 
(SD) and average (AVG) of the shift changes were first calculated and 
residues for which the shift change is greater than the sum of these two 
values (SD, AVG) were identified as statistically significant shifts [138]. The 
value of 0.012 ppm and 0.01 ppm was calculated as the cut-off for the 
backbone and methyl chemical shifts, respectively.  
 
Figure 4.20. A histogram showing the backbone chemical shift value (Δ) as a 
function of the TrBgl2 sequence and across the titration with 27 against apo 
TrBgl2. The threshold value for Δδ used as a criterion for significance (0.012) is 
marked using dashed line. Backbone CSPs corresponding to residues with Δδ > 
0.025 are coloured red, Δδ values 0.012-0.025 are shaded in a gradient yellow-
orange-red.  
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Figure 4.21. Amide chemical shift perturbations caused by the presence of 27 
mapped to the protein surface of the crystal structure of TrBgl2. Backbone CSPs 
corresponding to residues with Δδ > 0.025 are coloured red, Δδ values 0.012-
0.025 are shaded in a gradient yellow-orange-red. Unassigned residue are 
coloured grey. The figure was created in PyMOL. 
 
Figure 4.22. A histogram showing the methyl chemical shift value (Δ) as a 
function of the TrBgl2 sequence and across the titration with 27 against apo 
TrBgl2. The threshold value for Δδ used as a criterion for significance (0.011) is 
marked using dashed line.  
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Table 4.1. List of assigned CSPs after compound 27 titration.  
Backbone TROSY CSPs 
D22, G27, S29, T33, S46, Y130, 
L133, G175, S176, T178, F179, 
R183, L224, G226, F228, M295, 
N296, S300, N301, I303, V321, 
W339, A345, W425, Y440 
1H 13C HSQC of IVL methyl CSPs I17, V21, L167, I171, I303, V316, V321 
 
 
Figure 4.23. A small region of 1H 15N TROSY spectrum (700 MHz, 298 K) of apo 
TrBgl2 (blue) overlaid with spectra of TrBgl2 with 27 at 8 mM (green) and 16 mM 
(magenta) concentration. The figure shows three backbone CSPs (S46, G175, 
G226) which correspond to residues with Δδ > 0.025. Red arrows indicate the 
direction of chemical shifts on increasing ligand concentration. Spectra collected 
under identical conditions. 
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Figure 4.24. A small region of 1H 13C HSQC spectrum (700 MHz, 298 K) of an IVL 
methyl protonated sample of apo TrBgl2 (purple) overlaid with spectra of TrBgl2 
with 27 at 8 mM (red) concentration. The figure shows one methyl CSPs (L167) 
which corresponds to residue with Δδ > 0.011. Red arrows indicate the direction 
of chemical shifts on increasing ligand concentration. Spectra collected under 
identical conditions. 
It should be highlighted that the degree of saturation affects the absolute 
CSP measured. Ligands that bind in a well-defined orientation result in 
larger CSPs compare to ligands that bind in a less defined orientation [138]. 
In this system, the larger shift in Δδ is only 0.06 ppm. Due to the very weak 
binding of 27, it was not possible to use the ligand’s saturating 
concentration. Therefore, the observed CSPs represent only a proportion of 
the bound state. It is likely that the ligand adopts multiple bound 
conformations and the shifts are averaged which results in smaller CSPs 
[138].  
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Mapping CSPs of 27 to the TrBgl2 structure indicated the entrance of the 
active site as binding site (Figure 4.25). Although, most of the CSPs are 
located at the entrance of the active site, residues at the surrounding part 
of the active site are also significantly affected, potentially indicating that 
conformational changes are induced in the protein upon binding of activator 
27. 
 
Figure 4.25. Amide and IVL methyl chemical shift perturbations caused by the 
presence of 27 mapped to the protein surface of the crystal structure of TrBgl2. 
Backbone CSPs are coloured green and IVL methyl CSPs are coloured blue. 
Unassigned residues are coloured grey. The figure was created in PyMOL. 
The backbone CSPs (G27, S46, D52,  H127, L133, S169,  G175, G226, 
W232, F228, G288, G294, M295, N296, S300, N301, T335, W339, L340, 
I372, W425, F433) in the TROSY spectrum after adding inhibitor 30 were 
also mapped onto the known crystal structure of TrBgl2 (Appendix C; Figure 
C.1). The pattern of mapped CSPs of 30 is quite similar to that of 27 
indicating that the two compounds bind in the same binding site.    
180o
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4.6. Molecular docking  
The known 3D structure of TrBgl2 was used for molecular docking studies 
using HADDOCK-based semi-rigid, data-driven docking to investigate 
structurally the mechanism of the activation of TrBgl2 by activator 27 [139, 
140]. Although, the observed CSPs reflect only a fraction of the bound 
enzyme, docking is still informative as the CSPs are not used quantitatively 
but qualitatively. 
HADDOCK experiments were performed using the available apo structure 
of TrBgl2 (PDB ID 3AHY), the chemical structure of compound 27 and the 
larger CSPs located within the TrBgl2 active site (backbone CSPs: G175, 
S176, T178, F179, G226, M295, N296, N301, W339 and W425; IVL methyl 
group CPSs: L167, I171, V316 and V321) as these residues are more likely 
to directly interact with the ligand. 
The lowest energy cluster (model 1) exhibited a HADDOCK score of -45.8 
and a minimum restraint violation energy of 77.4 kcal/mol, while the next 
lowest energy ligand cluster (model 2) exhibited a HADDOCK score and a 
minimum restraint violation energy of -40.1 and 85.9 kcal/mol respectively.  
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Figure 4.26. Overlays of the lowest energy HADDOCK model 1 structures of 27 
docked with TrBgl2 using the backbone amide and methyl CSPs interpreted to 
locate at the TrBgl2’s active site. The figure was created in PyMOL Backbone 
(G175, S176, T178, F179, G226, M295, N296, N301, W339, W425) and IVL 
methyl group (L167, I171, V316, V321) CSPs used in HADDOCK are shown in 
green and blue respectively. The figure was created in PyMOL. 
HADDOCK model 1 structures were superimposed on the crystal structure 
of a close homologue of TrBgl2, termite Neotermes koshunensis glycosyl 
hydrolase (NkBgl-E193D) in complex with this enzyme’s substrate, p-
Nitrophenyl-β-D-glucopyranoside (pNPG) [2]. When observing the 
superposed structures, the substrate of NkBgl-E193D, pNPG, overlaps with 
the determined binding site for compound 27. However, the kinetic 
(Section 2.7), NMR (Section 3.2.1-4.3.4) and TSA experiments (Section 
3.3) performed have shown that 27 binds to both free enzyme and 
enzyme/MUG complex suggesting that it binds to an allosteric binding site. 
Notably, substrate and activator binding are enhanced following addition of 
the activator and MUG respectively stabilising the TrBgl2/27/MUG complex. 
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Figure 4.27. Structural overlay of the lowest energy HADDOCK model 1 
structures with the close homologue of TrBgl2, NkBgl-E193D bound to pNPG, (PDB 
ID 3AI0) in yellow. Backbone’s (G175, S176, T178, F179, G226, M295, N296, 
N301, W339, W425) and IVL methyl group’s (L167, I171, V316, V321) CSPs used 
in HADDOCK are shown in green and blue respectively. The figure was created in 
PyMOL. 
Due to a possible substrate role in the compound binding to TrBgl2, we 
sought to generate a model of the TrBgl2/MUG complex, and then 
TrBgl2/MUG/27 complex after docking 27 into the TrBgl2/MUG model using 
HADDOCK. 
Although attempts were made to determine the crystal structure of E367Q 
TrBgl2 complexed to MUG were not successful, the crystal structure of 
NkBgl-E193D in complex with pNPG as determined by Jeng is available [2]. 
NkBgl and TrBgl2 share a highly conserved active site. After binding of the 
substrate (pNPG) on NkBgl-E193D significant changes in the structure 
occurred at the sidechains of residues Glu/Asp193, Asp253, Trp374, 
Trp444, Asn449 and Glu451 (Appendix B). The substrate pNPG was 
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observed to form direct hydrogen bonds to Gln45, His148, Asn255, Glu402, 
Trp444, Glu451 and Trp452 of NkBgl-E193D corresponding to residues 
Gln16, His119, Asp227, Glu367, Trp417, Glu424 and Trp425 respectively 
of TrBgl2 after structural alignment performed between the homologues 
(Figure 4.28).  
 
Figure 4.28. Structural overlay of TrBgl2 and the homologue NkBgl-E193D bound 
to pNPG active site is shown as stick diagram. TrBgl2 (PDB ID 3AHY) is shown in 
cyan and NkBgl-E193D bound to pNPG (PDB ID 3AI0) is shown in green. pNPG is 
shown as yellow stick diagram. Hydrogen bonds are shown as black dashed lines. 
First, HADDOCK was performed using the apo structure of TrBgl2 (PDB ID 
3AHY), the chemical structure of the substrate (MUG) and the amino acids 
of TrBgl2 defined (Gln16, His119, Glu367, Trp417, Glu424, Trp425) after 
analysis of structural overlay of TrBgl2 and NtBgl2 bound to pNPG (PDB ID 
3AI0) (Figure 4.28). The amino acid, Asp227 that directly interacts with the 
nitrophenyl part of pNPG substrate, was excluded.  
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N255/D227
E402/E367
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The unique TrBgl2/MUG model 3 exhibited a HADDOCK score of -60 and a 
minimum restraint violation energy of 1.1 kcal/mol (Figure 4.29).  
 
Figure 4.29. Structural overlay of TrBgl2 bound to MUG (Model 3) and the 
homologue NkBgl-E193D bound to pNPG active site is shown as stick diagram. 
TrBgl2 bound to MUG (Model 3) is shown in cyan and NkBgl-E193D bound to pNPG 
(PDB ID 3AI0) is shown in green. MUG is shown in white and pNPG is shown in 
yellow, both as stick diagrams. Hydrogen bonds are shown as black dashed lines. 
Next, HADDOCK was used to generate a model of compound 27 docked 
into the TrBgl2/MUG cluster using model 3, the chemical structure of 27 
and the CSPs interpreted belonging to residues located at the TrBgl2 active 
site (backbone CSPs: G175, S176, T178, F179, G226, M295, N296, N301, 
W339 and W425; IVL methyl group CPSs: L167, I171, V316 and V321).  
The lowest energy cluster (Model 4) exhibited a HADDOCK score of -19.5 
and a minimum restraint violation energy of 35.4 kcal/mol, whereas the 
next ligand cluster (Model 5) exhibited a HADDOCK score and minimal 
Q45/Q16
H148/H119
E402/E367
W444/W417
E451/E424
pNPG
MUG
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restraint violation energy of -8.1 and 72.1 kcal/mol, respectively. Both 
models reveal the binding site of 27 at the substrate entrance of TrBgl2, 
confirming the experiments described above, and suggests a possible direct 
activator 27/MUG contact (Figure 4.30). 
  
Figure 4.30. Overlays of the lowest energy HADDOCK model structures of 27 
docked with TrBgl2/MUG complex using the backbone amide and methyl CSPs 
interpreted to locate at the TrBgl2’s active site. The figure was created in PyMOL. 
Although, mapping of CSPs and molecular docking provides information 
about the activator 27 binding site, determination of the precise orientation 
of ligand and intermolecular contacts is beyond the capabilities of CSP 
analysis. In principle, intermolecular NOE experiments should be able to 
detect interactions between the IVL methyl groups within the activator 
binding site and 27 that are within NOE distance (usually 5 Å). Although in 
this case, only a few IVL methyl groups of the active site could be assigned 
it was possible that some interactions may be observed. 
MUG
Compound 27
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Once binding of 27 to TrBgl2 was saturated, a 2D NOESY (Bruker pulse 
sequence: noesygpphwgx2) and a 3D 13C NOESY-HSQC (Bruker pulse 
sequence: hsqcgpnowgx33d) filtering out 13C- and 15N in the direct 
dimension were recorded [141-142] by Dr Alex Heyam (University of York) 
in collaboration with ZoBio B.V. (Leiden, The Netherlands). Unfortunately, 
intermolecular NOEs between the ligand resonances and IVL methyl groups 
as well as backbone amide protons of TrBgl2 were not detected. Although 
intermolecular NOE approaches are quite powerful, they suffer from several 
limitations regarding the requirement for many intermolecular NOE 
contacts and do not always work well with weakly binding ligands [143].  
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4.7. Conclusion   
This chapter has described the various experiments used to obtain 
structural information on the binding of activator 27 to TrBgl2 to get insight 
into the mechanism of activation. A number of crystallisation attempts were 
proven unsuccessful. Extensive multi-dimensional NMR experiments were 
therefore carried out on isotopically labelled TrBgl2. 
The initial good quality spectra of TROSY NMR of apo TrBgl2 laid the path 
for further NMR studies. Following the addition of activator 27 and inhibitor 
30, changes in amide chemical shifts across the protein occurred which 
clearly indicated a specific binding event. The possible role of the substrate 
MUG in fragment binding was also investigated by TROSY NMR 
measurements with inactive E367Q TrBgl2 mutant. Notably, substrate 
(MUG) specific chemical shifts were further enhanced following addition of 
27 indicating possible higher substrate affinity to the enzyme in the 
presence of activator 27. On the other hand, following the addition of 
inhibitor 30, the substrate-specific chemical shifts were reduced suggesting 
lower substrate affinity to TrBgl2 in the presence of this fragment inhibitor. 
Both observations demonstrate the important role of substrate in fragment 
binding and are in agreement with the kinetic (Section 2.7) and TSA 
(Section 3.3.) experiments. 
In the second part of this chapter, approximately 56% of backbone 
resonances and 40% of methyl resonances of apo TrBgl2 were successfully 
assigned. Although TrBgl2 was too large for full structure determination by 
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NMR, the assignments obtained were enough to elucidate the binding site 
of activator 27. Mapping of the observed CSPs of activator 27 onto the 
known apo structure of TrBgl2 indicated the entrance of the active site as 
a possible binding site. Although, most of the CSPs are located at the 
substrate entrance of TrBgl2, residues at the surrounding part of active site 
are also significantly affected indicating that conformational changes may 
be induced in TrBgl2 upon binding of 27. A previous study revealed that 
mutations of amino acids located in the entrance of TrBgl2’s active site 
result in a greater increase in catalytic efficiency of the enzyme compared 
to amino acids located much closer to the active site [144]. Interestingly, 
some of those amino acids (L167, T178, F179) are the same ones identified 
to cause the greater CSPs following the addition of 27 to TrBgl2. The CSPs 
of fragment inhibitor (30) were also mapped onto the apo structure of 
TrBgl2 revealing that both compound analogues bind in the same binding 
site.  
Molecular docking using HADDOCK was then used to generate a model of 
the TrBgl2/substrate/activator complex using the ability of HADDOCK to 
include CSPs as ambiguous restraints. The resulting model confirms the 
binding site of activator 27 at the entrance of TrBgl2’s active site and 
suggests possible direct activator-substrate contacts. Frequently, activator 
binding is accompanied by conformational changes in a protein. Indeed, 
although most of the CSPs observed are located at the entrance of TrBgl2’s 
active site, residues close to the active site are also significantly affected, 
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indicating that the protein may undergo conformational changes upon 
compound binding.  
After substrate binding, compound 27 was hypothesized to attach to the 
entrance of active site thereby blocking the substrate exit and stabilizing 
the enzyme-substrate complex. Depending on the fit between the substrate 
(MUG) and a 21-like compound, the substrate either properly fits in the 
active site acting as an improved substrate and adopting a productive 
conformation which leads to enhanced TrBgl2 activity (27) or obtains a less 
favor fit adopting a non-productive conformation which leads to TrBgl2 
inhibition (30). 
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Chapter 5: Other enzymes investigated  
5.1. The bacterial glycosyl hydrolase, CcBglA  
5.1.1. Introduction 
The bacterium Clostridium cellulovorans produces a thermostable 
cellulolytic enzyme, CcBglA, homologous to the fungal TrBgl2 (Figure 5.1) 
but which has higher activity [2]. CcBglA also belongs to the β-retaining 
glycoside hydrolase family 1 (CAZY) and consists of a typical (α/β)8-ΤΙΜ 
barrel-like fold. The structure and biochemical properties of CcBglA were 
determined by Jeng in 2011 [2]. Although, the protein does not share any 
specific interactions that promote oligomerisation according to the Protein 
Interfaces, Surfaces and Assemblies (PISA) server, four protein molecules 
of CcBglA crystallised in an asymmetric unit [2]. 
The active site of the enzyme forms a deep slot-like cleft and is surrounded 
by negatively charged residues. CcBglA and TrBgl2 share a highly 
conserved active site whereas there is more sequence divergence in the 
outer regions that surround the opening to the active site (Figure 5.2).  The 
catalytic acid/base for CcBglA is Glu166, located on the TXNEP sequence 
motif at the end of β-strand 4 (where X is a hydrophobic amino acid), while 
the catalytic nucleophile is Glu352, located on the I/VTENG sequence motif 
at the end of β-strand 7. Two cis-peptide bonds were also found at Ala181-
Pro182 and Trp399-Ser400 [110]. As discussed, TRIS-based buffers are 
potent inhibitors of glycosidases (Section 2.1.2) [111]. TRIS appeared to 
 154 
 
inhibit the activity of CcBglA although it was not detected in the active site 
of the enzyme’s crystal structure [2]. 
 
Figure 5.1. Amino acid sequence alignment of TrBgl2 and CcBglA enzymes.  The 
secondary structure elements of CcBglA are indicated. Numbering of the principal 
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secondary structure elements underlines the (α/β)8-TIM barrel structure; 
additional secondary elements are indicated by letters. The 310-helices are 
indicated by the character η [2]. Sequence alignment generated using the T-coffee 
service (http://tcoffee.crg.cat/apps/tcoffee/index.html). Figure generated with 
ESPript 3.0 (http://espript.ibcp.fr/ESPript/ESPript/) where identical residues are 
highlighted in red and similar residues are written with black bold characters and 
boxed in yellow [109]. The residue numbering is that for CcBglA.  
 
Figure 5.2. Cartoon representation of the structural alignment of TrBgl2 (PDB ID 
3AHY) and CcBglA (PDB ID 3AHX). The catalytic acid/proton donor, E166 and the 
catalytic nucleophile/base, E352 are shown as stick diagram in magenta. The 
helices of TrBgl2 and CcBglA are shown in cyan and green, strands in orange and 
red and loops in wheat and yellow respectively.  
5.1.2. Cloning and protein expression 
The CcbglA gene was cloned into the pET-YSBLIC3C plasmid under control 
of the T7 promoter as described in section 7.2. Figure 5.3 shows the 
E352
E165
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construct pET-YSBLIC3C_CcbglA which includes the His6 cleavable 
extension on the N-terminus.  
 
Figure 5.3.  Plasmid map of pET-YSBLIC3C with Ccbgla cloned into the YSBL-
LIC3C site. The ORF containing a gene encoding CcBglA is under control of the T7 
promoter and begins transcription with an N-terminal 3C-cleavage His6 affinity 
tag. The plasmid map was generated using SnapGene® Viewer.   
DNA was sent for sequencing to confirm that the desired sequence 
successfully inserted into the vector. Plasmid DNA was transformed into the 
E. coli BL21 DE3 bacterial strain and CcBglA was overexpressed (as 
described in Section 7.4) in soluble form. 
The recombinant protein with the His6 cleavable tag on the N-terminus has 
a molecular weight of 54 kDa. 
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5.1.3. Protein production and characterisation 
The protein purification protocol (Section 7.5.1) that was used for CcBglA 
yields approximately 25 mg/L in optimal conditions. Protein was isolated in 
two chromatographic steps comprising of a Ni2+ affinity capture of the His6-
tagged protein and subsequent size-exclusion (S200) chromatographic 
separation with purity more than 90% as determined by SDS-PAGE (Figure 
5.4). The CcBglA protein eluted in TRIS buffer as two populations, which 
was consistent with the protein being tetrameric (1st peak) and monomeric 
(2nd peak). 
  
Figure 5.4.  S200 column CcBglA eluate. A. S200 elution peaks detected by UV 
absorbance at 280 nm, obtained after 2 mL injection of CcBglA at 10 mg/mL 
concentration, B. SDS PAGE of the Sephacryl S200 column CcBglA eluate. Samples 
were electrophoresed on a 12% polyacrylamide gel under denaturing and reducing 
conditions. 
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Figure 5.5. SDS PAGE of the purified CcBglA. 1. Broad molecular weight marker, 
2. Cell culture crude extract, 3. Ni-NTA agarose column eluate, 4. Sephacryl S200 
column eluate. Samples were electrophoresed on a 12% polyacrylamide gel under 
denaturing and reducing conditions.  
5.1.4. Oligomerisation studies 
SEC-MALS was used to investigate the oligomeric state of the recombinant 
CcBglA. The analysis revealed the presence of one main population of the 
CcBglA which corresponds to an average mass of approximately 216 kDa 
and 208 kDa after cleavage of the N-terminus His6 tag (Figure 5.6). These 
masses were consistent with tetrameric forms of purified CcBglA in solution 
and indicate that the oligomeric state was not affected by the presence of 
His6 tag on the N-terminus. 
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Figure 5.6. SEC-MALS chromatograms of the elution of CcBglA from a S200 
10/300 analytical column. SEC-MALS analysis of CcBglA before (blue) and after 
(green) cleavage of the N-terminus Hi6. The chromatogram displays the UV at 280 
nm (dotted lines), light scattering at a 90o angle, LS, (solid line), refractive index, 
RI, (dashed line) together with the molar mass of each peak calculated by MALS. 
5.1.5. Assay development  
The kinetic properties of CcBglA were investigated by a continuous assay 
using the same assay as for TrBgl2 (Section 2.6), with pNPG and MUG as a 
substrate. For CcBglA, the assay was run at 45oC and pH 6.0 the previously 
reported pH and temperature optimum for activity of this enzyme [2] 
(Section 7.8). The Michaelis-Menten parameters were calculated (pNPG: 
kcat = 251.7±14.44 s-1, Km = 0.2±0.04 mM, MUG: kcat = 199±4.8 s-1, Km = 
0.28±0.02 mM) (Figure 5.7) through direct fit to the Michaelis-Menten 
equation and are displayed in Table 5.1. CcBglA shows higher affinity and 
catalytic efficiency toward the first substrate, pNPG, which is consistent 
with the results obtained previously by Jeng et al. [2].  
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Table 5.1.  Catalytic activity of CcBglA. 
 
pNPG 
 
 
MUG 
 
kcat 
(s-1) 
Km 
(mM) 
kcat/Km 
(s-1 mM-1) 
kcat 
(s-1) 
Km 
(mM) 
kcat/Km 
(s-1mM1) 
251.7±14.44 0.2±0.04 1266±349.72 199±4.8 0.28±0.02 714±234 
 
 
Figure 5.7. Michaelis-Menten plots for CcBglA. A. pNPG cleavage assay Michaelis-
Menten plot for CcBglA (100 nM) and B. MUG cleavage assay Michaelis-Menten 
plot for CcBglA (100 nM). 
The inhibition efficiency of CcBglA by the known glycosyl hydrolase inhibitor 
isofagomine (Figure 5.8) [115-116] was assessed by a continuous assay of 
hydrolysis of MUG at the optimal conditions (45oC, pH 6.0) (Section 7.8). 
Isofagomine showed inhibition of CcBglA with an IC50 value of 2.3±0.3 µM. 
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Isofagomine can thus be used to categorize any hit compound as either 
competitive or non-competitive with isofagomine.  
 
Figure 5.8. Inhibition of CcBglA by isofagomine. 
5.1.6. Crystal structures 
Crystals of CcBglA were obtained by repeating the published conditions [2] 
using the sitting drop vapour diffusion methodology in a 24-well plate 
format. Crystal optimisation was performed through variation of these 
published conditions after removing the His6 tag attached to the protein 
and the best results were obtained with 22% (w/v) PEG 3350, 0.3 M LiSO4 
in 0.1 M Hepes pH 7.5 at 293 K (Section 7.9). The triangular prism crystals 
of CcBglA grew within 14 days (Figure 5.9) but when tested on the Diamond 
beamline, diffracted only to 6 Å. 
Following this, CcBglA was screened against commercially purchased 
screens (Table 7.1) in a 96-well plate format, using sitting drop vapour 
diffusion methodology. Crystallization hits were obtained and were 
subjected to fine-screening in larger scale 24-well sitting drop format to 
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test and improve crystal size, reproducibility and diffraction quality. None 
of the attempts resulted in crystals suitable for diffraction. 
 
Figure 5.9. CcBglA crystals obtained after optimisation of the published 
conditions [2]. 
5.1.7. Fragment screening 
The York fragment library at the time of these experiments consisted of 
570 compounds. The inhibition of CcBglA by isofagomine confirmed that 
the MUG activity-based assay for CcBglA was robust enough for compound 
screening, as seen for TrBgl2 (Section 2.6). Fragment screening was 
performed at the optimal conditions of the enzyme (45oC, pH 6.0) (Section 
7.8). In the initial screen of 570 compounds, 54 fragments inhibited CcBglA 
activity and 8 fragments enhanced the ability of CcBglA protein to cleave 
MUG. However, none of the hits were confirmed as an activator in repeats 
of the MUG activity-based assay at different compound concentrations and 
after control experiments to identify any false positives due to possible 
interference from innate compound fluorescence. 
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5.1.8. Conclusion 
The enzyme, CcBglA, was successfully expressed and purified and an 
enzyme assay established and validated following the published work by 
Jeng et al [2]. SEC-MALS analysis revealed the presence of one main 
population at a molecular weight consistent with a tetrameric form of 
purified CcBglA. CcBglA showed higher affinity and catalytic efficiency for 
the pNPG substrate compared to MUG, in full agreement with previous 
published studies on this enzyme [2]. Crystallisation using published 
conditions and screening of new conditions did not generate crystals which 
diffracted adequately for structure determination. 
A screen of the York fragment library of 570 compounds in the enzyme 
assay did not identify any fragments which increased the activity of CcBglA 
to cleave MUG substrate.  
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5.2.  The α-amylase, TVB146 
5.2.1. Introduction  
α-amylases (E.C.3.2.1.1) are enzymes that hydrolyse the internal α-1,4-
glycosidic bond in starch into polymers composed of glucose units. 
Amylases constitute one of the largest industrial enzyme markets 
occupying an approximately 25% share worldwide. They have proved to be 
extremely useful in most industrial processes, such as in the starch industry 
for the production of fructose and glucose syrups, in the fuel industry for 
the production of first-generation bio-ethanol, as well as in the detergent, 
food, paper and pharmaceutical industries.  
The variant “Termamyl-like” α-amylase from Geobacillus 
stearothermophilus (TVB146) belongs to the GH13 family according to 
CAZY sequence-based classification system. This is a stabilised variant of 
the widely used subgrouping of industrial GH13 “Termamyl” α-amylase 
from Bacillus licheniformis. The mechanism of the GH13 family enzymes is 
well defined; they hydrolyse the α-1,4-glycosidic bonds with net retention 
of anomeric configuration through a covalent glycosyl-enzyme 
intermediate. TVB146 α-amylase features a two-residue deletion (Δ181-
182), which results in a much tighter turn, less exposed loop and a single-
point substitution (N193F). The Asp232, Glu262 and Asp329 residues of 
TVB146 act as the catalytic nucleophile, Bronsted acid/base and “helper” 
residue respectively.  
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The determination of the structure of TVB146 revealed the typical 
“Termamyl” α-amylase three-domain assembly [145]. It comprises 
domains A, B and C. Domain A is a (β/α)8-barrel which is located at the 
core of the structure. Domain B consists of three antiparallel β-sheets, one 
four stranded sheet and a short two-stranded sheet. Domain C displays a 
globular structure and consists of an eight-stranded β-sheet in which four 
strands are folded in a Greek-key motif. TVB146 contains the unusual Ca2+-
Na+-Ca2+ triad at the A/B interface as do all the “Termamyl” α-amylases 
[145]. 
 
Figure 5.10. Cartoon representation of the TVB146 amylase structure (PDB ID 
4UZU). The helices are shown in green, strands in orange and loops in wheat. 
 
Domain B
Domain C
Domain A
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5.2.2. Cloning and protein expression 
The α-amylase gene was cloned into the pET-YSBLIC3C plasmid under the 
control of the T7 promoter as described in section 7.2. Figure 5.11 shows 
the construct pET-YSBLIC3C_α-amylase, which incorporates the His6 
cleavable extension on the N-terminus.  
 
Figure 5.11. Plasmid map of pET-YSBLIC3C with a-amylase cloned into the YSBL-
LIC3C site. The ORF containing a gene encoding a-amylase is under control of the 
T7 promoter and begins transcription with an N-terminal 3C-cleavage His6 affinity 
tag. The plasmid map was generated using SnapGene® Viewer.   
DNA sequencing confirmed the success of the cloning process and was 
followed by the transformation of the construct pET-YSBLIC3C_α-amylase 
into the E. coli BL21 DE3 bacterial strain. Unfortunately, the TVB146 variant 
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was only obtained in insoluble form, present in the pellet after 
centrifugation, despite screening under various conditions of temperature 
(16-37oC) and IPTG concentration (0.2-1 mM).   
The molecular weight of the recombinant protein with the His6 cleavable 
extension on the N-terminus is 61 kDa. 
5.2.3. Conclusion 
TVB146 α-amylase variant from Geobacillus stearothermophilous was not 
soluble after expression in E. coli heterologous expression system despite 
testing under various conditions. This is an industrial α-amylase variant 
that has been previously expressed successfully in Bacillus licheniformis as 
many other industrial α-amylases [145]. This change of expression system 
probably leads to incorrect protein folding resulting in an insoluble form of 
TVB146. 
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Chapter 6: General conclusions  
Cellulose degrading enzymes are of central interest and extensive use in 
industrial biotechnology through their important role in the production of 
first-generation biofuels. These enzymes are used in enzymatic cocktails to 
degrade LC biomass but, as discussed, the low activity of glycoside 
hydrolases is regarded as the main limiting step in the process. Therefore, 
glycoside hydrolases with improved catalytic activity are urgently required 
to improve the economic feasibility for biofuel production. Novel glycoside 
hydrolases with excellent thermostability such as the fungal glycoside 
hydrolase, TrBgl2, have been the subject of considerable research interest.  
Although, the majority of drug discovery projects aim to discover enzyme 
inhibitors, there are several successful examples of enzyme activation by 
small molecules. This suggested that the discovery of TrBgl2 activators 
could be possible. In the work reported here, FBLD methods were used to 
identify small molecule activators for improving the activity of TrBgl2. 
Throughout this work a robust biochemical assay was efficiently used for 
the initial screen of the York 570 fragment library. Despite the good 
performance of the assay, false-positive results and the requirement of 
significant quantities of compounds were an issue and finally only one 
fragment, compound 21, was successfully identified as an activator of 
TrBgl2 for further investigation. Metal contaminants in stock compounds 
need to be regularly monitored since these are the cause of most false 
positives in activator discovery screening approaches. Contrary to this, 
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ligand observed NMR experiments and NMR CSPs have proved more precise 
and reliable to characterise and confirm the binding of small molecules to 
TrBgl2. Moreover, biophysical approaches are preferred for weak-binding 
compounds because of their improved sensitivity. However, NMR 
spectroscopy requires sufficiently concentrated samples which are not 
always available due to low expression yields of the protein of interest. 
Rational exploitation of the commercially available fragment analogues of 
the initial hit, resulted in the identification of activators with greater impact 
on the maximum rate of TrBgl2 and with much better solubility. It is 
important to point out that the maximum activation calculated reflects the 
mechanism of activation which is possibly due to conformational changes 
or stabilisation of some aspect of the mechanism. This is different from the 
AC50 value that is calculated which is related to the affinity of the compound 
for the binding site of ligand. As discussed, thiourea and chemical groups 
ortho to thiourea appear to be essential for this enzyme activation. Groups 
larger than methyl at the ortho position to thiourea twist the aryl ring out 
of the plane with the thiourea which could explain why other compound 
that had a group meta or para instead of ortho to thiourea were inactive. 
Interestingly, one of the fragment analogues (30) appeared to be a potent 
TrBgl2 inhibitor when retaining the thiourea group in the absence of any 
chemical group ortho to thiourea.  
Initially, this work intended to utilise X-ray crystallography to characterise 
the activator/protein/substrate complexes after library screening and 
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characterisation of the binding to the hit compounds. Despite considerable 
effort, it proved impossible to grow crystals of these complexes. However, 
a collaboration enabled the use of advanced NMR experiments determine 
and map the binding site of the activator identified. Although large proteins 
(>30 kDa) usually precludes analysis by NMR, selective labelling 
demonstrated that good quality spectra can be obtained identifying a 
sufficient number of restraints for a small molecule ligand bound to a 
protein. An extensive series of NMR experiments and data analyses were 
then used to make a partial assignment of the spectrum for TrBgl2 which 
was sufficient to allow the identification of the activator binding site. The 
CSPs observed in the TROSY spectrum are not necessarily correlated with 
proximity to the ligand-binding site as they can also result from ligand-
induced conformational changes. The number of TROSY CSPs from nuclei 
in the protein backbone are limited as most ligand-protein interactions are 
mediated by sidechains which are distant from the detected backbone 
amides. Therefore, selective labelling of I, V, and L residues was also 
performed to provide more information about the interaction of the bound 
ligand with the methyl sidechains interactions of these amino acids, 
although the assignments for these groups where not as good compared to 
the backbone. Although methyl groups have favourable relaxation 
properties resulting in good quality spectra even for large proteins, one 
limitation is the requirement for methyl groups within the ligand binding 
pocket which is not always the case. The effort invested to assign as much 
of the backbone and IVL methyl group resonances for TrBgl2 as possible, 
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followed by mapping the assigned CSPs determined and molecular docking 
experiments allowed the investigation of activator-enzyme interactions that 
provided very interesting data and insight into the mechanism of activation. 
Another limitation is that complete assignment will fail for large proteins 
due to issues involving spectra overlap, resolution and poor sensitivity 
[126][129]. However, partial assignment in combination with available 
structural data may be sufficient for mapping the assigned CSPs as seen in 
this work. While it is true that these techniques are not as accurate as 
obtaining high resolution X-ray crystal structures of the activator-protein 
complexes, they have proven extremely useful in the cases where crystals 
are not available or weakly binding fragments do not give rise to electron 
density in the crystal structures. Nevertheless, such advanced NMR 
experiments are a rather expensive approach which require isotopic 
labelling of the protein, long experimental times and NMR expertise. 
Although, mapping of CSPs and molecular docking was an alternative 
procedure to crystallography that provide some information about the 
activator binding site, the precise orientation of ligand and intermolecular 
contacts are well beyond the capabilities of CSPs analysis. Therefore, a set 
of intermolecular NOE experiments were performed where NOEs exchanged 
with the ligand to determine the accurate orientation of the bound 
activator, but this was not successful. Such approaches could provide 
valuable restrains to perform guided docking of small molecules. Although, 
intermolecular NOEs approaches are quite powerful and can provide the 
precise data about which protein nuclei are in contact with the compound, 
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they suffer from several limitations regarding the requirement for many 
intermolecular NOE contacts and the pattern of CSPs induced by ligand 
binding which might not be robust, is used by the resonance assignment 
[143].  
Mapping of observed CSPs for activator 27 onto the known crystal structure 
of TrBgl2 in combination with molecular docking including CSPs as 
ambiguous restraints, provided a useful model when crystallography was 
not an option for defining the substrate entrance to the active site as the 
activator binding site. Although, the most numerous and largest chemical 
shifts were observed at the entrance of TrBgl2’s active site, shifts for 
residues surrounding the active site were also observed indicating 
activator-induced conformational changes. The CSPs identified for fragment 
inhibitor 30 were also mapped onto the apo structure of TrBgl2 revealing 
the same binding site for both fragment analogues. Such observations 
allowed us to speculate that depending on the fit between the substrate, 
MUG and 21-like compound, the substrate is properly fitted in the active 
site acting as an improved substrate adopting a productive conformation 
which leads to enhanced TrBgl2 activity (27) or the substrate obtains a less 
favour fit adopting a non-productive conformation which leads to TrBgl2 
inhibition (30). The described mechanism is in fact similar to the model for 
sirtuin activation, which suggests that resveratrol binds close to the active 
site entrance and then traps the bound substrate resulting in a more 
suitable orientation of the substrate [75]. In summary, our results indicate 
a mechanism enabling 21-like compounds to directly modulate TrBgl2.  
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The activators identified in this thesis could be the starting point for future 
attempts to design higher affinity compounds that induce higher rates of 
TrBgl2 activation while retaining the same binding site. The long-term aim 
that was not realised in this work is to develop covalent strategies to cross-
link the activator to the enzyme increasing the economic feasibility and 
purity of the enzyme products. The activator is modified in order to tether 
covalently to a cysteine introduced into the enzyme. This is a strategy that 
has been already successfully applied to BtGH84, generating a 
constitutively-activated enzyme with significantly enhanced activity [80]. 
Although, NMR provided a solid platform for the initial steps towards a 
challenging aim, more precise characterisation of 
TrBgl2/activator/substrate interactions are required. 
As already discussed, FBLD has been widely used to identify enzyme 
inhibitors. This work expands the use of FBLD and small molecule activation 
to industrially relevant biocatalysts and has laid the path for FBLD use as 
an alternative to traditional protein engineering approaches affecting the 
conformational changes that many enzymes perform during catalysis. 
Directed evolution is the most widely used protein engineering approach, 
whereby random mutagenesis is performed by error-prone PCR to generate 
large libraries of enzyme variants. However, it can only explore the 
chemistries through the genetic code [80]. 
Although other enzymes were also explored for enzyme activation such as 
the close bacterial homologue of TrBgl2, CcBglA and the “Termamyl-like” 
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Geobacillus stearothermophilus α-amylase (TVB146), these were not 
successful. In the initial screen of the York library, none of the fragments 
appeared to enhance the activity of CcBglA. Alternative approaches such as 
mimicking the activator binding site identified through genetic mutations 
could be considered for CcBglA given the highly conserved active site that 
the TrBgl2 and CcBglA enzymes share. In addition, CcBglA exhibits higher 
activity and thermostability compared to TrBgl2 and therefore, CcBglA is a 
better starting point for enzyme activation studies. On the other hand, the 
α-amylase was not soluble in E. coli heterologous expression system, and 
thus failed to satisfy the desired criteria of an ideal target for FBLD. A 
catalytically active enzyme that could be readily generated through E. coli 
over-expression system would allow rapid and easy enzyme production for 
the library screening, crystallisation and possible introduction of mutations 
for compound tethering.  
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Chapter 7: Materials and methods  
7.1. Chemicals and reagents  
The fragment library was assembled as described by Schulz et al. [146] 
and dissolved in DMSO-d6 to a concentration of 200 mM and quality 
controlled using 1H NMR spectroscopy. The library is a subset of the 
Maybridge Ro3 diversity library 
(https://www.maybridge.com/portal/alias__Rainbow/lang__en/tabID__23
0/DesktopDefault.aspx). The entire library contains 2500 compounds of 
which 560 compounds were selected for maximum diversity in chemical 
representation, for improved distribution across a PMI plot in comparison 
to the Ro3 library and more reliability in terms of solubility.  
7.2. Cloning 
Genes from Geobacillus stearothermophilus (“Termamyl”-like α-amylase) 
and Trichoderma reesei (Trbgl2; AB003110) were synthesized and 
optimised to the favored codon usage for E. coli by Invitrogen. The α-
amylase gene fragment was amplified by polymerase chain reaction (PCR) 
with forward 5’-CCAGGGACCAGCAATGGCAGCACCGTTTAATGGC-3’ and 
reverse 5’-GAGGAGAAGGCGCGTTATTACGGCCATGCAACCAGAC-3’ primers 
(overhangs underlined). The Trbgl2 gene fragment was amplified by PCR 
with forward 5’-CCAGGGACCAGCA ATGCTGCCGAAAGATTTTCAGTGG-3’ and 
reverse 5’-GAGGAGAAGGCGCGTTATGCTGCTGCAATCAGTTCATCAAAC-3’ 
primers (overhangs underlined). Gene from Clostridium cellulovorans 
(CcbglA; NCBI accession number AY268940) was isolated from the genomic 
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DNA that was purchased by the DSMZ company. The CcBglA gene fragment 
was amplified by PCR with forward 5’-
CCAGGGACCAGCAATGGAAAAGCTAAGATTTCCCA-3’ and reverse 5’-
GAGGAGAAGGCGCGTTATTACTTATTAGATCTTTCTATAAGCTCC-3’ primers 
(overhangs underlined). Each PCR product of the three genes was cloned 
into the expression vector of pET-YSBLIC3C using the NEBuilder HiFi DNA 
Assembly Cloning kit (NEB) which allows rapid assembly of DNA fragments 
without any ligation step due to complementary overhangs on insert and 
vector. The vector linearised by PCR with forward 5’-
TTGCTGGTCCCTGGAACAGAACTTCC-3’ and reverse 5’-
CGCGCCTTCTCCTCACATATGGCTAGC-3’ primers. The expression vector of 
pET-YSBLIC3C carries the T7 promoter, a hexahistidine (His6) cleavable 
extension on the N-terminus and kanamycin resistance gene. All the 
resulted DNA constructs pET-YSBLIC3C_α-amylase, pET-YSBLIC3C_Trbgl2 
and pET-YSBLIC3C_CcbglA were sequenced and verified. 
7.3. Site-directed mutagenesis 
Selected codon in the pET-YSBLIC3C_Trbgl2 recombinant plasmid 
previously obtained (Section 8.2) was mutated by PCR in order to obtain 
the E367Q substitution in the TrBgl2. The E367Q TrBgl2 gene fragment was 
produced by polymerase chain reaction (PCR) with forward 5’-
CCTATTTATGTTACCCAAAATGGCACCAG-3’ and reverse 5’-
GCCATTTTGGGTAACATAAATAGGCGGA-3’ primers (overhangs underlined). 
The PCR product was cloned into the expression vector of pET-YSBLIC3C 
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using the Gibson Assembly Cloning kit (NEB) which allows rapid assembly 
of DNA fragments without any ligation step due to complementary 
overhangs. The resulted DNA construct pET-YSBLIC3C_E367QTrbgl2 was 
sequenced and verified.  
7.4. Protein expression  
7.4.1. Unlabelled protein 
The constructs pET-YSBLIC3C_Trbgl2 pET-YSBLIC3C_E367QTrbgl2, pET-
YSBLIC3C_CcbglA and pET-YSBLIC3C_α-amylase were transformed into E. 
coli Bl21 (DE3) competent cells which are deficient in Lon protease 
(cytoplasm) and OmpT protease (outer membrane) and are suitable for 
expression of genes cloned downstream of a T7 promoter. An overnight 
culture was used to inoculate 0.5 L of LB medium containing 100 µg/mL 
Kanamycin and was subsequently incubated at 37oC (for α-amylase) and 
30oC (for TrBgl2 and CcBglA) with shaking until the medium reached an 
optical density, OD600 of 0.8-1.0. The temperature was then reduced to 
13oC (for TrBgl2, E367Q TrBgl2 and CcBglA) for one h before adding the 
isopropyl β-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM 
for TrBgl2 and E367Q TrBgl2, and 0.2 mM for CcBglA. The cells (for TrBgl2, 
E367Q TrBgl2 and CcBglA) were pelleted by centrifugation after 16 h 
following the protocol from Jeng et al. [2]  
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7.4.2.  15N Isotope-Labelled TrBgl2 protein  
Production of 15N-labelled E367Q TrBgl2 followed a similar protocol to the 
unlabelled proteins. An overnight TrBgl2 LB medium preculture from a 
freshly transformed colony was pelleted by centrifugation at room 
temperature (4,000 rpm, 10 min) and resuspended in baffled flasks with 
0.5 L of M9 medium containing 3 g Na2HPO4, 1.5 g KH2PO4, 0.25 g NaCl, 
0.5 g  15NH4Cl, 2 mM MgSO4, 100 µM CaCl2, 0.4% glucose, 5 mL Gibco MEM 
vitamins solution (SIGMA) and 0.5 mL trace elements solution (50 mM 
FeCl3, 50 mM ZnSO4, 100 mM MnCl2, 10 mM CuSO4) and 100 µg/mL 
Kanamycin. Baffled flasks increase oxygenation of the medium during 
shaking for optimal protein expression. The 0.5 L M9 culture was 
subsequently incubated at 30oC with shaking until the medium reached an 
optical density, OD600 of 0.8-1.0. The temperature was then reduced to 
13oC for one h before adding the isopropyl β-thiogalactopyranoside (IPTG) 
to a final concentration of 0.5 mM. The cells were pelleted by centrifugation 
after incubation at 13oC overnight with shaking at 200 rpm.  
7.4.3.  15N, 13C, 2H Isotope-Labelled TrBgl2 protein  
A 5 mL LB rich growth medium (Preculture 1) inoculated with a freshly 
transformed colony containing 100 µg/mL Kanamycin and was 
subsequently incubated at 37oC in an orbital shaker, 200 rpm for 6-8 h. A 
5 mL M9/H2O medium (Preculture 2) containing 30 mg Na2HPO4, 15 mg 
KH2PO4, 2.5 mg NaCl, 5 mg 15NH4Cl, 7.5 mg [2H,13C] glucose, 100 µM CaCl2, 
2 mM MgSO4, 5 mL Gibco MEM vitamins solution (SIGMA) and 0.5 mL trace 
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elements solution (50 mM FeCl3, 50 mM ZnSO4, 100 mM MnCl2, 10 mM 
CuSO4) and 100 µg/mL Kanamycin was inoculated using Preculture 1 so 
that the starting OD600 = 0.05 and was subsequently incubated at 37oC in 
an orbital shaker, 200 rpm overnight. Preculture 2 was pelleted by 
centrifugation at room temperature (4,000 rpm, 10 min) and resuspended 
in 50 mL conical baffled flask with 10 mL M9/50% H20–50% D2O medium 
(Preculture 3) so that the starting OD600 = 0.05 and was subsequently 
incubated at 37oC in an orbital shaker, 200 rpm for 6-8 h. Conical baffled 
flasks increase oxygenation of the medium during shaking for optimal 
protein expression. Preculture 3 was pelleted by centrifugation at room 
temperature (4,000 rpm, 10 min) and resuspended in 250 mL conical 
baffled flask with 50 mL M9/D2O medium (Preculture 4) so that the 
starting OD600 = 0.25 and was subsequently incubated at 37oC in an orbital 
shaker, 200 rpm overnight. Preculture 4 was pelleted by centrifugation at 
room temperature (4,000 rpm, 10 min) and resuspended in 1 L conical 
baffled flask with 250 mL M9/D2O medium (Preculture 5) so that the 
starting OD600 = 0.25 and was subsequently incubated at 37oC in an orbital 
shaker, 200 rpm until the medium reached an optical density, OD600 of 0.7-
0.8. The temperature was then reduced to 16oC and isopropyl β-
thiogalactopyranoside (IPTG/D2O) was added to a final concentration of 0.5 
mM. The cells were pelleted by centrifugation after incubation at 16oC 
overnight with shaking at 200 rpm.  
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7.4.4.  15N, 13C, 2H and IVL methyl groups specifically 
labelled TrBgl2 protein  
A 5 mL LB rich growth medium (Preculture 1) inoculated with a freshly 
transformed colony containing 100µg/mL Kanamycin and was subsequently 
incubated at 37οC in an orbital shaker, 200 rpm for 6-8 h. A 5 mL M9/H2O 
medium (Preculture 2) containing 30 mg Na2HPO4, 15 mg KH2PO4, 2.5 
mg NaCl, 5 mg 15NH4Cl, 7.5 mg [2H,13C] glucose, 100 µM CaCl2, 2 mM 
MgSO4, 5 mL Gibco MEM vitamins solution (SIGMA) and 0.5 mL trace 
elements solution (50 mM FeCl3, 50 mM ZnSO4, 100 mM MnCl2, 10 mM 
CuSO4) and 100 µg/mL Kanamycin was inoculated using Preculture 1 so 
that the starting OD600 = 0.05 and was subsequently incubated at 37oC in 
an orbital shaker, 200 rpm overnight. Preculture 2 was pelleted by 
centrifugation at room temperature (4,000 rpm, 10 min) and resuspended 
in 50 mL conical baffled flask with 10 mL M9/50% H20–50% D2O medium 
(Preculture 3) so that the starting OD600 = 0.05 and was subsequently 
incubated at 37oC in an orbital shaker, 200 rpm for 6-8 h. Conical baffled 
flasks increase oxygenation of the medium during shaking for optimal 
protein expression. Preculture 3 was pelleted by centrifugation at room 
temperature (4,000 rpm, 10 min) and resuspended in 250 mL conical 
baffled flask with 50 mL M9/D2O medium (Preculture 4) so that the 
starting OD600 = 0.25 and was subsequently incubated at 37oC in an orbital 
shaker, 200 rpm overnight. Preculture 4 was pelleted by centrifugation at 
room temperature (4,000 rpm, 10 min) and resuspended in 1 L conical 
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baffled flask with 250 mL M9/D2O medium (Preculture 5) so that the 
starting OD600 = 0.25 and was subsequently incubated at 37oC in an orbital 
shaker, 200 rpm. When the optical density, OD600 = 0.4, 30 mg of Val/Leu 
precursor, 2-Keto-3-(methyl-d3)-butyric acid- 1,2,3,4-13C4, 3-d sodium salt 
(SIGMA, Cat. 637858) and 17.5 mg of IIe precursor, 2-Ketobutyric acid-
13C4,3,3-d2 sodium salt hydrate (SIGMA, Cat. 607541) was added and was 
subsequently incubated at 37oC in an orbital shaker, 200 rpm until the 
medium reached an optical density, OD600 of 0.7-0.8.  The temperature was 
then reduced to 16oC and isopropyl β-thiogalactopyranoside (IPTG/D2O) 
was added to a final concentration of 0.5 mM. The cells were pelleted by 
centrifugation after incubation at 16oC overnight with shaking at 200 rpm.  
7.5. Protein purification 
7.5.1. Unlabelled protein 
The bacterial cells (for TrBgl2, E367Q TrBgl2 and CcBglA) resuspended in 
a lysis buffer containing 20 mM TRIS-HCl pH 7.5, 400 mM NaCl, 10 mM 
Imidazole and one EDTA-free protease inhibitor cocktail tablet and then 
destroyed by using the Cell Disruption System (Benchtop, Constant 
Systems Ltd). The cell debris was removed by centrifuge at 18,000 rpm for 
45 min at 4oC. The supernatant was loaded on a chromatography column 
containing 5 mL Ni-NTA agarose (QIAGEN, Germany), equilibrated with 
lysis buffer. The His-tagged protein was subsequently washed with the 
same buffer and subsequently eluted by a linear gradient of 10-300 mM 
Imidazole. The purified His-tagged proteins were analysed on 12% SDS-
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PAGE and concentrated to a volume of 2 mL using 10 kDa cut-off size 
AMICON-ultra filters. The samples were loaded onto a pre-packed 
XK16/600 Sephacryl S200 column using an AKTA start purifier system (GE 
Healthcare). It was carried out using a buffer containing 50 mM TRIS-HCl 
pH 8.0, 100 mM NaCl, 3 mM dithiothreitol (DTT). The flow rate was 1 
mL/min, and elutions was monitored at 280 nm. The His6 tag CcBglA 
removed after incubation with 3C protease at 4oC for 18 h. The protein was 
then re-run through the Ni-NTA agarose column to retain the His6 tag 
fragment. His6-tag free CcBglA was obtained in the flow through fractions, 
was pooled and loaded again onto an S200 gel filtration column.  
Protein quantification was carried out using the optical density values of the 
sample at 280nm using extinction coefficient of 1.86 for TrBgl2 and E367Q 
TrBgl2 and 2 M-1 cm-1 for CcBglA as determined by the PROTPARAM 
program (EXPASY proteomics server).  
7.5.2. Isotope-labelled protein 
Purification followed the same protocol as unlabelled TrBgl2 protein above 
(Section 7.5.1).  
7.6. Estimation of purified protein concentration 
A Nanodrop ND-1000 spectrophotometer (Thermo Scientific) was used to 
estimate the concentration of purified protein samples. The theoretical 
extinction coefficient of each protein was calculated using the ExPASy 
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ProtParam tool (https://web.expasy.org/protparam/) and entered into the 
Nanodrop control software.  
7.7. Size Exclusion Chromatography with Multi-Angle 
Light Scattering (SEC-MALS) 
Size exclusion chromatography with multiple-angle light scattering (SEC-
MALS) is used to measure molecular mass and rms radius Rg of 
macromolecules in solution. Size-exclusion chromatography (SEC) 
separated the molecules based on their hydrodynamic volume and size 
while MALS measures the absolute molar mass and size of the molecules 
using the intensity and the light scattered by the sample at a range of 
angles. Therefore, combining SEC and MALS in an SEC-MALS experiments 
allows to obtain more accurate information about the size and shape of 
macromolecules in solution [113].  
Sample injection volume of 100 µl CcBglA (2.5 mg/mL) was fractionated 
on a Superdex S200 10/300 column (GE Healthcare) equilibrated with 
buffer containing 50 mM HEPES in pH 8.0, 100 mM NaCl, 3 mM 
dithiothreitol (DTT) at 0.5 mL/min flow rate.  The system comprises a UV 
280/254 nm detector, a Wyatt HELEOS-II multi-angle light scattering 
detector and Wyatt Rex refractive index detector for the sample monitoring. 
Data analysis were performed using ASTRA V software (Wyatt Technology) 
and MWs were estimated using the Zimm fit method with degree 1. 
Detector normalization was performed using BSA. 
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7.8. Enzyme kinetics determination 
pNPG (4-nitrophenyl-β-D-GlcNAc) and 4-methylumbelliferyl-β-D-
glucopyranoside (MUG) substrates were used for kinetic analysis for TrBgl2 
and CcBglA. Both reactions were performed in 160 mM phosphate-citrate 
buffer in pH 6.0, were initiated by adding 20 µL of the enzyme to give a 
final concentration of 100 nM and were assayed at 40 and 45oC for TrBgl2 
and CcBglA respectively. Reactions were carried out using 0-12 mM and 0-
3 mM pNPG for TrBgl2 and CcBglA respectively, in a total volume of 150 µL 
per well. The released p-nitrophenol was monitored continuously at 400 nm 
by BMG Labtech POLARstar OPTIMA.  
The fluorescent kinetic assay was performed using 31.25-4000 µM MUG in 
a total volume of 100 µL per well. Fluorescent 4-methylumbelliferyl release 
was recorded continuously at 355 nm excitation and 460 nm emission for 
20 s by BMG Labtech POLARstar OPTIMA. Corrections were made to the 
detected gradients to adjust for the inner filter effect of MUG and covert 
the gradients into units of µmol min-1 according to a standard curve of MUG. 
Values quoted throughout are mean and standard deviation of two 
independent replicates. Km and kcat values were calculated by fitting the 
data to the Michaelis- Menten equation.  
The same fluorescent kinetic assay was performed for library screening for 
TrBgl2 and CcBglA using 500 and 300 µM MUG in a total volume of 150 per 
well. Compounds dissolved in DMSO were added to each well to yield a final 
concentration from 1 to 2 mM (2.3% DMSO). The reactions were initiated 
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by adding 20 µL of the enzyme to give a final concentration of 100 nM. 
Control experiments to evaluate a possible interference from innate 
compounds library fluorescence were done by repeating the assay in the 
absence of the enzyme.  
Inhibition of TrBgl2 and CcBglA by isofagomine (IC50) was performed using 
a final concentration of 100 nM protein and 500 µM MUG with various 
concentrations of isofagomine (0-100 µM) in a total volume of 100 µL per 
well. The reactions were performed in 160 mM phosphate-citrate buffer in 
pH 6.0 and were assayed at 40 and 45oC for TrBgl2 and CcBglA 
respectively. Reactions were initiated with the addition of enzyme, and 
reactions progress were monitored continuously at 355 nm excitation and 
460 nm emission. All curve fitting for enzyme kinetics and inhibition 
experiments was performed using GraphPad Prism 5.0. 
AC50 measurements of fragment activators were determined in a similar 
manner to the IC50 values. Assays were carried out in a 96 well plate (Black 
Nunc F96 MicroWell Plates) at 40 and 45oC for TrBgl2 and CcBglA 
respectively in a total volume of 150 µl per well, buffer (160 mM phosphate-
citrate pH 6.0, 2.5% DMSO) with 500 µM MUG, as substrate, 100 nM 
protein and various concentrations of activators (0-8 mM) depending on 
the solubility limits of each compound. Reactions were initiated by addition 
of 20 µl of protein to a final concentration of 100 nM, followed by 5 s of 
shaking. Fluorescent 4-methylumbelliferyl release was recorded 
continuously at 355 nm excitation and 460 nm emission for 20 s by BMG 
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Labtech POLARstar OPTIMA. Rates were calculated using GraphPad Prism 
5.0 as the slope of the curve of the collected data. The initial slopes were 
fitted to sigmoidal dose response curves using GraphPad Prism 5.0 and the 
AC50 values extracted. For generating AC50 values assays were repeated 3 
times. Final AC50 values are reported as mean and standard deviation of 3 
AC50 curve fits.  
Apparent Km and kcat values were calculated from a Michaelis-Menten curve 
fit to 9-point substrate titrations at a constant concentration of the 
activator. The covariation experiments used the same range of substrate 
concentrations across an activator concentration range. The data obtained 
from these experiments was fit to the nonessential activator equation:  
 
[S] is the concentration of the enzyme, [A] the concentration of the 
activator, α modifies Km, β modifies Vmax and KA is the half max 
concentration of the activator.  
7.9. Crystallization and structure determination 
7.9.1. Crystallisation 
Crystallization conditions for TrBgl2 and CcBglA were screened using the 
sitting-drop vapor diffusion method. The drops were made up of 0.5 µL of 
protein solution with an equal volume of reservoir solution and were 
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equilibrated against 54 µL reservoir solution at 20oC. The concentration of 
the TrBgl2 and CcBglA protein was 1.2 mg mL-1 in a buffer containing 50 
mM TRIS pH 8.0, 100 mM NaCl and 3 mM DTT. Initial crystallization 
screening was performed using commercially available crystallization kits 
(Table 7.1).  
Table 7.1. Commercially available screens. 
Crystal Screen HT (Hampton Research) 
The JCSG+ (Molecular Dimensions) 
Peg Ion HT (Hampton Research) 
PDB Screen (Jobie's) 
MPD screen (Qiagen) 
Morpheus (Molecular Dimensions) 
Index (Hampton Research) 
 
The crystals of native TrBgl2 were obtained with 35% (w/v) PEG 3350, 
0.2 M NaCl and 0.1 M TRIS pH 8.5 at 293 K. The final crystal size was 
reached in 3 d. Crystals of TrBgl2/isofagomine complex were obtained at 
similar conditions to that of native TrBgl2 containing saturated isofagomine 
at 1 mM final concentration. The crystals transferred to cryo-protectant 
solutions containing mother liquor supplemented with 15% ethyl glycol and 
cryo-cooled using liquid N2. Diffracting crystals were sent to Diamond Light 
Source for data collection using a Pilatus 6M-F detector (DecTRIS) at 100 
K. An oscillation range of 0.1o degree was chosen and 180o were collected.  
7.9.2. Structure determination 
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Diffraction images for crystals of apo TrBgl2 and for TrBgl2/isofagomine 
complex were indexed and integrated using iMOSFLM [147]. POINTLESS 
was used to determine the crystallographic space group [148] and structure 
factor amplitudes were scaled and merged using AIMLESS [149].  
The crystals of apo TrBgl2 and complexed with isofagomine grew in a P1 
21 1 space group, and these crystals were almost isomorphous to each 
other. The apo structure was solved by molecular replacement of (MOLREP 
[150]) using the structure of already determined structure of apo TrBgl2 
(PDB ID 3AHY) as a model. MOLREP was run using default parameters. The 
model was improved by manual rebuilding and real-space refinement in 
COOT [151] and maximum-likelihood refinement using Refmac [152].  
As the space group of TrBgl2 liganded with isofagomine was isomorphous 
to the apo crystal, coordinates from the apo structure were used directly 
for determination of the isofagomine complex structure. Rfree sets were 
assigned as they had been for the apo-structure to maintain the uniqueness 
and integrity of the cross-validation Free R set throughout. Figures were 
created using CCP4MG [114].  
7.10. Thermal Shift Assay (TSA) 
Thermal shift assay (TSA) is a technique used to determine protein thermal 
stability. It is usually used to optimise buffer conditions for crystallographic 
screening aiming to maximise the protein stability and to assess the effects 
of ligands on protein targets. TSA exploits an environmentally sensitive 
dye, SYPRO Orange, which binds non-specifically to hydrophobic surfaces 
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and water quenches its fluorescence. By gradually heating a protein and 
dye mixture buried hydrophobic sidechains are revealed and bind the dye 
as the protein unfolds. When the dye is exposed to this hydrophobic 
environment the fluorescence intensity of the sample increases by 
excluding the water molecules and enables an estimation of a protein 
melting point (Tm). Addition of stabilizing or destabilising ligands the Tm will 
be altered, this change is known as a thermal shift, or ΔTm. [153]. 
Thermal shift screens were performed in 96-well polypropylene PCR plates 
(Agilent 401334) with a final volume 25 µl/well. Well components were  
E367Q TrBgl2 (300 nM), SYPRO orange dye (8X), DMSO (5.2%), substrate, 
MUG (4 mM) and compound at 4 mM in the same buffer as used for the 
enzymatic assay (phosphate-citrate, pH 6.0). Melting data was collected 
using the Agilent Stratagene Mx3005P rtPCR machine ramping from 25oC 
to 95oC at 30 s per degree. Data was analysed with a combination of the 
Agilent MxPro software, MTSA [154], JTSA (http://paulsbond.co.uk/jtsa) 
and the DSF analysis spreadsheet in Excel [153].  
7.11. NMR Spectroscopy 
NMR experiments were carried out on a Bruker Avance Neo 700 MHz NMR 
spectrometer equipped with a 5 mm triple-resonance nitrogen-cooled 
cryoprobe. All NMR data were collected at 298 K.  
7.11.1. STD NMR 
 
The Saturation Transfer Difference (STD) NMR experiment relies on the fast 
exchange between the bound and the free ligand state (dissociation 
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constant, KD, ranging from 10-8 mol L-1 to 10-3 mol L-1). In STD-NMR 
experiment radiofrequency pulses are applied by irradiating at a region of 
the spectrum that contains only resonances of the protein (on-resonance 
spectrum); this magnetization is transferred to binding ligands via spin 
diffusion through Nuclear Overhauser effect (NOE) during the timescale of 
the experiment leading to partial saturation of ligand resonances (Figure 
7.1). The binding of a ligand can be detected as a reduction in signal 
intensity in the 1D spectrum recorded for the ligand subtracting the on-
resonance spectrum from the off-resonance spectrum which recorded 
without protein saturation [155]. 
 
Figure 7.1. Schematic illustration of the STD experiment.  
The samples contained 20 µM of the enzyme, fragments at a concentration 
of 500 µM per compound and 100 µM DSS in 50 mM phosphate buffer 
containing 25 mM NaCl and 5% D2O at pH 6.0 with or without 500 µM MUG 
substrate depending on the experiment performed. The experiments were 
recorded by using a Bruker standard pulse sequence (stddiffesgp.3 [156]). 
The on-resonance frequency was set to 0.25 ppm and off-resonance 
irradiation was applied at 40 ppm. STD NMR spectra were collected using 
standard pulse sequences with a total of 16 scans (NS), 5 s delay between 
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the scans (d1) and 1.5 s acquisition time (AQ). Data were processed using 
Topspin 3.2 software. 
7.11.2. WaterLOGSY 
WaterLOGSY is based on the NOESY experiment involving transfer of 
magnetization from bulk water molecules during the mixing time to the 
bound ligand via an intermolecular NOE and spin diffusion (Figure 7.2.). 
The observed WaterLOGSY signs are opposite for signals of free (positive 
NOE) and protein-bound ligands (negative NOE) due to different tumbling 
that they experience. This allows easily discrimination of binders and non-
binders [122] [123]. 
 
Figure 7.2. Schematic illustration of the WaterLOGSY experiment.  
The sample contained 20 µM of the inactive mutant E367Q TrBgl2, 500 µM 
of compound 30, 500 µM of MUG substrate and 100 µM DSS in 50 mM 
phosphate buffer containing 25 mM NaCl and 5% D2O at pH 6.0. 
WaterLOGSY spectra were collected by using a Bruker standard pulse 
sequence (ephogsygpno.2 [123]) with a total of 32 scans (NS), 3 s delay 
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between the scans (d1), 1.5 s acquisition time (AQ) and 1.5 s mixing time 
(D8). Data were processed using Topspin 3.2 software. 
7.11.3. TROSY NMR 
Small molecules in solution relaxes slowly resulting in a long transverse 
relaxation time (T2) (large T2 values) which is translated into narrow line 
widths (Δν) after Fourier transformation (FT). As molecular masses 
increase (masses greater than 25 kDa), spectra become crowded due to 
large numbers of resonances and lines becomes broad due to fast 
transverse relaxation (smaller T2 values). Although, the overlap of NMR 
signals can be overcome by a proper choice of isotope-labelling, there is 
still the limitation caused by parts of the signals that relax quickly. In a 
standard experiment all the parts (parts that relax fast and slow) get mixed 
together, so everything appears to relax at an averaged fairly fast rate. 
Transverse Relaxation Optimized Spectroscopy (TROSY) carefully keeps 
these components separate, and just detects the slow relaxation part which 
improves spectra resolution and sensitivity of large molecules [124]. TROSY 
experiment transfers magnetisation via 1JHN coupling from amide protons 
to the attached nitrogen and then the magnetisation is transferred back to 
the proton for detection. The result is a correlation of a protein’s amide 
proton and nitrogen resonances which can be considered as a structural 
‘’fingerprint’’, generating one peak for each backbone amide, with the 
exception of proline, and some additional peaks for amino acid sidechains 
that contain NH groups where buffer exchange is slow enough for detection. 
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The schematic diagram below (Figure 7.3) indicate the detected nuclei and 
the flow of magnetisation between them during the experiment.  
 
Figure 7.3. Schematic diagram of 2D 1H 15N TROSY experiment. Magnetisation: 
HN →N(t1) →HN(t2). 
Ligand binding will induce changes in chemical shifts of the protein’s 1H and 
15N nuclei. The largest changes will be observed for the 1H 15N that 
correspond to amide backbone groups of the protein that are closest to the 
ligand binding site.  
Each sample was prepared with 120 µM of the wild type TrBgl2 or inactive 
mutant E367Q TrBgl2, 8 mM/16 mM of compound 27/compound 30, 5 mM 
of MUG substrate and 100 µM DSS in 50 mM TRIS buffer containing 100 
mM NaCl and 10% D2O at pH 8.0. DMSO concentration was usually not 
above 3.8%.  TROSY spectra of the enzyme with DMSO in the buffer were 
collected as controls. 1H 15N TROSY spectra were collected by using a Bruker 
standard pulse sequence (trosyetf3gpsi [157, 158]) with 128 scans (NS), 
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1.5 s delay between the scans (d1), 35 ppm spectra width (SW), 256-time 
domain data size (TD) and 117 ppm irradiation carrier frequency offset 
(O1P). 
7.11.4. Constant time (CT)1H 13C HSQC  
1H 13C HSQC is the carbon equivalent of the 1H 15N HSQC and shows all H-
C correlations. 1H 13C HSQC experiment transfers magnetisation via 1JHN 
coupling from 1H to 13C and then back to the proton for detection. The 
constant time (CT) version of 1H 13C HSQC is used to circumvents the 
splitting of signals due to homonuclear 13C 13C J-coupling constant allowing 
to get higher resolution in the carbon dimension in cases that relaxation is 
not a major issue (despite the size of TrBgl2 here). The constant time refers 
to the evolution period between the two INEPT[1] steps which is kept 
constant during the experiment [159].  
 
Figure 7.4. Schematic diagram of 2D 1H 13C HSQC experiment. Magnetisation: 
HC →C(t1) →HC(t2). 
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Each sample was prepared with 250 µM of the wild type TrBgl2, 8 mM of 
compound 27, in 50 mM TRIS buffer containing 100 mM NaCl and 10% D2O 
at pH 8.0. DMSO concentration was usually not above 3.8%.  1H 13C HSQC 
spectra of the enzyme with DMSO in the buffer were collected as controls. 
1H 13C HSQC spectra were recorded by using a Bruker standard pulse 
sequence (hsqcctetgpsp [159]) with 8 scans (NS), 1.5 s delay between the 
scans (d1), 30 ppm spectra width (SW), 256-time domain data size (TD) 
and 15 ppm irradiation carrier frequency offset (O1P). 
[1] Insensitive nuclei enhanced by polarization transfer (INEPT) is a signal 
enhancement process which increases the amount of bulk magnetisation of 
the insensitive nucleus. The enhancement occurs through transfer of 
nuclear spin polarization from proton to less sensitive nucleus (e.g. 13C, 
15N) with the appropriate 1H-X coupling.  
7.12. Protein assignment 
7.12.1. Sample preparation 
Each sample was prepared with 250 µM of the 2H, 13C, 15N labelled TrBgl2 
for backbone assignments and methyl protonated {I(δ1 only), 
L(13CH3,12CD3), V(13CH3,12CD3)} U-[15N, 13C, 2H] sample of TrBgl2 for 
methyl groups assignment, 100 µM sodium 2,2-dimethyl-2-silapentane-5-
sulfonate (DSS) as reference in 50 mM TRIS-HCl containing 100 mM NaCl 
and 10% D2O at pH 8.0.  
7.12.2. Data collection 
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The majority of the NMR spectra presented in this section were collected 
by Dr Alex Heyam at the University of York and Dr Marta Carneiro from the 
ZoBio B.V. at University of Leiden. Two spectrometers were used, a 700 
MHz Bruker Avance Neo and an 800 MHz Bruker Avance II, both controlled 
by TopSpin 3 (Bruker). Spectra were recorded at 298 K.  
Table 7.2. List of NMR experiments recorded. 
Experiment Sample labelling 
HNCO 2H, 13C, 15N  
HN(CA)CO 2H, 13C, 15N  
HNCA 2H, 13C, 15N  
HN(CO)CA 2H, 13C, 15N  
HN(CO)CACB 2H, 13C, 15N  
HNCACB 2H, 13C, 15N  
HN(CA)CB 2H, 13C, 15N  
15N-resolved NOESY 2H, 13C, 15N  
13C-resolved NOESY 2H, 13C, 15N  
HMCM(CG)CBCA {I(δ1 only), L(13CH3,12CD3), V(13CH3,12CD3)} U-
[15N, 13C, 2H]  
CH3-CH3 NOESY {I(δ1 only), L(13CH3,12CD3), V(13CH3,12CD3)} U-
[15N, 13C, 2H]  
 
The spectra collected are described in Appendix A.  
7.12.3. Software and data analysis 
3D spectra were collected using non-uniform sampling (NUS) for all the 
backbone and side-chain assignment experiments. The advantage of NUS 
is that the evolution period (t1) changes in a semi-random way requiring 
significantly fewer t1 increments to achieve the same level of resolution as 
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in a normal 2D experiment. Backbone and sidechain assignments were 
automated using FLYA [133]. Analysis and assignment were aided by 
several scripts written by Eiso AB (ZoBio B.V.). 
7.13. Molecular Docking  
HADDOCK (High Ambiguity Driven DOCKing) Web server [139, 140] used 
1000 protein structures for initial rigid body docking solutions. The best 200 
solutions based on their intermolecular energy were used for a semi-flexible 
refinement. After initial docking iterations, a final explicit solvent 
refinement was performed on all 200 models which then clustered based 
on root mean square deviation criteria. Analysis of HADDOCK scores which 
is a weighted sum of van der Waals, electrostatic, desolvation and restraint 
violation energies, was performed to select the best docking solutions. 
HADDOCK calculations were driven by the available chemical shift 
perturbations (CSPs) recorded after binding of compound 27 to TrBgl2. 
Three-dimensional (3D) conformations of the ligand (27) were generated 
using the SMILES as input.  
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Appendix A: NMR experiments used for the 
assignment   
Here, it is provided clear descriptions for the variety of 3D NMR experiments 
used for the protein assignment during this thesis.  
 
HNCO [160-162] 
HNCO is the simplest and most sensitive backbone experiment. It correlates 
the HN-N pair of one residue (i) with the carbonyl C’ resonance of the 
preceding residue (i-1). The magnetisation is transferred from HN to N via 
1JHN coupling using an INEPT pulse sequence and then from N to C’ via 1JNC’ 
coupling. This results in a 3D spectrum containing a single peak for each 
C’-N connection correlating the resonances of each of the three nuclei. The 
experiment was recorded by Dr Alex Heyam (University of York) using the 
pulse sequence named trhncogp3d [163].  
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Figure A.1. Schematic diagram of 3D HNCO experiment. Magnetisation: HN →N 
→C’(t1) →N(t2) →HN(t3). 
HN(CA)CO [164] 
HN(CA)CO is useful in combination with the HNCO. Similar to HNCO J-
couplings is used to correlate the HN-N pair and the C’ resonance via the 
Cα without evolving the chemical shift. This results in a 3D spectrum 
containing a strong peak for the C’ of the residue i, and a weak one for the 
C’ of the residue i-1. The experiment was recorded by Dr Alex Heyam 
(University of York) using the pulse sequence named trhncacogp2h3d 
[165].  
 
Figure A.2. Schematic diagram of 3D HN(CA)CO experiment. Magnetisation: H 
→N →CA →C’(t1) →CA →N(t2) →H(t3). 
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HNCA [160] 
HNCA correlates the HN-N pair with the Cα resonance of the same and 
previous residue. The magnetisation is transferred from HN to N and then 
via N- Cα- J- coupling to the Cα and then back again to 15N and 1H. This 
results in a 3D spectrum containing the Cα peak of the residue i and may 
the Cα peak of the previous residue i-1, but much weaker. The experiment 
was recorded by Dr Alex Heyam using the pulse sequence named 
trhncagp3d [163].  
 
Figure A.3. Schematic diagram of 3D HNCA experiment. Magnetisation: H →N 
→CA(t1) →N(t2) →H(t3). 
HN(CO)CA [160] 
HN(CO)CA correlates the HN- N pair of the residue i with the Cα resonance 
of the residue i-1. The magnetisation is transferred from HN to N of the 
residue i and then to C’ of the residue i-1. From C’ of the residue i-1 the 
magnetisation is passed to Cα of the same residue and then back again via 
C’ to 15N and 1H of the residue i for detection. This results in a 3D spectrum 
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containing the Cα peak of the residue i-1. The experiment was recorded by 
Dr Alex Heyam using the pulse sequence named trhncocagp2h3d [166].  
 
Figure A.4. Schematic diagram of 3D HNCA experiment. Magnetisation: H →N 
→C’ →CA(t1) →C’ →N (t2) → H (t3) 
HN(CO)CACB [160] 
HN(CO)CACB contains useful information for making sequential matches 
and inferring residue type correlating Cα, Cβ, N and HN resonances via J-
coupling. Magnetisation is transferred from Hα and Hβ to Cα and Cβ and 
then it is passed via the C’, without detection, and on to the N and then HN 
for detection. This results in a 3D spectrum containing two peaks for each 
HN group for the Cα and Cβ of the i-1 residue. The experiment was recorded 
by Dr Alex Heyam using the pulse sequence named trhncocacbgp2h3d 
[166].  
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Figure A.5. Schematic diagram of 3D HN(CO)CACB experiment. Magnetisation: 
HA+HB →CA+CB(t1) →C’ →N(t2) →H(t3). 
HNCACB [167] 
HNCACB correlates Cα, Cβ, N and H resonances via J-coupling. 
Magnetisation is transferred from Hα and Hβ to Cα and Cβ and from there 
it is passed directly to the N and then HN for detection. This results in a 3D 
spectrum containing the Cα and Cβ shifts of the i residue and may the Cα 
and Cβ shifts of the previous i-1 residue, but much weaker. The experiment 
was recorded by Dr Alex Heyam using the pulse sequence named 
trhncacbgp2h3d [166].  
 
Figure A.6. Schematic diagram of 3D HNCACB experiment. Magnetisation: 
HA+HB →CA+CB(t1) →N(t2) →H(t3). 
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HN(CA)CB [167] 
HN(CA)CB correlates the HN-N pair with the Cβ resonance of the same 
residue. The magnetisation is transferred from HN to N of the residue i and 
then via N- Cα- J-coupling to the Cα of the same residue. From Cα of the 
residue i the magnetisation is passed to Cβ of the same residue i and then 
back again via Cα to 15N and 1H for detection. This results in a 3D spectrum 
containing the Cβ peak of the residue i and may the Cβ peak of the previous 
residue i-1, but much weaker. This experiment was recorded by Dr Marta 
Carneiro at ZoBio (The Netherlands).  
 
Figure A.7. Schematic diagram of 3D HN(CA)CB experiment. Magnetisation: H 
→N →CA →CB(t1) →CA →N(t2) →H(t3). 
15N-resolved NOESY [168, 169] 
3D 1H 15N NOESY correlates all 1H spins within NOE distance of the amide 
proton. 1H nuclei mixes spins within approximately 5 Å distance allow NOE 
transfer between them. J-coupling between HN and N is preceded before 
detection at the HN proton. The experiment was recorded by Dr Alex Heyam 
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(University of York) using the pulse sequence named noesyhsqcgpsm3d.2 
[170].  
 
Figure A.8. Schematic diagram of 3D 1H- 15N NOESY experiment. Magnetisation: 
1H-NOE (t1) →N (t2) →HN (t3). 
13C-resolved NOESY [168, 169] 
3D 1H 13C NOESY correlates all 1H spins within NOE distance of the HC 
proton. 1H nuclei mixes spins within approximately 5 Å distance allow NOE 
transfer between them. J-coupling between H and C is preceded before 
detection at the HC proton. This experiment was recorded by Dr Marta 
Carneiro at ZoBio (The Netherlands). 
 
Figure A.9. Schematic diagram of 3D 1H- 13C NOESY experiment. Magnetisation: 
1H-NOE (t1) →C (t2) →HC (t3). 
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HMCM(CG)CBCA [126, 135] 
HMCM(CG)CBCA methyl detected experiment relays magnetisation in an 
out-and-black manner from methyl carbon and proton spins of Ile (I), Leu 
(L) and Val (V) residues to all aliphatic carbons (HMCM(CG)CBCA) and from 
methyl groups to carbonyls and back (Val-HMCM(CBCA)CO and Ile, Leu- 
HMCM(CGCBCA)CO) in which the shifts of each carbon are collected in 
separate experiments. This experiment was recorded by Dr Marta Carneiro 
at ZoBio (The Netherlands). 
 
Figure A.10.  Schematic diagram of the magnetization along the carbon skeletons 
of I, L, V residues. In dashed lines is shown the final transfer from 13Cα to 13CO.  
CH3-CH3 NOESY [135, 171] 
 Methyl-methyl NOESY experiment correlates all methyl proton spins within 
NOE distance. 1H nuclei mixes spins within approximately 5 Å distance allow 
NOE transfer between them. It is important to note that there is not intra- 
residue NOE cross-peaks because only one of two methyl groups of each V 
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and L residue is protonated. This experiment was recorded by Dr Marta 
Carneiro at ZoBio (The Netherlands). 
 
Figure A.11. Magnetization transfer for the methyl- methyl NOESY experiment.  
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Appendix B: Structural overlay of bound and unbound 
NkBgl active site 
 
Figure B.1. Structural overlay of bound and unbound NkBgl active site is shown 
as a stick diagram. NkBgl-E193D bound to pNPG (PDB ID 3AI0) is shown in green 
and the apo NkBgl (PDB ID 3AHZ) is shown in purple. pNPG is shown as yellow 
stick diagram. Oxygen atoms are shown in red and nitrogen in blue. Hydrogen 
bonds are shown as black dashed lines. 
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Appendix C: CSPs of compound 30 mapped on TrBgl2 
 
Figure C.1. Amide chemical shift perturbations caused by the presence of 30 
mapped to the protein surface of the crystal structure of TrBgl2. Backbone CSPs 
are coloured orange. Unassigned residues are coloured grey. The figure was 
created in PyMOL. 
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Appendix D: Chemical structure of compound 31 
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Appendix E: List of fragments caused more than 50 
% inhibition after library screening for TrBgl2 
 
Chemical structure 
 
% inhibition [1] 
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N
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Chemical structure 
 
% inhibition [1] 
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Chemical structure 
 
% inhibition [1] 
 
91 
             [1] Inhibition obtained at 1 mM fragment concentration 
             (substrate conc. = 500 µM) 
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Appendix F: Trbgl2 gene sequence and transcript in 
pET-YSBL3C vector  
F.1. Trbgl2 gene sequence in pET-YSBL3C vector 
A T G C T G C C G A A A G A T T T T C A G T G G G G T T T T G C A A C C 
G C A G C A T A T C A G A T T G A A G G T G C A G T T G A T C A G G A T 
G G T C G T G G T C C G A G C A T T T G G G A T A C C T T T T G T G C A 
C A G C C T G G T A A A A T T G C A G A T G G T A G C A G C G G T G T T 
A C C G C A T G T G A T A G C T A T A A T C G T A C C G C A G A A G A T 
A T T  G C A C T G C T G A A A A G C C T G G G T G C A A A A A G C T A T 
C G T T T T A G C A T T A G C T G G T C A C G C A T T A T T C C G G A A 
G G T G G T C G C G G T G A T G C C G T T A A T C A G G C A G G T A T T 
G A T C A C T A T G T G A A A T T C G T T G A T G A T C T G C T G G A T 
G C A G G T A T T A C C C C G T T T A T T A C C C T G T T T C A T T G G G 
A T C T G C C G G A A G G T C T G C A T C A G C G T T A T G G T G G T C 
T G C T G A A T C G C A C C G A A T T T C C G C T G G A T T T T G A A A 
A T T A T G C C C G T G T T A T G T T T C G T G C C C T G C C T A A A G T 
T CG TA A T T G G  A T T A C C T T T A A T G A A C C G C T G T G T A G C 
G C A A T T C C T G G T T A T G G T A G CG G C A C C T T T G C A C C G 
G G TCG T C A G A G C A C C A G C G A A C C G T G G A C C G T T G G T 
C A T A A T A T T C T G  G T T G C A C A T G G T C G T G C A G T T A A A 
G C A T A T C G T G A T G A T T T C A A A C C G G C A A G C G G T G A T 
G G T C A G A T T G G T A T T G T T C T G A A T G G C G A T T T T A C C T 
A T C C G T G G G A T G C A G C A GA T C CT G C A G AT A A A G A A G 
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CA G C A G A A C G T C G T C T G G A A T T T T T C A C C G C A T G G T T 
T G C A G A T C C G A T T T A T C T G G G T G A T T A T C C G G C A A G 
C A T G C G T A A A C A G C T G G G T G A T C G T C T G C C G A C C T T 
T A C A C C G G A A G A A C G T G C A C T G G T G C A T G G T A G C A A 
T G A T T T T T A T G G C A T G A A C C A C T A T A C C A G C A A C T A T 
A T T C G T C A T C G T A G C A G T C C G G C A A G T G C A G A T G A T 
A C C G T T G G T A A T G T T G A T G T G C T G T T T A C C A A C A A A 
C A G G G C A A T T G T A T T G G T C C G G A A A C A C A G A G C C C G 
T G G C T G C G T C C G T G T G C A G C A G G T T T  
 T C G T G A T TT T C T G G T T T G G A T T A G C A A A C G C T A T G G T 
T A T C C G C C T A T T T A T G T T A C C G A A A A T G G C A C C A G T A 
T T A A A G G T G A A A G C G A T C T G C C C A AA G A A A A G A TT C T 
G G A A G A T G A T T T TC G C G T G A A G T A C T A C A A T G A A T A T 
A T C C G T G C A A T G G T T A C C G C A G T G G A A C T G G A T G G T 
G T T A A T G T G A A A G G T T A T T T T G C A T G G T C C C T G A T G 
G A T A A T T T T G A A T G G G C A G A T G G T T A T G T G A C C C G T 
T T T G G T G T T A C C T A T G T G G A T T A T G A A A A C G G C C A G 
A A A C G C T T T C C G A A A A A A A G C G C A A A A A G C C T G A A A 
C C G C T G T T T GAT G A A C T G A T T G CA G C A G C A T A A  
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F.2. TrBgl2 transcript in pET-YSBL3C vector 
MGSSHHHHHHSSGLEVLFQGPA M L P K D F Q W G F A T A A Y Q I E G A V 
D Q D G R G P S I W D T F C A Q P G K I A D G S S G V T A C D S Y N R T 
A E D I A L L K S L G A K S Y R F S I S W S R I I P E G G R G D A V N Q A 
G I D H Y V K F V D D L L D A G I T P F I T L F H W D L P E G L H Q R Y G 
G L L N R T E F P L D F E N Y A R V M F R A L P K V R N W I T F N E P L C 
S A I P G Y G S G T F A P G R Q S T S E P W T V G H N I L V A H G R A V K 
A Y R D D F K P A S G D G Q I G I V L N G D F T Y P W D A A D P A D K E 
A A E R R L E F F T A W F A D P I Y L G D Y P A S M R K Q L G D R L P T F 
T P E E R A L V H G S N D F Y G M N H Y T S N Y I R H R S S P A S A D D T 
V G N V D V L F T N K Q G N C I G P E T Q S P W L R P C A A G F R D F L V 
W I S K R Y G Y P P I Y V T E N G T S I K G E S D L P K E K I L E D D F R V 
K Y Y N E Y I R A M V T A V E L D G V N V K G Y F A W S L M D N F E W A 
D G Y V T R F G V T Y V D Y E N G Q K R F P K K S A K S L K P L F D E L I 
A A A 
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Appendix G: E367Q Trbgl2 gene sequence and 
transcript in pET-YSBL3C vector  
G.1. E367Q Trbgl2 gene sequence in pET-YSBL3C 
vector 
A T G C T G C C G A A A G A T T T T C A G T G G G G T T T T G C A A C C 
G C A G C A T A T C A G A T T G A A G G T G C A G T T G A T C A G G A T 
G G T C G T G G T C C G A G C A T T T G G G A T A C C T T T T G T G C A 
C A G C C T G G T A A A A T T G C A G A T G G T A G C A G C G G T G T T 
A C C G C A T G T G A T A G C T A T A A T C G T A C C G C A G A A G A T 
A T T  G C A C T G C T G A A A A G C C T G G G T G C A A A A A G C T A T 
C G T T T T A G C A T T A G C T G G T C A C G C A T T A T T C C G G A A 
G G T G G T C G C G G T G A T G C C G T T A A T C A G G C A G G T A T T 
G A T C A C T A T G T G A A A T T C G T T G A T G A T C T G C T G G A T 
G C A G G T A T T A C C C C G T T T A T T A C C C T G T T T C A T T G G G 
A T C T G C C G G A A G G T C T G C A T C A G C G T T A T G G T G G T C 
T G C T G A A T C G C A C C G A A T T T C C G C T G G A T T T T G A A A 
A T T A T G C C C G T G T T A T G T T T C G T G C C C T G C C T A A A G T 
T CG TA A T T G G  A T T A C C T T T A A T G A A C C G C T G T G T A G C 
G C A A T T C C T G G T T A T G G T A G CG G C A C C T T T G C A C C G 
G G TCG T C A G A G C A C C A G C G A A C C G T G G A C C G T T G G T 
C A T A A T A T T C T G  G T T G C A C A T G G T C G T G C A G T T A A A 
G C A T A T C G T G A T G A T T T C A A A C C G G C A A G C G G T G A T 
G G T C A G A T T G G T A T T G T T C T G A A T G G C G A T T T T A C C T 
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A T C C G T G G G A T G C A G C A GA T C CT G C A G AT A A A G A A G 
CA G C A G A A C G T C G T C T G G A A T T T T T C A C C G C A T G G T T 
T G C A G A T C C G A T T T A T C T G G G T G A T T A T C C G G C A A G 
C A T G C G T A A A C A G C T G G G T G A T C G T C T G C C G A C C T T 
T A C A C C G G A A G A A C G T G C A C T G G T G C A T G G T A G C A A 
T G A T T T T T A T G G C A T G A A C C A C T A T A C C A G C A A C T A T 
A T T C G T C A T C G T A G C A G T C C G G C A A G T G C A G A T G A T 
A C C G T T G G T A A T G T T G A T G T G C T G T T T A C C A A C A A A 
C A G G G C A A T T G T A T T G G T C C G G A A A C A C A G A G C C C G 
T G G C T G C G T C C G T G T G C A G C A G G T T T T C G T G A T T T T 
C T G G T T T G G A T T A G C A A A C G C T A T G G T T A T C C G C C T 
A T T T A T G T T A C C C A A A A T G G C A C C A G T A T T A A A G G T 
G A A A G C G A T C T G C C C A A A G A A A A G A TT C T G G A A G A T 
G A T T T TC G C G T G A A G T A C T A C A A T G A A T A T A T C C G T G 
C A A T G G T T A C C G C A G T G G A A C T G G A T G G T G T T A A T G 
T G A A A G G T T A T T T T G C A T G G T C C C T G A T G G A T A A T T T 
T G A A T G G G C A G A T G G T T A T G T G A C C C G T T T T G G T G T 
T A C C T A T G T G G A T T A T G A A A A C G G C C A G A A A C G C T T 
T C C G A A A A A A A G C G C A A A A A G C C T G A A A C C G C T G T T 
T G A T G A A C T G A T T G C A G C A G C A T A A  
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G.2. E367Q TrBgl2 transcript in pET-YSBL3C vector 
MGSSHHHHHHSSGLEVLFQGPA M L P K D F Q W G F A T A A Y Q I E G A V 
D Q D G R G P S I W D T F C A Q P G K I A D G S S G V T A C D S Y N R T 
A E D I A L L K S L G A K S Y R F S I S W S R I I P E G G R G D A V N Q A 
G I D H Y V K F V D D L L D A G I T P F I T L F H W D L P E G L H Q R Y G 
G L L N R T E F P L D F E N Y A R V M F R A L P K V R N W I T F N E P L C 
S A I P G Y G S G T F A P G R Q S T S E P W T V G H N I L V A H G R 3A V 
K A Y R D D F K P A S G D G Q I G I V L N G D F T Y P W D A A D P A D K 
E A A E R R L E F F T A W F A D P I Y L G D Y P A S M R K Q L G D R L P T 
F T P E E R A L V H G S N D F Y G M N H Y T S N Y I R H R S S P A S A D D 
T V G N V D V L F T N K Q G N C I G P E T Q S P W L R P C A A G F R D F L 
V W I S K R Y G Y P P I Y V T Q N G T S I K G E S D L P K E K I L E D D F 
R V K Y Y N E Y I R A M V T A V E L D G V N V K G Y F A W S L M D N F E 
W A D G Y V T R F G V T Y V D Y E N G Q K R F P K K S A K S L K P L F D E 
L I A A A 
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Appendix H: Ccbgla gene sequence and transcript in 
pET-YSBL3C vector  
H.1. Ccbgla gene sequence in pET-YSBL3C vector 
A T G G A A A A G C T A AG ATT T C C C A A A G A T T T T A T T TT T G G 
A A C A G C C A CT G C A G CA T A T C A A A T T G A A G G A G C T T A C 
A A A G A A G A T G A G A A A G G T G A A T C T A T T T G G G A T A G G 
T T T A G T C A T A T A C C A G G A A A T G T A G C T A A A A T G C A T A 
A T G G T G A T A T T G C T T G T G A T C A C T A T C A T A G A T A T A A 
A G A A G A T G T T C A G C T A T T A A A A A G C C T T G G A A T T A A 
A A G T T A T A G G T T T T C AA T T G C T T G G C C T A G A A T T T T C 
C C A A A A G G T T T T G G C G A G A T A A A C C A G A A G G G A A T T 
C A G T T CT A T A G G G A T T T A A T T G A T G A A C T A A T T A A A A 
A T G A T A T A G A A C C AG C T A T A A C A A T T T A TC A T T G G G A 
T C T T C C A C A A A A G C T T C A G G A T A T T G G A G G G T G G G C 
A A A T C C G C A A G T T G C TG A T T A C T A T G T T G A T T A T G C A 
A A C T T A T T A T T C A G A G A G T T C G G A G A T A G A G T A A A A 
A C A T G G A T A A C T C A T A A T G A G C C A T G G G T T G C A T C A 
T A T C T T G G C T A T G C T T T A G G A G T T C A T G C T CC A G G A A 
TT A A A G A T A T G A A A A T G G C A T T G T T A G C T G C A C A T A A 
C A T A T T A T T A T C G C A C T T T A A G G C A G T T A A A G C T T A T 
A G A G A A T T A G A A C A A G A T G G G C A A A T A G G T A T A A C A 
T T A A A T C T T T C A A C C TG T T A T T C A A A T T C A G C T G A T G 
A A G A A G A T A T T G C T G C A G C C C A T A G A A G T G A T G G A T 
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G G A A C A A C A G A T G G T T T T TA G A T G C T G C A T T A A A A G G 
A A C T T A T C C T G A G G A T A T G A T A A A A A T C T T T A G C G A T 
A C A A A T A T T A T G C C T G A A C T A C C T A A A G A G T T A T T T A 
CT G A G G T A T T T G A A A C T T C T G A T T T T T T A G G A A T A A A 
T T A T T A T A C A C G A C A A G T T G T A A A G A A T A A C T C T G AA 
G C T T T T A T C G G T G C T G A A A G T G T A G C A A T G G A T A A T 
C C T A A A A C A G A A A TG G G T T G G G A G A T A T A T C C G C A A 
G G G C TT T A TG A T T T G C T A A C G A G G A T A C A C A G G G A T T 
A T G G G A A C A T A G A T T T A T A C A T A A C A G A A A A C G G T G 
C A G C T T T T A A T G A T A T G G T T A A T A G A G A C G G T A A A G 
T T G A A G AT G A A A A T A G A T T A G A T T A T T T A T A C A C T C A 
T T T T G C T G C T G C A T T A A G T G C T A T A G A A G C G G G A G T 
A C C T T T A A A G G G A T A T T A T A T T T G G T C T T T C A T G G A T 
A A T T T T G A G T G G G C T G A A G G A T A T G A A A A A A G A T TT G 
G A A T A G T A C A T G T A A A C T A T A A A A C T C A G G A G A G A A 
C A A T A A A G A A G A G T G C T T AT T G G T A T A A G G A G C T T A T 
A G A A A G A T C T A A T A A G T A A 
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H.2. CcBglA transcript in pET-YSBL3C vector 
MGSSHHHHHHSSGLEVLFQGPA M E K L R F P K D F I F G T A T A A Y Q I E 
G A Y K E D E K G E S I W D R F S H I P G N V A K M H N G D I A C D H Y 
H R Y K E D V Q L L K S L G I K S Y R F S I A W P R I F P K G F G E I N Q K 
G I Q F Y R D L I D E L I K N D I E P A I T I Y H W D L P Q K L Q D I G G W 
A N P Q V A D Y Y V D Y A N L L F R E F G D R V K T W I T H N E P W V A 
S Y L G Y A L G V H A P G I K D M K M A L L A A H N I L L S H F K A V K A 
Y R E L E Q D G Q I G I T L N L S T C Y S N S A D E E D I A A A H R S D G 
W N N R W F L D A A L K G T Y P E D M I K I F S D T N I M P E L P K E L F 
T E V F E T S D F L G I N Y Y T R Q V V K N N S E A F I G A E S V A M D N 
P K T E M G W E I Y P Q G L Y D L L T R I H R D Y G N I D L Y I T E N G A 
A F N D M V N R D G K V E D E N R L D Y L Y T H F A A A L S A I E A G V P 
L K G Y Y I W S F M D N F E W A E G Y E K R F G I V H V N Y K T Q E R T I 
K K S A Y W Y K E L I E R S N K 
 
 
 
 
 
 
 
 
 222 
 
Appendix I: a-amylase gene sequence and transcript 
in pET-YSBL3C vector  
I.1. a-amylase gene sequence in pET-YSBL3C vector 
A T G C C A G G G A C C A G C A G C A G C A C C G T T T A A T G G C A C 
C A T G A T G C A G T A T T T T G A A T G G T A T C T G C C G G A T G A 
T G G C A C C C T G T G G A C C A A A G T T G C A A A T G A A G C A A A 
T A A TC T GAG C A G C C T G G G T A T T A C C G C A C T G T G G C T G 
C C T C C G G C A T A T A A A G G C A C C A G C C G T A G T G A T G T T 
G G T T A T G G T G T T T A T G A T C T G T A T G A C C T G G G C G AA T 
T T A A T C A G A A A G G C A CC G T T C G T A C C AA A T AT G G C A C 
C A A A G C A C A G T A T C T G C A G GC A A T T C A G G C A G C A C A 
T G C A G C A G G  TA T G C A G G T T T A T G C A G A T G T T G T G T T 
T G A T C A T A A A G G T G G T G C A G A T G G C A C C G A A T G G G T 
T GA T G C A G T T G A A G T T A A T C C G A G C G A T C G C A A TC A A 
G A A A T T A G C G G C A C C T A T C A G A T T C A G G C A T G G A C C 
A A A T T T G A T T T T C C G G G T C G T G G T A A T A C C T A C A G C 
A G C T T T A A A T G G C G T T G G T A T C A T T T T G A T G G T G TG G 
A T T G G G A T G A A A G C C G T A A A C T G A GC C G T A T T T A C A A 
A T TT CG T G G T A A A G C A T G G G A T T G G G A A G T G G A T A C C 
G A A T T T G G C A A TT A T G A TT A T C T G A TG T A T G C C G A T C T 
G G A T A T GG A T C A T C C G G A A G T T G T T A C C G A A C T G A A 
A A A T T G G G G T A A A T G G T A T G T G A A C A C C A C C A A C A T 
T G A T G G T T T T C G T C T G G A T G C A G T G A A A C A C A T C A A 
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A T T T A G C T T T T T T C C GG A T T G G C T G A G C T A T G T T C G T 
A G C C A G A C C G G T A A A C C G C T G T T T A C A G T T G G T G A A 
T A T T G G A G C T A T G A T A T C A A C A A A C T G C A C A A C T A C A 
T C A C C A A A A C C G A T G G T A C A A T G A G C C T G T T T G A TG C 
A C C G C T GC A T A A C A A A T T C T A T A C C G C A A G C A A A A G C 
G G T G G T G C A T T T G A T A T G C G T A C C C T G A T G A C C A A T 
A C A C T G A T G A A A G A T C A G C C G A C C C T G G C A G T T A C C 
T T T G T G G A T A A T C A T G A T A C C G A A C C G G G T C A G G C A 
C T G C A G A G C T G G G T T GA T C C G T G G T T C A A A C C G C T G 
G C A T A T G C A T T T A T T C T G A C C C G T C A A G A A G G T T A T C 
C T T G C G T T T T T T A T G G C G A T T A T T A T G G C A T T C C G C A 
G T A T A A C A T T C C G A G C C T G A A A A G C A A A A T T G A T C C 
G C T G C T G A T T G C A C G T C G T G A T T  A T G C C T A T G G C A C 
C C A G C A C G A T T A T C T G G A T C A T A G C G A T A T T A T T G G 
T T G G A C C C G  T G A A G G T G G T A C A G A A A A A C C G G G T A 
G C G G T C T G G C A G C A C T G A T T A C C G A T G G T C C G G G T G 
G T A G C A A A T G G A T G T A T G T T G G T A A  A C A G C A T G C C G 
G T A A A G T G T T T T A T G A C C T G A C C G G T A A T C G T A G C G 
A T A C C G T T AC C A T T AA T A G T G A T G G T TG G G GT G A A T T  C 
A A A G T G A A T G G T G G T A G C G T T A G C G T T T G G G T T C C G 
C G T A A A A C C A C C G T T A G C A C C A T T G C C C G T C C G A T T 
A C C A C C C G T C C G T G G A C C G G T G A A T T T G T T C G T T G G 
A C C G A A C C G C G T C T G G T T G C A T G G C C G T A A T A A C G C 
G C C T T C T C C T C T A A 
 224 
 
I.2. a-amylase transcript in pET-YSBL3C vector 
MGSSHHHHHHSSGLEVLFQGPA M A A P F N G T M M Q Y F E W Y L P D D G 
T L W T K V A N E A N N L S S  L G IT A L W L P P A Y K G T S R S D V G Y 
G V Y D L Y D L G E F N Q  K G T V R T K Y G T K A Q  Y L Q A I Q A A H A 
A G M Q V Y A D V V F D H K G G A D G T E W V D A V E V N P S D R N Q 
E I S G T Y Q I Q A W T K F D F P G R G N T Y S S F K W R W Y H F D G V 
D W D E S R K L S R I Y K F R G K A W D W E V D T E F G N Y D Y L M Y A 
D  L D   M D H P E V V T E L K N W G K W Y V N T T N I D G F R L D A V K 
H I K F S F F P D W L S Y V R S Q T G K P L F T V G E Y W S Y D I N K L H 
N Y I T K T D G T M S L F D A P L H N K F Y T A S K S G G A F D M R T L M 
T N T L M K D Q P T L A V T F V D N H D T E P G Q A L Q S W V D P W F K 
P LA Y A F I L T R Q E G Y P C V F Y G D Y Y G I P Q Y N I P S L K S K I D P 
L L I A R R D Y A Y G T Q H D Y L D H S D I I G W T R E G G T E K P G S G 
L A A L I T D G P G G S K W M Y V G K Q H A G K V F Y D L T G N R S D T 
VT I N S D G W G E F K V N G G S V S V W V P R K T T V S T I A R P I T T 
R P W T G E F V R W T E P R L V A W P 
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